
<html lang="en"     class="pb-page"  data-request-id="231c1b30-dc7c-41f1-a4cb-e0c6d385fab9"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2018.61.issue-3;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.7b01914;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4" /></meta><meta name="dc.Creator" content="Qingyun  Ren" /></meta><meta name="dc.Creator" content="Xinchang  Liu" /></meta><meta name="dc.Creator" content="Guanghua  Yan" /></meta><meta name="dc.Creator" content="Biao  Nie" /></meta><meta name="dc.Creator" content="Zhifu  Zou" /></meta><meta name="dc.Creator" content="Jing  Li" /></meta><meta name="dc.Creator" content="Yunfu  Chen" /></meta><meta name="dc.Creator" content="Yu  Wei" /></meta><meta name="dc.Creator" content="Jianzhou  Huang" /></meta><meta name="dc.Creator" content="Zhonghua  Luo" /></meta><meta name="dc.Creator" content="Baohua  Gu" /></meta><meta name="dc.Creator" content="Siegfried  Goldmann" /></meta><meta name="dc.Creator" content="Jiancun  Zhang" /></meta><meta name="dc.Creator" content="Yingjun  Zhang" /></meta><meta name="dc.Description" content="The inhibition of hepatitis B virus (HBV) capsid assembly is a novel strategy for the development of chronic hepatitis B (CHB) therapeutics. On the basis of the preclinical properties and clinical ..." /></meta><meta name="Description" content="The inhibition of hepatitis B virus (HBV) capsid assembly is a novel strategy for the development of chronic hepatitis B (CHB) therapeutics. On the basis of the preclinical properties and clinical ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 30, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01914" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01914" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01914" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01914" /></link>
        
    
    

<title>3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01914" /></meta><meta property="og:title" content="3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0018.jpeg" /></meta><meta property="og:description" content="The inhibition of hepatitis B virus (HBV) capsid assembly is a novel strategy for the development of chronic hepatitis B (CHB) therapeutics. On the basis of the preclinical properties and clinical results of GLS4, we carried out further investigation to seek a better candidate compound with appropriate anti-HBV potency, reduced hERG activity, decreased CYP enzyme induction, and improved pharmacokinetic (PK) properties. To this end, we have successfully found that morpholine carboxyl analogues with comparable anti-HBV activities to that of GLS4 showed decreased hERG activities, but they displayed strong CYP3A4 induction in a concentration-dependent manner, except for morpholine propionic acid analogues. After several rounds of modification, compound 58 (HEC72702), which had an (R)-morpholine-2-propionic acid at the C6 position of its dihydropyrimidine core ring, was found to display no induction of the CYP1A2, CYP3A4, or CYP2B6 enzyme at the high concentration of 10 μM. In particular, it demonstrated a good systemic exposure and high oral bioavailability and achieved a viral-load reduction greater than 2 log in a hydrodynamic-injected (HDI) HBV mouse model and has now been selected for further development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01914"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01914">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01914&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01914&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01914&amp;href=/doi/10.1021/acs.jmedchem.7b01914" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 1355-1374</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b01845" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b01388" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">3-((<i>R</i>)-4-(((<i>R</i>)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qingyun++Ren">Qingyun Ren</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-0000-0417" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xinchang++Liu">Xinchang Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guanghua++Yan">Guanghua Yan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Biao++Nie">Biao Nie</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhifu++Zou">Zhifu Zou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Li">Jing Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yunfu++Chen">Yunfu Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yu++Wei">Yu Wei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jianzhou++Huang">Jianzhou Huang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhonghua++Luo">Zhonghua Luo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Baohua++Gu">Baohua Gu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Siegfried++Goldmann">Siegfried Goldmann</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-4776-0360" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiancun++Zhang">Jiancun Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yingjun++Zhang">Yingjun Zhang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">The State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan 523871, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Anti-infection Innovation Department, New Drug Research Institute, HEC Pharma Group, Dong Guan 523871, China</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China</span></div><div class="corresp-info"><strong>*</strong>Tel.: +86 18676907182, E-mail: <a href="/cdn-cgi/l/email-protection#e193848f90888f8698948fa1898482cf828f"><span class="__cf_email__" data-cfemail="e7958289968e89809e9289a78f8284c98489">[email protected]</span></a> (Q.R.).</div><div class="corresp-info"><strong>*</strong>Tel.: +86 13925592278, E-mail: <a href="/cdn-cgi/l/email-protection#364c5e5758514f5f58515c4358765e5355185558"><span class="__cf_email__" data-cfemail="92e8faf3fcf5ebfbfcf5f8e7fcd2faf7f1bcf1fc">[email protected]</span></a> (Y.Z.).</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01914&amp;href=/doi/10.1021%2Facs.jmedchem.7b01914" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 1355–1374</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 30, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>28 December 2017</li><li><span class="item_label"><b>Published</b> online</span>30 January 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 February 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01914" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01914</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1355%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DQingyun%2BRen%252C%2BXinchang%2BLiu%252C%2BGuanghua%2BYan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D3%26contentID%3Dacs.jmedchem.7b01914%26title%3D3-%2528%2528R%2529-4-%2528%2528%2528R%2529-6-%25282-Bromo-4-fluorophenyl%2529-5-%2528ethoxycarbonyl%2529-2-%2528thiazol-2-yl%2529-3%252C6-dihydropyrimidin-4-yl%2529methyl%2529morpholin-2-yl%2529propanoic%2BAcid%2B%2528HEC72702%2529%252C%2Ba%2BNovel%2BHepatitis%2BB%2BVirus%2BCapsid%2BInhibitor%2BBased%2Bon%2BClinical%2BCandidate%2BGLS4%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1374%26publicationDate%3DFebruary%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01914"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1930</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">9</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01914" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Qingyun&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Xinchang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Guanghua&quot;,&quot;last_name&quot;:&quot;Yan&quot;},{&quot;first_name&quot;:&quot;Biao&quot;,&quot;last_name&quot;:&quot;Nie&quot;},{&quot;first_name&quot;:&quot;Zhifu&quot;,&quot;last_name&quot;:&quot;Zou&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Yunfu&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Yu&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Jianzhou&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Zhonghua&quot;,&quot;last_name&quot;:&quot;Luo&quot;},{&quot;first_name&quot;:&quot;Baohua&quot;,&quot;last_name&quot;:&quot;Gu&quot;},{&quot;first_name&quot;:&quot;Siegfried&quot;,&quot;last_name&quot;:&quot;Goldmann&quot;},{&quot;first_name&quot;:&quot;Jiancun&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Yingjun&quot;,&quot;last_name&quot;:&quot;Zhang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;1355-1374&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01914&quot;},&quot;abstract&quot;:&quot;The inhibition of hepatitis B virus (HBV) capsid assembly is a novel strategy for the development of chronic hepatitis B (CHB) therapeutics. On the basis of the preclinical properties and clinical results of GLS4, we carried out further investigation to seek a better candidate compound with appropriate anti-HBV potency, reduced hERG activity, decreased CYP enzyme induction, and improved pharmacokinetic (PK) properties. To this end, we have successfully found that morpholine carboxyl analogues with comparable anti-HBV activities to that of GLS4 showed decreased hERG activities, but they displayed strong CYP3A4 induction in a concentration-dependent manner, except for morpholine propionic acid analogues. After several rounds of modification, compound 58 (HEC72702), which had an (R)-morpholine-2-propionic acid at the C6 position of its dihydropyrimidine core ring, was found to display no induction of the CYP1A2, CYP3A4, or CYP2B6 enzyme at the high concentration of 10 μM. In particular, it demonstrated a good sy&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01914&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01914" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01914&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01914" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01914&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01914" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01914&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01914&amp;href=/doi/10.1021/acs.jmedchem.7b01914" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01914" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01914" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01914%26sid%3Dliteratum%253Aachs%26pmid%3D29381358%26genre%3Darticle%26aulast%3DRen%26date%3D2018%26atitle%3D3-%2528%2528R%2529-4-%2528%2528%2528R%2529-6-%25282-Bromo-4-fluorophenyl%2529-5-%2528ethoxycarbonyl%2529-2-%2528thiazol-2-yl%2529-3%252C6-dihydropyrimidin-4-yl%2529methyl%2529morpholin-2-yl%2529propanoic%2BAcid%2B%2528HEC72702%2529%252C%2Ba%2BNovel%2BHepatitis%2BB%2BVirus%2BCapsid%2BInhibitor%2BBased%2Bon%2BClinical%2BCandidate%2BGLS4%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D3%26spage%3D1355%26epage%3D1374%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291012" title="Organic acids">Organic acids</a>,</li><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/3" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/jmcmar.2018.61.issue-3/20180208/jmcmar.2018.61.issue-3.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01914&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The inhibition of hepatitis B virus (HBV) capsid assembly is a novel strategy for the development of chronic hepatitis B (CHB) therapeutics. On the basis of the preclinical properties and clinical results of GLS4, we carried out further investigation to seek a better candidate compound with appropriate anti-HBV potency, reduced hERG activity, decreased CYP enzyme induction, and improved pharmacokinetic (PK) properties. To this end, we have successfully found that morpholine carboxyl analogues with comparable anti-HBV activities to that of GLS4 showed decreased hERG activities, but they displayed strong CYP3A4 induction in a concentration-dependent manner, except for morpholine propionic acid analogues. After several rounds of modification, compound <b>58</b> (HEC72702), which had an (<i>R</i>)-morpholine-2-propionic acid at the C6 position of its dihydropyrimidine core ring, was found to display no induction of the CYP1A2, CYP3A4, or CYP2B6 enzyme at the high concentration of 10 μM. In particular, it demonstrated a good systemic exposure and high oral bioavailability and achieved a viral-load reduction greater than 2 log in a hydrodynamic-injected (HDI) HBV mouse model and has now been selected for further development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38426" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38426" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">HBV infection is a serious global public-health problem, with more than 350 million people, especially in Asia-Pacific regions, chronically infected by this small enveloped DNA virus. The disease progression for many of the infected persons will finally develop into more life-threatening diseases, such as liver failure, cirrhosis, or hepatocellular carcinomas (HCC).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> It has been estimated that HBV infections directly or indirectly account for the deaths of 600 000 patients annually. Current treatment regimens rely mainly on the use of interferon-α (IFN) and nucleoside- or nucleotide-based reverse-transcriptase inhibitors. However, the clinical use of IFN and peg-IFN is limited by their low response rates (20–30%) among CHB patients and a slew of side effects, such as flu-like symptoms, anemia, leucopenia, thrombocytopenia, anorexia, and depression.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> A major drawback of the nucleotide analogues is the emergence of drug resistance during long-term treatment, with approximately 70% of patients becoming resistant to lamivudine;<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> resistance to entecavir also occurs among lamivudine-pretreated patients at a rate of 43% after 4 years.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In order to improve the treatment of CHB and reduce drug resistance, the development of novel agents with different therapeutic targets besides viral polymerase is highly necessary.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">The HBV capsid plays indispensable roles in viral DNA synthesis from the pregenome and in intracellular trafficking. HBV persistence and transmission require HBV replication, which depends on the assembly of a nucleocapsid composed of capsid proteins, reverse transcriptase, and pregenomic RNA.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Furthermore, the encapsidation of HBV pregenomic RNA (pgRNA) is an evolutionarily constrained process,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and this genetic stability makes HBV-capsid formation a better drug target against various genotypes of HBV polymerase-resistant mutants.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p">Some phenylpropenamide derivatives, such as <b>1</b> (AT-61), <b>2</b> (AT-130),<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a> the sulfamoylbenzamide <b>3</b> (DVR23),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and <b>4</b> (isothiafludine),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>, have been shown to inhibit pgRNA packaging, which leads to the formation of pgRNA-free empty capsids. These agents were found to be potent against HBV replication in various human hepatoma cell lines. Among them, NVR-3778 (unreported structure), a sulfamoylbenzamide compound, has progressed into phase I, and the clinical-phase Ib results show that at a dosage of 600 mg twice daily (b.i.d.), this compound could reduce serum HBV-DNA levels to 1.72 log 10.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Jassen has also completed the phase I clinical trials of JNJ-379 (unreported structure), which is reported to possess the same mechanism as NVR-3778 but with improved efficacy and a better safety profile.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of the reported HBV-capsid inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01914&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Bay 41-4109 (<b>5</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) has been reported to disrupt or misdirect the assembly of the HBV capsid, which leads to capsid depletion and then termination of the viral replication process.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> Bay 41-4109 was shown to prevent HBV infections in a transgenic HBV model by reducing HBV viral DNA in the liver and plasma, but it was found to be hepatotoxic at high doses in rats; thus, the follow-up studies of this compound were suspended.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> A currently reported compound in clinical stage I with a similar mechanism as Bay 41-4109 was RG7689 (unreported structure), and preclinical experiments of this compound showed that it could suppress viral replication continually and prevent the formation of new cccDNA.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a></div><div class="NLM_p">GLS4 (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) also possesses the same mechanism as BAY41-4109, having been developed as a capsid inhibitor, and is currently in the phase II clinical stage. The preclinical anti-HBV efficacy, mechanism of action, and pharmacological properties of GLS4 have been recently published in several articles.<a onclick="showRef(event, 'ref22 ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24 ref25">(22-25)</a> It was reported that GLS4 demonstrated potent inhibitory activities against wild and various drug-resistant HBV strains in a HepG2-cell-transfection assay. However, it was found that GLS4 alone could not achieve anticipated blood concentrations to show the desired antiviral effect in phase I clinical trials, which likely resulted from its fast metabolism and moderate induction of the CYP3A4 enzyme (see <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). To address this problem, a combination of GLS4 and ritonavir (RTV) was used in the ensuing clinical trials. This approach proved to be successful, with significant increases in the plasma concentrations in the healthy volunteers and substantial decreases in HBV-DNA levels in CHB patients.</div><div class="NLM_p">Some drugs have been withdrawn from the market because of prolonged QT intervals due to hERG inhibition.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> At first glance, GLS4 might cause some concerns of a QT-prolongation risk, because of its moderate inhibition of the hERG channel (hERG IC<sub>50</sub> = 1.34 μM, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). However, after careful reasoning and assessment, we believe that GLS4 should be safe enough for humans because of following results: (i) the safety window of GLS4 is large enough (hERG IC<sub>50</sub>/EC<sub>50</sub> > 1000), (ii) no cardiac toxicity is associated with hERG in 6 month repeated toxicity tests with mice and 9 month repeated toxicity tests with beagle dogs, and (iii) no obvious side effects have been observed so far from monitoring cardiac-toxicity-associated indicators (QT durations) in clinical trials. In conclusion, GLS4 was found to be safe enough in clinical trials, and continuing clinical trials are currently underway. However, having the potential safety risk of the use of GLS4 in the long-term treatment of HBV patients in mind, we aimed to search for a second-generation backup compound for GLS4. Thus, we set out with the goal of finding a backup compound for GLS4 with the appropriate anti-HBV potency, significantly reduced hERG activity, decreased induction of the CYP enzyme, and improved pharmacokinetic (PK) properties. Herein, we report the discovery of compound <b>58</b>, which appeared to be free of all the drawbacks associated with GLS4 and has been selected for further development as an oral anti-HBV-infection agent.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Anti-HBV Activities and hERG Activities of Molecules Generated via C2 and C4 Modifications</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0006.gif" alt="" id="GRAPHIC-d46e430-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0007.gif" alt="" id="gr6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> represents the mean values for the reduction of HBV-DNA levels by 50% in HepG.2.2.15 cells. Experiments were done in duplicate with variations of <15%.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">hERG IC<sub>50</sub> represents the mean values for the 50% inhibition of hERG in CHO cells (<i>N</i> = 3). Cisapride was used as a positive control, and the maximum concentration used was 10 μM. IC<sub>50</sub> > 10 μM is reported if the inhibition at 10 μM is lower than 50%.</p></div></div><div></div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57074" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57074" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Structure and hERG Activity</h3><div class="NLM_p">To ameliorate the hERG inhibition of GLS4, we started to search for a backup compound for GLS4. We set to design and synthesize new derivatives with reduced or diminished hERG activity. Common approaches to decrease hERG activity include structural modifications, formation of zwitterions, control of lipophilicity, and attenuation of the p<i>K</i><sub>a</sub> of the molecule.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> To this end, we first separated the racemate of GLS4 and found that the <i>R</i> and <i>S</i> enantiomers showed no difference in their hERG activities (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Then, we replaced the dihydropyrimidine core with triazine and several other fused heterocycles to give compounds <b>6</b>–<b>9</b>. The dihydropyrimidine core was oxidized to give pyrimidine compound <b>10</b>, and N-alkylation with a hydrophilic hydroxyethyl halide gave compound <b>11</b>. As shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, although these compounds displayed decreased hERG inhibitions (for compound <b>10</b>, hERG IC<sub>50</sub> > 10 μM), they also exhibited dramatic drops in their anti-HBV activities (EC<sub>50</sub> > 16.4 μM). Thus, we started to modify the peripheral substituents while keeping the dihydropyrimidine core ring unchanged.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Previous design structure of molecules from GLS4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01914&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our previous studies indicated that the ester group at the C5 position of GLS4 (see structure of GLS4 for the numbering convention) contacted a limited hydrophobic pocket so that polar and large groups were generally not tolerated.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> After investigating various ester substitutions at the C5 position, we found that only the methyl ester and ethyl ester were well tolerated. We therefore decided to focus on conducting further modifications at the C2, C4, and C6 positions of the core dihydropyrimidine structure to improve or retain anti-HBV activity while decreasing hERG-inhibitory activity. The reported cocrystal structure (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2G34">2G34</a>)<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> indicated that the C4 position of the core dihydropyrimidine was located in a conserved and large hydrophobic pocket, and we also found that bulky groups, such as biphenyl groups, and hydrophilic substituents, such as carboxyl groups, were not tolerated.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Thus, we made some small changes on the substituents at the C4 phenyl and found that these changes had no significant effect on anti-HBV activity (GLS4, <b>12</b>, <b>13</b>, and <b>14</b>; <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). These compounds, however, showed no obvious improvement in their hERG activities. It was also observed that the hERG activities of these compounds increased with increasing cLogP. The order of the hERG activities of compounds GLS4 to <b>14</b> was as follows: <b>13</b> (hERG IC<sub>50</sub> = 0.30 μM, cLogP = 5.17) > GLS4 (hERG IC<sub>50</sub> = 1.34 μM, cLogP = 4.75) > <b>12</b> (hERG IC<sub>50</sub> = 2.31 μM, cLogP = 4.60) > <b>14</b> (hERG IC<sub>50</sub> = 4.04 μM, cLogP = 4.45). Replacement of the 2-bromine atom on the 4-phenyl group in GLS4 with NO<sub>2</sub> or phenyl gave compounds <b>15</b> and <b>16</b>, but these two compounds were less active against HBV than GLS4, and their hERG activities showed no obvious improvements.</div><div class="NLM_p">Next, we investigated the modification at the C2 position. Replacing the C2 thiazolyl with thiadiazolyl and thiophenyl resulted in compounds <b>17</b> and <b>18</b>, respectively. These two compounds showed similar anti-HBV activities to each other but decreased activities in comparison with GLS4. In the hERG-activity studies, compound <b>17</b> showed decreased hERG inhibition (IC<sub>50</sub> = 3.49 μM), whereas compound <b>18</b> showed increased hERG activity (IC<sub>50</sub> = 0.9 μM). Apparently, lipophilicity was a key determinant for the cLogP of the 2-thiophenyl compound, <b>18</b>, being much higher than that of compound <b>17</b> (cLogP = 6.05 vs 3.66). Further replacement of the thiazolyl group in GLS4 with pyridine, <i>N</i>-methyl-imidazole, triazole, and substituted thiazole led to compounds <b>19</b>, <b>20</b>, <b>21</b>, <b>23</b>, and <b>24</b>, but none of these compounds showed obvious improvements in hERG inhibition. However, we found that modification with a tetrazole at the C2 position (compound <b>22</b>) showed decreased hERG activity (IC<sub>50</sub> > 10 μM) but at the expense of decreased anti-HBV activity (EC<sub>50</sub> > 16.4 μM). The 3-methyl acetate of thiazole <b>24</b> was hydrolyzed to carboxylic acid to give compound <b>25</b>, which showed decreased hERG activity (IC<sub>50</sub> > 10 μM), but this compound also lost the anti-HBV activity. On the basis of the above results, we believed that it would be difficult to obtain compounds with optimal anti-HBV activities and low hERG activities when the structure modifications were made on the C2 and C4 positions of dihydropyrimidine, and importantly, it seemed possible to reduce hERG activity when a hydrophilic group, such as carboxylic acid or tetrazole, was introduced.</div><div class="NLM_p">On the basis of the preliminary SARs at the C2 and C4 positions, we decided to introduce less lipophilic or hydrophilic groups to the C6 position by replacing the morpholine moiety of GLS4 (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). First, the substitution of the morpholine group with thiomorpholine monoxide or dioxide led to compounds <b>26</b> and <b>27</b> whose anti-HBV activities were about 10 times less than that of GLS4. The more hydrophilic thiomorpholine monoxide, <b>26</b>, showed less hERG inhibition than thiomorpholine dioxide, <b>27</b>. It was further confirmed that the hERG activity could be adjusted by lipophilicity, and thus some hydrophilic groups, such as phenylalanine and proline, were introduced. The resultant compounds, <b>28</b> and <b>29</b>, exhibited moderate anti-HBV activities and lower hERG activities. The common “bioisosteres” of proline, piperdine carboxylic acid and piperazine carboxylic acid, on the C6 position led to compounds <b>30</b> and <b>31</b>, which showed decreased hERG inhibitions and lower anti-HBV activities. It seemed reasonable that compounds <b>30</b> and <b>31</b> showed decreased anti-HBV activities because a polar carboxylic acid substituent was not tolerated in the large hydrophobic binding pocket located at the interface of the capsid dimers. However, to our delight, the introduction of various morpholine carboxyl groups at the C6 position, affording compounds <b>32</b>, <b>33</b>, and <b>34</b>, resulted in comparable anti-HBV activities to that of GLS4 and lower hERG inhibitions (hERG IC<sub>50</sub> > 10 μM). Moreover, an additional methyl group, as in compound <b>35</b> (EC<sub>50</sub> = 0.0093 μM), resulted in a 5-fold higher potency than that of <b>32</b> (EC<sub>50</sub> = 0.043 μM). In contrast, the dimethyl morpholine carboxylic acid analogue, <b>36</b>, demonstrated reduced anti-HBV activity (EC<sub>50</sub> = 3.924 μM), suggesting that the substituent position of the methyl was important.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Anti-HBV Activities and hERG Activities of Molecules Generated via C6 Modifications</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0008.gif" alt="" id="GRAPHIC-d46e714-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0009.gif" alt="" id="gr7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a,b</sup><p class="last">The definitions of EC<sub>50</sub> and hERG IC<sub>50</sub> are the same as those described in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>.</p></div></div><div></div></div><div class="NLM_p">Further derivatization of the carboxylic acid of <b>32</b> gave rise to esters <b>37</b> and <b>38</b>, carboxamides <b>39</b> and <b>40</b>, sulfonamide <b>41</b>, and alcohols <b>42</b> and <b>43</b>, and all of these compounds maintained low hERG activities. Among them, <b>37</b>, <b>38</b>, <b>39</b>, <b>42</b>, and <b>43</b> showed increased or comparable anti-HBV potencies to that of GLS4. Large substitutions on the morpholine carboxyls of the ester and carboxamide were did not result in good anti-HBV activities, as in <b>40</b> and <b>41</b>. Although the ester <b>37</b> and the carboxamide <b>39</b> displayed favorable increases in anti-HBV activities and significantly decreased hERG activities as compared with those of <b>32</b> and GLS4, further development of these compounds (<b>37</b>–<b>43</b>) was not continued because of their high liver-microsome clearances (data not shown). Further studies revealed that both the substitution position and chain length of the carboxyl group were crucial for anti-HBV activity. The corresponding morpholine-2-carboxyl analogue, <b>44</b>, was much less active than <b>32</b>, and the extended acetic acid analogues, <b>45</b> and <b>46</b>, also showed reduced anti-HBV activities. In addition, to our surprise, the extended propanoic acid analogues, <b>47</b> and <b>48</b>, showed comparable anti-HBV activities to that of <b>32</b> and decreased hERG activities (hERG IC<sub>50</sub> > 10 μM).</div><div class="NLM_p">To further investigate the relationship between anti-HBV activity and hERG activity, a series of compounds with good anti-HBV activities and low hERG activities in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> were selected for chiral separation to obtain the chiral isomers to be screened.</div><div class="NLM_p">All compounds with carboxyl groups in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> showed no hERG inhibition at concentrations as high as 30 μM, except compound <b>54</b>, which bore an alcohol group and showed an hERG IC<sub>50</sub> of 24.2 μM. These data further reveal the essential role of carboxyl groups in reducing the hERG activities of the analogues of GLS4.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Anti-HBV Activities and hERG Activities of Selected Chiral Isomers</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0010.gif" alt="" id="GRAPHIC-d46e846-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0011.gif" alt="" id="gr8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">The definition of EC<sub>50</sub> is the same as that described in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">hERG IC<sub>50</sub> represents the mean values for the 50% inhibition of hERG in HEK-293 cells (<i>N</i> = 3). Quinidine is used as a positive control, and the maximum compound concentration used is 30 μM. IC<sub>50</sub> > 30 μM is reported if the inhibition at 30 μM is lower than 50%.</p></div></div><div></div></div><div class="NLM_p">Chirality is important for anti-HBV activity. It was found that the C4 <i>R</i>-configuration analogues have better anti-HBV activities than their corresponding C4 <i>S</i>-isomers. For example, without changing the C6 substituent, (<i>S</i>)-morpholine-3-carboxylic acid, the C4 <i>R</i>-configuration of compound <b>49</b>, <b>(<i>R</i>)-49</b>, showed the most potent anti-HBV activity, which was almost 400-fold more potent than that of the C4 <i>S</i>-isomer, <b>(<i>S</i>)-49</b> (0.0057 vs 2.432 μM). This was in accordance with the result that (<i>R</i>)-GLS4 also showed 400-fold greater potency than (<i>S</i>)-GLS4 (0.0098 vs 3.367 μM). In addition, we further confirmed that the (<i>S</i>)-morpholine-3-carboxylic acid analogue demonstrated better anti-HBV activity than the corresponding (<i>R</i>)-morpholine-3-carboxylic acid analogue. For example, the (<i>S</i>)-morpholine-3-carboxylic acid analogue, <b>(<i>R</i>)-49</b>, showed nearly 50-fold greater potency than the corresponding (<i>R</i>)-morpholine-3-carboxylic acid analogue, <b>(<i>R</i>)-50</b> (0.0057 vs 0.292 μM).</div><div class="NLM_p last">Substitutions on the C4 phenyl ring affect activity, and the following order of anti-HBV activity was found: 2-Cl-4-Cl (<b>49</b>, EC<sub>50</sub> = 0.0086 μM) > 2-Br-4-F (<b>53</b>, EC<sub>50</sub> = 0.019 μM) > 2-Cl-4-F (<b>51</b>, EC<sub>50</sub> = 0.024 μM), which is in agreement with earlier modification trend (such as GLS4 and compounds <b>12</b> and <b>13</b> in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). In addition, compounds with ethyl esters at the 5-position of dihydropyrimidine demonstrated about 2-fold higher potencies than compounds with methyl esters, as with compounds <b>51</b> and <b>52</b> (0.024 vs 0.047 μM). After chiral separation, the <i>R</i>-enantiomer of <b>(<i>R</i>)-53</b> showed a nearly 2-fold greater potency than racemic compound <b>53</b> (0.01 vs 0.019 μM), and the same situation occurred with <b>(<i>R</i>)-49</b> than <b>49</b> (0.0057 vs 0.0086 μM). An additional methyl introduction near the morpholine carboxyl group of <b>(<i>R</i>)-53</b> (EC<sub>50</sub> = 0.01 μM) led to <b>55</b>, which also showed a 2-fold improvement with an EC<sub>50</sub> of 0.005 μM. With a gem-dimethyl substituent on the other side of morpholine carboxyl, as in <b>(<i>R</i>)-53</b>, the anti-HBV potency was dramatically decreased, as compound <b>56</b> had an EC<sub>50</sub> of 0.914 μM. The 4,4-difluoroprolino carboxyl analogue, <b>57</b>, was highly active, with an EC<sub>50</sub> of 0.005 μM, a potency comparable to those of <b>(<i>R</i>)-52</b> and <b>55</b>. The substitution position of the propionic acid on morpholine had no consistent influence on anti-HBV activity, as compound <b>58</b> showed reduced activity compared with <b>60</b>, whereas <b>59</b> showed increased activity compared with <b>61</b>. Additionally, the influence of the absolute configuration of a propionic acid group on anti-HBV activity was studied in compounds <b>59</b> versus <b>58</b> and <b>61</b> versus <b>60</b> (EC<sub>50</sub> values of 0.094 versus 0.039 μM and 0.154 versus 0.008 μM, respectively). Once again, these analogues in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> revealed that the substitution position on the morpholine moiety (such as morpholine-2-carboxylic acid vs morpholine-3-carboxylic acid), the chain length of the carboxyl group (such as formic acid vs propionic acid), and the absolute configuration of the carboxylic acid group (such as <i>R</i>-carboxylic acid vs <i>S</i>-carboxylic acid) directly influenced anti-HBV activity but had no obvious influence on hERG activity, as all of these compounds showed no sign of hERG inhibition (IC<sub>50</sub> > 30 μM). This is probably because of the introduction of the carboxyl group, which led to reduced lipophilicity and basicity or a certain amount of zwitterions.</div></div><div id="sec2-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Induction Effect of CYP3A4</h3><div class="NLM_p">It was reported that the CYP3A4 induction of 4-<i>H</i> heteroaryldihydropyrimidine (HAP) analogues was likely related to the 4-<i>H</i> HAP core, as over 250 compounds of 4-<i>H</i> HAP were screened and most of them were found to have CYP3A4-induction liabilities.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Our previous studies also showed that most of the GLS4-like compounds possessed potent inductions of CYP3A4 enzymes (>40% increases compared with the positive control rifampicin at 10 μM). Although the series of compounds shown in <a class="ref internalNav" href="#tbl2" aria-label="Tables 2">Tables 2</a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> showed favorable potencies and decreased hERG inhibitions, we continued to investigate their CYP-enzyme-induction properties. After excluding the nonactive compounds in <a class="ref internalNav" href="#tbl2" aria-label="Tables 2">Tables 2</a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> and taking into consideration the effects of different substituents on the C2, C4, and C6 positions and the effects of the chiral isomers, some representative compounds were selected for further studies of their induction activities on the CYP3A4 enzyme. As shown in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>, the more potent enantiomer displayed higher induction activity than the less potent enantiomer. For example, <b>(<i>R</i>)-49</b> showed a 103.5% increase of CYP3A4-enzyme activity, whereas <b>(<i>S</i>)-49</b>, which has weaker anti-HBV activity, showed no induction (<40% increase compared with rifampicin). A similar trend was observed with the anti-HBV activities and induction abilities of the GLS4 enantiomers, <i>R</i>-GLS4 and <i>S</i>-GLS4. In addition, the compounds induced the CYP3A4 enzyme in a concentration-dependent manner. For example, compound <b>53</b> displayed no induction of CYP3A4 at lower concentrations (0.05–0.5 μM), but it showed serious induction effects at the higher concentration of 1 μM. At a concentration of 1 μM, the selected compounds with potent anti-HBV activities, such as the morpholine-3-carboxylic acid analogue, <b>53</b>; derivatives of <b>53</b> such as <b>55</b> and the carboxamide <b>40</b>; and the 4,4-difluoroproline carboxylic acid analogue, <b>57</b>, also showed strong CYP3A4 inductions.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Relative Induction Values of the CYP3A4 Enzyme by the Selected Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0012.gif" alt="" id="GRAPHIC-d46e1162-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0013.gif" alt="" id="gr9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Experiments were done in human primary hepatocytes (<i>N</i> = 3). The positive control had a minimum of a 2-fold increase in enzyme activity. The cutoff of a true inducer of P450 activity in vitro is generally considered to be 40% of the positive control.</p></div></div><div></div></div><div class="NLM_p">Minor variations of the C4 phenyl showed no obvious CYP3A4-induction changes, as compounds <b>49</b> (2-Cl-4-Cl), <b>53</b> (2-Br-4-F), and <b>(<i>R</i>)-52</b> (2-Cl-4-F) displayed similar induction effects on CYP3A4 at the same concentration of 1 μM. To investigate the effect of the 2-heterocycle substituent (C2 position) on CYP3A4 induction, we replaced the thiazole group with <i>N</i>-methyl imidazole to obtain compound <b>62</b>. Although this compound showed no significant induction of CYP3A4 at the concentration of 1 μM, it was found to be a strong inducer conferring a 50.8% increase at a concentration of 10 μM. The extended carboxyl analogues of <b>46</b>, which possessed a morpholine acetic acid at the C6 position, also showed dose-dependent CYP3A4 induction. In addition, it is surprising to find that compound <b>58</b>, which possessed an (<i>R</i>)-morpholine-2-propionic acid at the C6 position displayed inconspicuous induction of CYP3A4 at either concentration of 1 or 10 μM.</div><div class="NLM_p">On the basis of the observation that the (<i>R</i>)-morpholine-2-propionic acid analogue, <b>58</b>, possessed good anti-HBV activity and decreased induction of the CYP3A4 enzyme, we further tested the anti-HBV activities of several compounds with morpholine-propionic acid moieties and tested their induction effects on the CYP3A4 enzyme at concentrations of 1 μM. The results revealed that both the substitution position and stereochemistry of the propionic acid group were crucial for the anti-HBV activity and ability to induce the CYP3A4 enzyme. As shown in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>, the (<i>S</i>)-morpholine-2-propionic acid analogue, <b>59</b>, showed about 3-fold-reduced anti-HBV activity than <b>58</b> while displaying the same induction of the CYP3A4 enzyme as <b>58</b>. In addition, the anti-HBV activity of (<i>R</i>)-morpholine-3-propionic acid analogue <b>61</b> was 20 times lower than that of the <i>S</i>-analogue, compound <b>60</b>, but <b>61</b> showed a little more CYP3A4-enzyme induction than <b>60</b> (>40% for <b>61</b> vs 17.9% for <b>60</b>). It was also found that the methyl ester analogues, <b>63</b>, <b>64</b>, and <b>65</b>, which had different substituents on their C4 phenyls, showed decreased induction effects compared with that of <b>58</b> and lower anti-HBV activities than that of <b>58</b>. It was very fulfilling to find that the (<i>S</i>)-morpholine-3-propionic acid analogue, <b>60</b>, not only exhibited greater potency than the (<i>R</i>)-morpholine-2-propionic acid analogue, <b>58</b>, with an EC<sub>50</sub> value of 0.008 μM, but it also displayed a weak induction effect. The (<i>S</i>)-difluoropyrrolidine-2-propionic acid analogue, <b>66</b>, had a slightly decreased induction ability and less anti-HBV activity compared with those of <b>60</b> and <b>58</b>. On the basis of the above results, we concluded that the morpholine propionic acid played an essential role in decreasing the CYP3A4-induction capability, as unsubstituted morpholine, morpholine formic acid, and morpholine acetic acid analogues showed strong induction effects on the CYP3A4 enzyme.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Anti-HBV Activities and Relative Induction Values of the CYP3A4 Enzyme by Selected Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0014.gif" alt="" id="GRAPHIC-d46e1303-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0015.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">The definition of EC<sub>50</sub> is the same as that described in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>.</p></div><div class="footnote" id="t5fn2"><sup>Table b</sup><p class="last">The definition of % of positive control is the same as that described in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>.</p></div></div><div></div></div></div><div id="sec2-3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Molecular-Docking Studies</h3><div class="NLM_p">In our previously published study, we demonstrated that GLS4 could prevent the normal assembly of core proteins and lead to aberrant formation of the capsid.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Furthermore, in an AAV-HBV model (chronic infection), GLS4 treatment significantly reduced intrahepatic HBc levels as determined by immunohistochemistry (IHC) of liver sections (unpublished data). As derivatives of GLS4 with similar structures and in the class of 4-<i>H</i> HAP compounds, compound <b>58</b> and the other analogues were supposed to have similar mechanisms of action as GLS4.</div><div class="NLM_p">Klumpp<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> has recently reported the cocrystal structure of the Cp149 Y132A-mutant hexamer in complex with compound NVR-010-001-E2 (an analogue of GLS4), which supports the result that the introduction of a morpholine group on BAY41-4109 could improve anti-HBV activity. In the article, Klumpp proposed that optimizations focusing on the replacement of this morpholine group would lead to improved protein interactions. To explore the interaction mode of the GLS4 analogues with the active site of the HBV capsid protein, several molecular-docking-simulation studies were carried out by using the SURFLEX module of the SYBYL package. The crystal coordinates of the capsid (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5E0I">5E0I</a>) were downloaded from protein data bank (<a href="http://www.rcsb.org" class="extLink">www.rcsb.org</a>), and compounds <b>58</b> and <b>60</b> were used as ligand examples.</div><div class="NLM_p">As shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>, both compounds are well docked in the active site of the crystal coordinate of <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5E0I">5E0I</a>. For both compounds, the substituted phenyl group fits into the well-defined, largely hydrophobic pocket created by Pro25, Asp29, Leu30, Thr33, Trp102, and Ile105, with the bromine pointing toward the protein and deep into the hydrophobic pocket. Given the limited space around the substituted phenyl group, large substituents are generally not well tolerated. The thiazole moiety on each of these two compounds is coplanar with the dihydropyrimidine core, as anticipated, and is buried in a hydrophobic environment created by the aromatic residues Phe23, Pro25, Tyr118, Trp102, and Thr128. Moreover, a water-bridged HB network exists between the 2-thiazole and Leu140, and a π–π interaction is found between the thiazole residue and Phe23. The N3 atom of the dihydropyrimidine ring forms a hydrogen bond with the main-chain nitrogen of Trp102. The ester moiety on each of these two compounds contacts the outer rim of a pocket formed by Leu37 and Thr109, so that polar and large groups may not be favored at this position. Compared with <b>58</b>, <b>60</b> has achieved an approximately 5-fold improvement in antiviral activity, which can be clarified from the different binding effects of these two compounds with the core protein dimer. As shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>, the carboxylic acid moiety of <b>60</b> makes a water-bridged HB interaction with Ser121, whereas the carboxylic acid moiety of <b>58</b> cannot make HB interactions with Ser121 in the binding site. Interestingly, the oxygen atom of the morpholino group of compound <b>58</b> could form a double water-bridged HB interaction with Ser121, though it shows reduced activity relative to that of <b>60</b>. Apart from the docking simulation, which showed that compound <b>58</b> could interact with the HBV-capsid-protein dimer, the activity of compound <b>58</b> against HBV-capsid assembly was also demonstrated in an HBV-capsid-assembly-quenching assay, in which it had an IC<sub>50</sub> value of 0.14 μM.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Optimal-binding model for compounds <b>58</b> (left) and <b>60</b> (right) in the active site of the capsid docked by the SURFLEX module. The ligand is shown in sticks, and some key residues are shown in lines. Hydrogen bonds are shown in dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01914&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2-4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Microsome Stability and PK</h3><div class="NLM_p">On the basis of their anti-HBV activities, hERG inhibitions, and CYP3A4-enzyme inductions, a few analogues were selected for further in vitro liver-microsome-stability tests and in vivo pharmacokinetic studies in rats. Previous investigations indicated that the major metabolic pathway of GLS4 was often associated with N–C and O–C cleavages of the 6-morpholine moiety. It was hypothesized that the introduction of substituents on the morpholine would lead to decreased metabolism and improved exposure. As shown in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>, <b>(<i>R</i>)-53</b> showed improved metabolic stability in three types of liver microsomes compared with that of GLS4 and correspondingly increased systemic exposure. It should be noted that the oral exposure increased much more than the exposure by the intravenous route, which suggested that the introduction of the polar carboxylic acid also led to higher aqueous solubility. Thus, compound <b>(<i>R</i>)-53</b> displayed better oral bioavailability. In addition, compound <b>55</b>, which had an additional methyl substitution on the side of the carboxylic acid, showed more metabolic stability than <b>(<i>R</i>)-53</b> and also displayed increased systemic exposure compared with that of <b>(<i>R</i>)-53</b> whether by intravenous (iv) or oral (po) administration. These results indicated that when the metabolic hot spots on the morpholine group of GLS4 were blocked, the plasma concentration and systemic exposure of the parent drug would increase.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Anti-HBV Activities, Microsome Stabilities, and Pharmacokinetics of Selected Compounds in Rats</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0016.gif" alt="" id="GRAPHIC-d46e1454-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0017.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">The definition of EC<sub>50</sub> is the same as that described in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>.</p></div><div class="footnote" id="t6fn2"><sup>Table b</sup><p class="last">Scaled intrinsic clearances in human liver microsomes (HLM), mouse liver microsomes (MLM) and dog liver microsomes (DLM). Experiments were run in duplicate, with variations of <10%.</p></div><div class="footnote" id="t6fn3"><sup>Table c</sup><p class="last">Single-dose-pharmacokinetics (SDPK) studies of selected compounds were carried out in rats according to standard procedures. The major parameters, including the area under the curve (AUC), plasma clearance (CL), volume of distribution at steady state (<i>V</i><sub>ss</sub>), and oral bioavailability (<i>F</i>) are reported.</p></div></div><div></div></div><div class="NLM_p">In addition, both the substitution position and stereochemistry of the propionic acid group were crucial for metabolic stabilities and pharmacokinetic properties. The metabolic stabilities of the analogues with propionic acid groups (<b>58</b>, <b>59</b>, <b>60</b>, and <b>66</b>) were assessed in vitro in mouse-, dog-, and human-liver-microsome assays. In the experiment, all four of these compounds were more stable in the human and dog liver microsomes than in the mouse liver microsomes. Compound <b>60</b> was highly potent in vitro and showed no induction of the CYP3A4 enzyme, but its low systemic exposure prevented its further development. In addition, compounds <b>59</b> and <b>66</b> also showed higher clearances and lower systemic exposures in rats. To our delight, compound <b>58</b> displayed greatly increased systemic exposures and low clearances by both intravenous (iv) and oral (po) routes even though its metabolic stability in mouse liver microsomes was not satisfactory. We reasoned that <b>58</b> would show much higher exposure when dosed in large animals, such as beagle dogs, as it was stable in dog and human liver microsomes.</div><div class="NLM_p">The PK profile of <b>58</b> was further evaluated in beagle dogs. As shown in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>, <b>58</b> exhibited longer half-lives of 5.7 h (iv) and 5.1 h (po) as well as a lower plasma clearance of 1.93 mL/min/kg, and it also showed a high systemic exposure with areas under the curves (AUC) of 16 540 h·ng/mL (iv) and 47 900 h·ng/mL (po) with an oral bioavailability (<i>F</i>) of 114.1%. Although the half-life of compound <b>58</b> is shorter than that of GLS4, the drug exposure and the concentration 24 h after the oral dose (<i>C</i><sub>24</sub>, 232 ng/mL) for compound <b>58</b> were much higher than those of GLS4 (AUC = 1008 h·ng/mL, <i>C</i><sub>24</sub> = 9 ng/mL). Considering GLS4 is dosed b.i.d. in combination with ritonavir to increase its drug exposure in the current clinical study, both once daily (q.d.) and b.i.d. dosings of compound <b>58</b> will be evaluated in the further clinical experiments to determine the best dosing regimen. The good systemic exposure and oral bioavailability of <b>58</b> in beagle dogs suggested that this compound could have desirable PK properties in human, as the liver microsome stability of <b>58</b> displayed similar tendencies in beagle dogs and human liver microsomes.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Pharmacokinetics of GLS4 and <b>58</b> in Beagle Dogs<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">AUC<sub>0–24h</sub> (h·ng/mL)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>24</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2">GLS4</td><td class="colsep0 rowsep0">iv (2)</td><td class="colsep0 rowsep0" align="center">1472</td><td class="colsep0 rowsep0" align="center">1423</td><td class="colsep0 rowsep0" align="center">15</td><td class="colsep0 rowsep0" align="center">17.9</td><td class="colsep0 rowsep0" align="center">15.83</td><td class="colsep0 rowsep0" align="center">16.6</td><td class="colsep0 rowsep0" align="center">23.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">po (5)</td><td class="colsep0 rowsep0" align="center">1008</td><td class="colsep0 rowsep0" align="center">391</td><td class="colsep0 rowsep0" align="center">9</td><td class="colsep0 rowsep0" align="center">11.5</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2"><b>58</b></td><td class="colsep0 rowsep0">iv (2)</td><td class="colsep0 rowsep0" align="center">16 540</td><td class="colsep0 rowsep0" align="center">2050</td><td class="colsep0 rowsep0" align="center">47</td><td class="colsep0 rowsep0" align="center">5.71</td><td class="colsep0 rowsep0" align="center">0.76</td><td class="colsep0 rowsep0" align="center">1.93</td><td class="colsep0 rowsep0" align="center">114.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">po (5)</td><td class="colsep0 rowsep0" align="center">47 900</td><td class="colsep0 rowsep0" align="center">6330</td><td class="colsep0 rowsep0" align="center">232</td><td class="colsep0 rowsep0" align="center">5.1</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">Single-dose pharmacokinetics (SDPK) studies of selected compounds were carried out in beagle dogs according to standard procedures. The major parameters, including the area under the curve (AUC), maximal concentration (<i>C</i><sub>max</sub>), concentration 24 h after the oral dose (<i>C</i><sub>24</sub>), half-life (<i>t</i><sub>1/2</sub>), plasma clearance (CL), volume of distribution at steady state (<i>V</i><sub>ss</sub>), and oral bioavailability (<i>F</i>), are reported.</p></div></div></div><div class="NLM_p">Since compound <b>58</b> demonstrated the optimal overall profile in its in vitro potency, in vitro metabolic stability, PK properties, hERG inhibition, and CYP3A4 induction, it was studied further for its induction effects on other CYP enzymes. As shown in <a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>, this compound was not a CYP1A2, CYP3A4, or CYP2B6 inducer in primary human hepatocytes as determined by the corresponding CYP1A2-, CYP3A4-, and CYP2B6-enzyme levels (<40% increases compared with the positive control) at either low concentrations of l μM or higher concentrations of 10 μM. This unique property reduces the potential risk of drug–drug interactions when HBV patients are treated.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Relative Induction Values of the CYP1A2, CYP2B6, and CYP3A4 Enzymes by <b>58</b><a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">enzyme subtype</th><th class="colsep0 rowsep0" align="center">concentration (μM)</th><th class="colsep0 rowsep0" align="center">% of positive control</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2">1A2 positive control (omeprazole, 50 μM)</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">4.19 (<40%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">10</td><td class="colsep0 rowsep0" align="center">2.96 (<40%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2">3A4 positive control (rifampicin, 25 μM)</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">–13.2 (<40%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">10</td><td class="colsep0 rowsep0" align="center">–10.6 (<40%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2">2B6 positive control (phenobarbital, 1000 μM)</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">11.8 (<40%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">10</td><td class="colsep0 rowsep0" align="center">10.0 (<40%)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Experiments were run in human primary hepatocytes (<i>N</i> = 3). Positive controls induced a minimum of 2-fold increases in enzyme activities. The cutoff of a true positive sign of the induction of P450 activity in vitro is generally considered to be 40% of the positive control.</p></div></div></div><div class="NLM_p">On the basis of these results, compound <b>58</b> was selected as the candidate compound and was further assessed against HBV infections in the hydrodynamic-injection (HDI) mouse model.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> In this study, female BALB/c mice were hydrodynamically injected with replication-competent HBV-DNA plasmids through the tail vein. Entecavir (ETV, 0.1 mg/kg) was used as the positive control. Twenty hours after plasmid injection, the mice were orally dosed with a blank vehicle or different doses of compound <b>58</b> for 8 days. Plasma and liver samples were collected at the indicated time points for HBV-DNA quantification by real-time quantitative polymerase chain reaction (qPCR).</div><div class="NLM_p">A PK study was done, and the effective dose of the compound was estimated in the same BALB/c mice prior to the anti-HBV-activity HDI experiment. Considering the short half-life of compound <b>58</b>, b.i.d. doses were chosen in the HDI mouse-model experiment. The mice were given compound <b>58</b> in a dosage of 12.5 mg/kg, and the drug concentrations in the plasma and liver were assayed at different times. The plasma <i>C</i><sub>24</sub> (the concentration 24 h after dosage) was 849 ng/mL and the liver <i>C</i><sub>24</sub> was 361 ng/g, which were much higher than the EC<sub>50</sub> (0.039 μM) of compound <b>58</b>. Considering the plasma protein binding and linear correlation between the concentration and dosage, the dosages for the HDI mouse-model experiment were set to 50 and 100 mg/kg.</div><div class="NLM_p">The hydrodynamic-injection mouse model was established for HBV to transiently replicate in the mouse liver. Inhibition of HBV replication can thus be studied during this transient time of about 8 days. As shown in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, <b>58</b> demonstrated a dose-dependent reduction of HBV DNA in the plasma of infected mice when the compound was orally administered b.i.d. at 50 mg/kg (mpk), and 100 mpk, respectively. In comparison to the vehicle control group, the treatment with 50 and 100 mpk of <b>58</b> b.i.d. had achieved an over 2 log viral-load reduction in the plasma of the HDI mice on day 4. The levels of HBV DNA in the mouse livers were determined 8 days after the hydrodynamic injections of the HBV DNA plasmids. Consistent with the results in the mouse plasma, with oral dosings of compound <b>58</b> at 50 or 100 mpk b.i.d., HBV-DNA copy numbers were markedly reduced by over 100-fold in the liver, demonstrating a strong anti-HBV effect. The maximum efficacy of <b>58</b> was comparable to the maximum efficacy of ETV in this model.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effects of treatment with <b>58</b> (HEC72702) on the inhibition of HBV replication in the HDI mouse model. Mice (<i>N</i> = 6) were orally dosed with the vehicle control, compound <b>58</b> (HEC72702, 50 or 100 mpk, b.i.d.), or ETV. (A) Levels of HBV DNA in plasma. At 2, 4, 6, and 8 days postinfection, the serum HBV of all the treatment group (groups 2–4) were quantified and showed significant reductions in HBV DNA compared with that of the vehicle control. Error bar indicate the standard error of the mean (<i>N</i> = 6). *** indicates p < 0.001 for 50 mpk HEC72702 b.i.d. vs the vehicle, <sup>###</sup> indicates p < 0.001 for 100 mpk HEC72702 b.i.d. vs the vehicle, and <sup>&&&</sup> indicates p < 0.001 for 0.1 mpk ETV q.d vs the vehicle. (B) Quantified levels of HBV DNA in mouse livers. All the treatment groups (group 2–4) had significant reductions in liver HBV DNA compared with the vehicle control. *** indicates p < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01914&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It was believed that compound <b>58</b> and the other analogues of GLS4 would have activities against other HBV genetypes because of the mechanisms of action of these compounds and the conservation of the capsid protein sequence. The inhibition experiments of compound <b>58</b> against other HBV genetypes is still ongoing. Another compound, <b>(<i>R</i>)-52</b>, showed almost the same activity against four genetypes (A, B, C, and D; shown in the <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>). In addition, other reported capsid inhibitors, such as JNJ-379, were also shown to be active against full-length genotype-A–H clinical isolates in vitro.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_p">Compound <b>58</b> exhibited low CYP inhibition, with IC<sub>50</sub> > 10 μM, against the six major CYP enzymes (1A2, 2C9, 2D6, 3A4, 2C19, and 2B6) and was also not a time-dependent CYP inhibitor. The in vitro toxicology profiles of compound <b>58</b> were favorable, with no signs of hERG inhibition (IC<sub>50</sub> > 30 μM), and it was less cytotoxic to HepG2 cells, with a CC<sub>50</sub> value of 96.76 μM determined by a CellTiter-Blue assay. It was also negative in preliminary in vitro safety evaluations such as Ames as well as micronucleus-test (MNT) assays. A 14-day in vivo toxicology assessment in mice supported the further development of compound <b>58</b>, which showed a supportive safety margin as defined by the ratio of the plasma exposure (<i>C</i><sub>max</sub> and AUC) in mice at the NOAEL versus the exposure at the projected human efficacious dose.</div><div class="NLM_p last">The capsid inhibitor is different from nucleoside or nucleotide analogues such as tenofovir (TDF) and entecavir (ETV) in its viral inhibition mechanism. It is believed that a combination of these two kinds of drugs would benefit HBV treatment. As shown above, compound <b>58</b> displayed low CYP inhibition (IC<sub>50</sub> > 10 μM) against the six major enzymes, and it was not a CYP (1A2, 2B6 and 3A4) inducer. These properties would reduce the potential risk of drug–drug interactions of <b>58</b> and the nucleoside and nucleotide analogues. However, whether there will be drug–drug interactions needs to be further studied.</div></div><div id="sec2-5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Chemistry</h3><div class="NLM_p">As exemplified by the synthesis of compound <b>58</b>, the synthetic approach to obtain targeted dihydropyrimidines was outlined in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. First, a three-component reaction of thiazole-2-carboxamidine hydrochloride, 2-bromo-4-fluorobenzaldehyde, and (<i>S</i>)-1-isopropoxy-1-oxopropan-2-yl 3-oxobutanoate (<b>58I-1</b>) was conducted to give the racemic dihydropyrimidine <b>58I-2</b>. After the recrystallization of the crude product of racemic dihydropyrimidine <b>58I-2</b>, the enantiomerically pure <b>(<i>R</i>)-58I-2</b> could be obtained, and the absolute stereochemistry of <b>(<i>R</i>)-58I-2</b> was unambiguously determined by an X-ray-diffraction study. The enantiomerically pure <b>(<i>R</i>)-58I-2</b> was then reacted with lithium to afford enantiomerically pure <b>(<i>R</i>)-58I-3</b> as the desired intermediate. Bromination of <b>(<i>R</i>)-58I-3</b> gave <b>(<i>R</i>)-58I-4</b>, which was finally reacted with (<i>R</i>)-3-(morpholin-2-yl) propanoic acid to provide <b>58</b> after purification. This short and concise synthetic route was successfully applied to the synthesis of the other dihydropyrimidine analogues described in this paper, which greatly facilitated and expedited our SAR studies.</div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>58</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01914&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.2 equiv NaOAc, EtOH, reflux, 16 h; (b) recrystallization with ethanol; (c) 2 equiv Li, EtOH, reflux, 2 h; (d) 1.1 equiv NBS, CCl<sub>4</sub>, reflux, 1 h; (e) K<sub>2</sub>CO<sub>3</sub>, EtOH, 25 °C, 2 h.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34807" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34807" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In summary, GLS4 in combination with RTV is currently in clinical phase II for chronic HBV infections and has demonstrated good efficacy. On the basis of the preclinical and clinical properties of GLS4, we obtained novel GLS4 derivatives with the appropriate anti-HBV potencies, significantly reduced hERG activities, decreased CYP enzyme inductions, and improved pharmacokinetic (PK) properties. After the extensive modification of GLS4, we have found that the morpholine carboxyl analogues showed decreased hERG activities and comparable anti-HBV activities to GLS4. With regard to CYP-enzyme induction, we found that unsubstituted morpholine, morpholine carboxylic acid, and morpholine acetic acid analogues displayed strong CYP3A4 inductions in concentration-dependent manners, and we found that the morpholine propionic acid analogues showed decreased induction liabilities. Furthermore, the substitution position and stereochemistry of the propionic acid groups were crucial for the pharmacokinetic properties. In particular, <b>58</b>, which possessed an (<i>R</i>)-morpholine-2-propionic acid at the C6 position of the dihydropyrimidine core ring, displayed a very weak induction of CYP3A4, even at the higher concentration of 10 μM, and it also displayed a greatly increased systemic exposure and a low clearance both in rats and in beagle dogs.</div><div class="NLM_p last">Finally, compound <b>58</b> exhibited a desirable overall profile as a drug candidate in terms of its in vitro potency, in vitro metabolic stability, PK properties, and hERG inhibition. Further, it was not a CYP1A2, CYP3A4, or CYP2B6 inducer in primary human hepatocytes, avoiding the potential risk of drug–drug interactions in HBV patients. In the in vivo studies, compound <b>58</b> dose-dependently reduced HBV DNA in both the plasma and livers of HBV-infected HDI mice, achieving an over 2 log viral-load reduction on day 4 with 50 mpk b.i.d. dosings. Safety evaluations, including an Ames toxicity study and oral toxicity study in mice, indicated that compound <b>58</b> was safe enough. On the basis of these results, compound <b>58</b> will be selected for further development as an oral anti-HBV-infection agent.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38770" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38770" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Synthetic-Chemistry General Comments</h3><div class="NLM_p">All commercially available starting materials and solvents were reagent grade and used without further purification unless otherwise noted. Anhydrous THF and CH<sub>3</sub>CN were obtained by distillation over a sodium wire and CaH<sub>2</sub>, respectively. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker-600, Bruker-500, or Bruker-400 spectrometer (Bruker, Billerica, MA) and were referenced to the residual protio signals in CDCl<sub>3</sub> at 7.26 ppm or DMSO-<i>d</i><sub>6</sub> at 2.50 ppm (<sup>1</sup>H NMR) and CDCl<sub>3</sub> at 77.23 ppm or DMSO-d6 at 39.52 ppm (<sup>13</sup>C NMR). Data for NMR spectra are reported as follows: chemical shift (δ ppm), multiplicity integration (s = singlet, brs = broad singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m = multiplet), coupling constant (Hz). HRMS analyses were performed on an Agilent 6530 Q-TOF mass spectrometer, and ESIMS was carried out on an Agilent 6120 mass spectrometer (Agilent Technologies, Santa Clara, CA). TLC was performed on Huanghai HSGF 254 silica gel plates (China). Silica gel 60 H (200–300 mesh), manufactured by Qingdao Haiyang Chemical Group Company (Qingdao, China), was used for general chromatography. The purities of all the final derivatives for biological testing were confirmed to be >95%, as determined using an Agilent 1200 series HPLC instrument at 278 nm, using the following conditions: an Alltima C18 column (4.6 × 250 mm, 5 μm; Hichrom, Reading, U.K.); solvent A, 10 mM KH<sub>2</sub>PO<sub>4</sub> (pH 3.0); solvent B, acetonitrile; a gradient from 20–80% B (0 min, 20% B; 15 min, 80% B; 25 min, 80% B). Note that almost all the compounds possess similar dihydropyrimidine core structures, and representative compounds were selected for testing the <sup>13</sup>C NMR.</div><div class="NLM_p last">The synthesis and characterization of compounds <b>12</b>–<b>25</b> were reported in published article<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and in the <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>, although their hERG activities were reported in this article. For compounds <b>26</b>–<b>66</b>, except for those described specifically, all the analogues were prepared in analogy to <b>58</b> from commercially available building blocks.</div></div><div id="sec4-1-1-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Ethyl 4-(2-Bromo-4-fluorophenyl)-6-((1-oxidothiomorpholino)methyl)-2-(thiazol-2-yl)-1,4-dihydro-pyrimidine-5-carboxylate (<b>26</b>)</h3><div class="NLM_p last">HRMS: calcd (MH<sup>+</sup>) 540.0301, exptl (MH<sup>+</sup>) 541.360. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.51 (s, 1H), 7.85 (s, 1H), 7.47 (s, 1H), 7.34 (d, <i>J</i> = 6.7 Hz, 2H), 6.97 (s, 1H), 6.21 (s, 1H), 4.22 (d, <i>J</i> = 17.0 Hz, 1H), 4.06 (s, 2H), 3.91 (d, <i>J</i> = 16.7 Hz, 1H), 3.45–3.26 (m, 2H), 3.04 (s, 4H), 2.86–2.71 (m, 2H), 1.15 (t, <i>J</i> = 13.2 Hz, 3H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 166.02, 162.87, 162.23, 160.57, 145.13, 144.26, 143.14, 139.65, 130.51, 130.46, 129.92, 123.36, 123.69, 120.30, 120.27, 120.11, 114.98, 114.84, 98.70, 60.78, 60.05, 58.83, 56.34, 46.77, 14.14.</div></div><div id="sec4-1-1-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Ethyl 4-(2-Bromo-4-fluorophenyl)-6-((1,1-dioxidothiomorpholino)methyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate (<b>27</b>)</h3><div class="NLM_p last">HRMS: calcd (MH<sup>+</sup>) 556.0250, exptl (MH<sup>+</sup>) 557.0345. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.38 (s, 1H), 7.88 (d, <i>J</i> = 3.0 Hz, 1H), 7.48 (d, <i>J</i> = 3.0 Hz, 1H), 7.35 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 7.28 (t, <i>J</i> = 7.3 Hz, 1H), 6.97 (td, <i>J</i> = 8.3, 2.2 Hz, 1H), 6.22 (s, 1H), 4.34 (d, <i>J</i> = 17.1 Hz, 1H), 4.11–4.01 (m, 2H), 3.97 (d, <i>J</i> = 17.1 Hz, 1H), 3.33–3.09 (m, 8H), 1.15 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 165.95, 162.67, 162.27, 160.61, 144.43, 144.13, 143.26, 139.48, 139.46, 130.47, 130.42, 123.42, 123.39, 123.33, 115.01, 114.87, 99.22, 60.16, 58.80, 55.13, 51.57, 51.40, 14.12.</div></div><div id="sec4-1-1-3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 2-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)amino)-3-phenylpropanoic Acid (<b>28</b>)</h3><div class="NLM_p last">HRMS: calcd (MH<sup>+</sup>) 586.0686, exptl (MH<sup>+</sup>) 587.077. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.03 (s, 2H), 7.58 (d, <i>J</i> = 7.6 Hz, 1H), 7.50–7.40 (m, 1H), 7.36–7.17 (m, 6H), 5.97 (d, <i>J</i> = 3.5 Hz, 1H), 4.27 (s, 2H), 3.95 (q, <i>J</i> = 6.9 Hz, 2H), 3.30–2.99 (m, 3H) 0.05 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.33, 162.34, 162.07, 160.69, 144.54, 140.52, 131.97, 129.80, 129.77, 128.95, 127.36, 122.64, 120.16, 119.99, 116.11, 115.98, 60.22, 56.50, 19.02, 14.42</div></div><div id="sec4-1-1-4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 1-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)pyrrolidine-2-carboxylic Acid (<b>29</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 536.0529, exptl (MH<sup>+</sup>) 537.0569. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.97–7.88 (m, 2H), 7.56–7.52 (m, 1H), 7.47–7.44 (m, 1H), 7.27–7.14 (m, 1H), 6.19 (s, 1H), 4.78 (d, <i>J</i> = 14.6 Hz, 1H), 4.54–4.38 (m, 1H), 4.30–4.17 (m, 1H), 4.11 (q, <i>J</i> = 7.0 Hz, 2H), 4.05–3.87 (m, 1H), 3.31–3.23 (m, 1H), 2.61–2.45 (m, 1H), 2.40–2.26 (m, 1H), 2.26–2.13 (m, 1H), 2.12–1.98 (m, 1H), 1.15 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 165.20, 163.33, 161.42, 161.38, 160.84, 144.22, 144.15, 139.04, 131.77, 131.62, 131.54, 125.30, 121.99, 121.89, 119.84, 119.80, 119.59, 119.55, 115.54, 115.48, 115.33, 115.27, 72.03, 69.22, 60.51, 55.59, 55.37, 29.01, 23.56, 13.02.</div></div><div id="sec4-1-1-5" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 1-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)piperidine-2-carboxylic Acid (<b>30</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 550.0686, exptl (MH<sup>+</sup>) 551.0757. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.98 (d, <i>J</i> = 2.9 Hz, 1H), 7.88 (s, 1H), 7.62–7.50 (m, 1H), 7.50–7.39 (m, 1H), 7.20–7.16 (m, 1H), 6.19 (s, 1H), 4.75–4.58 (m, 2H), 4.09 (q, <i>J</i> = 6.9 Hz, 2H), 3.96–3.51 (m, 2H), 3.24–3.11 (m, 1H), 2.30–2.10 (m, 2H), 2.03–1.72 (m, 4H), 1.14 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 166.51, 164.73, 162.73, 162.23, 145.69, 140.43, 133.12, 133.04, 126.58, 123.60, 123.50, 123.40, 121.63, 121.31, 121.20, 121.06, 120.95, 116.89, 116.78, 116.68, 116.55, 67.64, 66.75, 61.71, 58.36, 52.99, 33.09, 30.76, 23.75, 14.49.</div></div><div id="sec4-1-1-6" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 1-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)-4-methylpiperazine-2-carboxylic Acid (<b>31</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 565.0795, exptl (MH<sup>+</sup>) 566.0866. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.95 (s, 1H), 7.72 (s, 1H), 7.51–7.38 (m, 2H), 7.11 (t, <i>J</i> = 8.2 Hz, 1H), 6.14 (d, <i>J</i> = 10.2 Hz, 1H), 4.28–4.13 (m, 1H), 4.09–3.88 (m, 3H), 3.72–3.54 (m, 1H), 3.20–3.05 (m, 2H), 2.97–2.78 (m, 2H), 2.70–2.52 (m, 3H), 2.45 (d, <i>J</i> = 10.6 Hz, 2H), 1.18–1.11 (m, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 166.12, 162.73, 162.18, 160.25, 143.33, 143.20, 140.52, 140.04, 131.00, 123.31, 122.63, 119.41, 119.16, 114.93, 114.72, 62.17, 59.72, 59.62, 58.09, 55.16, 53.73, 53.53, 44.35, 13.18, 13.02.</div></div><div id="sec4-1-1-7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 4-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic Acid (<b>32</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 552.0478, exptl (MH<sup>+</sup>) 553.0567. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.97 (t, <i>J</i> = 3.0 Hz, 1H), 7.79 (d, <i>J</i> = 2.9 Hz, 1H), 7.52–7.45 (m, 1H), 7.42 (dd, <i>J</i> = 8.4, 2.5 Hz, 1H), 7.12 (td, <i>J</i> = 8.4, 2.6 Hz, 1H), 6.17 (s, 1H), 4.55–4.43 (m, 1H), 4.35–4.25 (m, 1H), 4.17–4.00 (m, 4H), 3.96–3.81 (m, 2H), 3.75–3.64 (m, 1H), 3.47–3.35 (m, 1H), 2.83 (s, 1H), 1.15 (td, <i>J</i> = 7.1, 2.7 Hz, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 165.76, 162.93, 161.75, 160.45, 147.24, 143.57, 139.65, 131.13, 131.5, 124.10, 122.56, 122.46, 119.62, 119.38, 115.02, 114.81, 68.03, 65.73, 63.33, 62.97, 59.89, 55.05, 49.94, 13.11.</div></div><div id="sec4-1-1-8" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 4-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic Acid (<b>33</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 508.0983, exptl (MH<sup>+</sup>) 509.1078. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.97 (t, <i>J</i> = 2.9 Hz, 1H), 7.80 (d, <i>J</i> = 2.9 Hz, 1H), 7.53–7.45 (m, 1H), 7.24 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 7.08 (td, <i>J</i> = 8.4, 2.6 Hz, 1H), 6.19 (s, 1H), 4.55–4.40 (m, 1H), 4.35–4.25 (m, 1H), 4.13–4.05 (m, 4H), 3.94–3.83 (m, 2H), 3.75–3.65 (m, 1H), 3.48–3.37 (m, 1H), 2.84 (s, 1H), 1.15 (td, <i>J</i> = 7.1, 3.1 Hz, 4H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 171.32, 165.73, 163.09, 161.68, 160.61, 147.22, 143.61, 137.91, 133.21, 133.10, 131.25, 131.16, 124.13, 116.42, 116.17, 114.44, 114.23, 67.95, 65.64, 63.29, 59.92, 55.04, 49.89, 13.03.</div></div><div id="sec4-1-1-9" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 4-((6-(2,4-Dichlorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic Acid (<b>34</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 524.0688, exptl (MH<sup>+</sup>) 525.0771. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.97–7.96 (m, 1H), 7.79 (s, 1H), 7.51–7.41 (m, 2H), 7.32 (d, <i>J</i> = 8.3 Hz, 1H), 6.18 (s, 1H), 4.53–4.42 (m, 1H), 4.33–4.22 (m, 1H), 4.18–3.99 (m, 4H), 3.94–3.83 (m, 2H), 3.69 (d, <i>J</i> = 19.7 Hz, 1H), 3.42 (s, 1H), 2.78 (d, <i>J</i> = 31.5 Hz, 1H), 1.15 (td, <i>J</i> = 7.0, 2.8 Hz, 3H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 171.59, 167.93, 165.69, 165.66, 161.65, 161.63, 147.43, 143.63, 143.58, 140.44, 133.74, 133.25, 133.15, 132.20, 130.99, 130.97, 128.97, 128.91, 128.47, 127.58, 127.51, 124.19, 67.71, 63.26, 62.91, 59.95, 55.04, 54.88, 49.89, 49.19, 13.05.</div></div><div id="sec4-1-1-10" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (2<i>R</i>,3<i>S</i>)-4-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)-2-methylmorpholine-3-carboxylic Acid (<b>35</b>)</h3><div class="NLM_p last">The synthetic procedure was described in the <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>. HRMS: calcd (M) 566.0635, exptl (MH<sup>+</sup>) 567.0731. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.95 (t, <i>J</i> = 3.4 Hz, 1H), 7.81–7.73 (m, 1H), 7.47–7.42 (m, 1H), 7.41–7.38 (m, 1H), 7.12–7.08 (m, 1H), 6.14 (d, <i>J</i> = 18.0 Hz, 1H), 4.43–4.32 (m, 1H), 4.06–3.97 (m, 3H), 3.94 (d, <i>J</i> = 11.3 Hz, 1H), 3.89–3.78 (m, 2H), 3.21 (s, 1H), 3.01–2.78 (m, 2H), 1.32 (d, <i>J</i> = 6.2 Hz, 3H), 1.12 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 173.39, 167.01, 164.31, 163.12, 163.03, 161.82, 161.79, 148.37, 148.09, 145.03, 144.98, 141.18, 141.01, 140.97, 132.56, 132.48, 132.42, 125.46, 125.36, 123.97, 123.89, 123.80, 121.06, 120.98, 120.82, 120.74, 116.48, 116.39, 116.27, 116.18, 75.46, 75.31, 73.57, 73.49, 66.69, 66.52, 61.30, 57.86, 56.95, 56.63, 52.67, 52.51, 18.77, 14.50.</div></div><div id="sec4-1-1-11" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 4-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)-6,6-dimethylmorpholine-3-carboxylic Acid (<b>36</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 580.0791, exptl (MH<sup>+</sup>) 581.0875. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.96–7.89 (m, 1H), 7.75 (d, <i>J</i> = 2.8 Hz, 1H), 7.49–7.38 (m, 2H), 7.15–7.08 (m, 1H), 6.15 (d, <i>J</i> = 13.5 Hz, 1H), 4.18 (s, 1H), 4.13–3.97 (m, 5H), 3.43 (d, <i>J</i> = 41.7 Hz, 1H), 3.04–2.93 (m, 1H), 2.48–72.42 (m, 1H), 1.42–1.31 (m, 6H), 1.14 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (150 MHz, MeOD) δ 176.00 (s), 167.37, 163.78, 163.30, 163.21, 162.13, 149.00, 148.72, 144.65, 144.61, 141.58, 141.39, 132.37, 132.31, 129.86, 125.15, 125.12, 124.07, 124.01, 120.97, 120.94, 120.81, 120.77, 116.25, 116.11, 72.98, 71.30, 69.10, 65.48, 64.44, 61.14, 61.12, 60.90, 59.09, 56.40, 56.07, 26.28, 26.07, 24.39, 24.13, 14.53.</div></div><div id="sec4-1-1-12" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Methyl 4-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylate (<b>37</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 566.0635, exptl (MH<sup>+</sup>) 567.0729. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.72 (d, <i>J</i> = 28.9 Hz, 1H), 7.87 (d, <i>J</i> = 1.9 Hz, 1H), 7.45 (d, <i>J</i> = 2.6 Hz, 1H), 7.39–7.29 (m, 2H), 6.99–6.94 (m, 1H), 6.20 (s, 1H), 4.28 (dd, <i>J</i> = 17.6, 8.5 Hz, 1H), 4.15–3.96 (m, 5H), 3.85 (s, 2H), 3.80 (d, <i>J</i> = 6.2 Hz, 3H), 3.57–3.46 (m, 1H), 3.25–3.11 (m, 1H), 2.60–2.50 (m, 1H), 1.15 (t, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 171.10, 170.99, 166.17, 166.13, 163.00, 162.97, 162.18, 160.53, 146.24, 146.08, 144.50, 144.47, 143.26, 143.23, 140.00, 139.98, 139.94, 139.92, 130.70, 130.64, 130.57, 130.51, 123.31, 123.25, 123.21, 123.15, 123.00, 122.97, 120.20, 120.10, 120.03, 119.94, 114.99, 114.91, 114.85, 114.77, 98.12, 97.93, 69.18, 67.29, 62.76, 62.66, 59.91, 59.89, 58.91, 58.75, 55.03, 54.84, 52.13, 49.82, 49.17, 14.16.</div></div><div id="sec4-1-1-13" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Isopropyl 4-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydro-pyrimidin-4-yl)methyl)morpholine-3-carboxylate (<b>38</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 594.0948, exptl (MH<sup>+</sup>) 595.1021. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.97 (d, <i>J</i> = 2.1 Hz, 1H), 7.75 (d, <i>J</i> = 2.0 Hz, 1H), 7.41 (d, <i>J</i> = 8.1 Hz, 2H), 7.11–7.07 (m, 1H), 6.16 (s, 1H), 5.15–5.06 (m, 1H), 4.32 (<i>J</i> = 14.9 Hz, 1H), 4.12–3.98 (m, 5H), 3.83 (s, 2H), 3.55 (d, <i>J</i> = 35.9 Hz, 1H), 3.24–3.11 (m, 1H), 2.61–2.50 (m, 1H), 1.27 (d, <i>J</i> = 6.1 Hz, 6H), 1.15 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 171.78, 171.71, 167.43, 163.73, 163.47, 163.42, 162.08, 148.29, 148.15, 146.49, 146.39, 144.62, 144.59, 141.42, 141.40, 132.19, 132.13, 125.03, 124.23, 124.16, 120.94, 120.78, 116.18, 116.04, 99.05, 98.96, 70.35, 70.29, 70.14, 70.04, 68.41, 64.16, 63.95, 61.06, 59.92, 59.87, 56.10, 55.84, 50.76, 50.20, 49.14, 49.00, 48.86, 22.10, 22.09, 22.07, 22.05, 14.57.</div></div><div id="sec4-1-1-14" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Ethyl 4-(2-Bromo-4-fluorophenyl)-6-((3-carbamoylmorpholino)methyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate (<b>39</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 551.0638, exptl (MH<sup>+</sup>) 552.0726. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.99–7.94 (m, 1H), 7.74 (s, 1H), 7.50–7.35 (m, 2H), 7.16–7.05 (m, 1H), 6.15 (d, <i>J</i> = 10.3 Hz, 1H), 4.21 (q, 11.6 Hz, 1H), 4.11–3.97 (m, 3H), 3.93–3.69 (m, 4H), 3.09–2.87 (m, 1H), 2.65–2.47 (m, 1H), 1.47 (s, 1H), 1.15 (t, <i>J</i> = 7.2 Hz, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 174.80, 167.47, 163.59, 161.74, 146.65, 144.63, 139.61, 132.30, 132.22, 131.25, 124.93, 123.51, 121.01, 120.94, 120.76, 120.70, 116.29, 116.28, 116.22, 116.17, 116.07, 116.01, 70.61, 68.03, 66.80, 61.11, 59.72, 55.13, 52.68, 52.56, 14.52.</div></div><div id="sec4-1-1-15" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Ethyl 4-(2-Bromo-4-fluorophenyl)-6-((3-(methylcarbamoyl)morpholino)methyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate (<b>40</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 565.0795, exptl (MH<sup>+</sup>) 566.0886. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.98 (d, <i>J</i> = 2.8 Hz, 1H), 7.74 (s, 1H), 7.51–7.36 (m, 2H), 7.10 (t, <i>J</i> = 8.2 Hz, 1H), 6.15 (d, <i>J</i> = 10.5 Hz, 1H), 4.27–3.99 (m, 3H), 3.99–3.68 (m, 5H), 3.31–3.23 (m, 1H), 3.07–2.85 (m, 1H), 2.78 (d, <i>J</i> = 20.5 Hz, 3H), 2.62–2.49 (m, 1H), 1.14 (td, <i>J</i> = 6.8, 2.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 171.29, 166.04, 162.15, 146.37, 146.29, 143.23, 130.94, 130.86, 123.55, 123.29, 122.68, 119.59, 119.29, 114.85, 114.64, 98.49, 69.09, 68.81, 66.58, 66.49, 65.82, 59.70, 58.32, 53.54, 51.34, 24.92, 13.12.</div></div><div id="sec4-1-1-16" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Ethyl 4-(2-Bromo-4-fluorophenyl)-6-((3-((methylsulfonyl)carbamoyl)morpholino)methyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate (<b>41</b>)</h3><div class="NLM_p last">The synthetic procedure was described in the <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>. HRMS: calcd (M) 629.0414, exptl (MH<sup>+</sup>) 630.0525. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.97 (d, <i>J</i> = 3.0 Hz, 1H), 7.79 (d, <i>J</i> = 2.9 Hz, 1H), 7.53–7.45 (m, 1H), 7.45–7.38 (m, 1H), 7.13 (td, <i>J</i> = 8.4, 2.3 Hz, 1H), 6.17 (d, <i>J</i> = 3.9 Hz, 1H), 4.40 (d, <i>J</i> = 16.9 Hz, 1H), 4.17–4.03 (m, 4H), 3.93–3.81 (m, 3H), 3.58 (s, 1H), 3.31–3.16 (m, 4H), 2.76 (s, 1H), 1.15 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (150 MHz, MeOD) δ 172.76, 167.16, 163.90, 163.15, 162.24, 148.49, 144.93, 140.98, 132.61, 132.56, 132.38, 129.88, 125.48, 123.91, 123.84, 121.03, 120.92, 120.87, 120.76, 116.49, 116.35, 116.23, 72.90, 69.49, 67.37, 66.65, 66.13, 65.63, 61.29, 55.93, 51.85, 51.31, 14.52.</div></div><div id="sec4-1-1-17" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Ethyl 4-(2,4-Dichlorophenyl)-6-((3-(hydroxymethyl)morpholino)methyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate (<b>42</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 510.0895, exptl (MH<sup>+</sup>) 511.0973. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.96 (d, <i>J</i> = 2.1 Hz, 1H), 7.75 (d, <i>J</i> = 2.5 Hz, 1H), 7.51–7.36 (m, 2H), 7.30 (d, <i>J</i> = 7.8 Hz, 1H), 6.18 (s, 1H), 4.36–4.23 (m, 1H), 4.15–4.01 (m, 3H), 3.94 (d, <i>J</i> = 8.6 Hz, 1H), 3.85–3.62 (m, 5H), 2.95–2.75 (m, 1H), 2.74–2.51 (m, 2H), 1.15 (t, <i>J</i> = 7.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 175.16, 167.03, 164.30, 163.13, 163.10, 161.82, 147.93, 144.92, 141.05, 141.02, 132.48, 132.44, 132.39, 132.35, 125.54, 125.51, 123.99, 123.97, 123.90, 123.87, 121.07, 120.82, 116.42, 116.40, 116.21, 116.19, 111.37, 75.59, 75.33, 66.26, 66.05, 61.51, 61.34, 57.97, 56.07, 55.82, 53.92, 53.72, 14.51.</div></div><div id="sec4-1-1-18" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Ethyl 4-(2-Bromo-4-fluorophenyl)-6-((2-(hydroxymethyl)morpholino)methyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate (<b>43</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 538.0686, exptl (MH<sup>+</sup>) 539.0753. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.62 (d, <i>J</i> = 7.1 Hz, 1H), 7.86 (d, <i>J</i> = 2.9 Hz, 1H), 7.46 (d, <i>J</i> = 3.0 Hz, 1H), 7.37–7.29 (m, 2H), 6.97 (t, <i>J</i> = 8.1 Hz, 1H), 6.21 (s, 1H), 4.16–3.97 (m, 4H), 3.94–3.80 (m, 3H), 3.77–3.57 (m, 2H), 2.85–2.75 (m, 1H), 2.68 (t, <i>J</i> = 11.2 Hz, 1H), 2.50–2.30 (m, 1H), 2.06 (s, 1H), 1.15 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 166.15, 162.92, 162.21, 160.55, 145.86, 145.82, 144.37, 144.36, 143.20, 143.19, 139.89, 139.87, 139.84, 130.56, 130.51, 123.31, 123.25, 123.11, 123.09, 120.21, 120.05, 114.98, 114.84, 109.99, 98.33, 98.28, 76.11, 66.63, 66.55, 63.78, 59.93, 58.78, 58.77, 56.63, 54.85, 54.57, 53.34, 53.06, 14.15.</div></div><div id="sec4-1-1-19" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 4-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-2-carboxylic Acid (<b>44</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 552.0478, exptl (MH<sup>+</sup>) 553.0542. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.95 (s, 1H), 7.77 (s, 1H), 7.53–7.36 (m, 2H), 7.12 (t, <i>J</i> = 6.8 Hz, 1H), 6.17 (s, 1H), 4.41–4.21 (m, 2H), 4.18–4.06 (m, 4H), 3.89 (t, <i>J</i> = 8.8 Hz, 1H), 3.49–3.24 (m, 1H), 3.01 (t, <i>J</i> = 14.0 Hz, 1H), 2.92–2.69 (m, 2H), 1.14 (t, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 175.16, 167.03, 164.30, 163.13, 163.10, 161.82, 147.93, 144.92, 141.05, 141.02, 132.48, 132.44, 132.39, 132.35, 125.54, 125.51, 123.99, 123.97, 123.90, 123.87, 121.07, 120.82, 116.42, 116.40, 116.21, 116.19, 111.37, 75.59, 75.33, 66.26, 66.05, 61.51, 61.34, 57.97, 56.07, 55.82, 53.92, 53.72, 14.51.</div></div><div id="sec4-1-1-20" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 2-(4-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-3-yl)acetic Acid (<b>45</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 566.0636, exptl (MH<sup>+</sup>) 567.0713. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ7.96 (s, 1H), 7.77 (s, 1H), 7.52–7.38 (m, 2H), 7.11 (t, <i>J</i> = 7.2 Hz, 1H), 6.17 (s, 1H), 4.40–4.04 (m, 4H), 4.02–3.71 (m, 4H), 3.23 (s, 1H), 3.04 (s, 1H), 2.70–2.65 (m, 3H), 1.22–1.08 (m, 3H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 174.25, 165.84, 162.46, 161.91, 160.78, 147.27, 143.40, 139.79, 131.00, 123.97, 122.61, 119.59, 119.55, 119.41, 119.38, 114.95, 114.81, 69.48, 59.83, 56.61, 53.20, 53.16, 52.84, 50.46, 49.84, 13.12.</div></div><div id="sec4-1-1-21" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 2-(4-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)acetic Acid (<b>46</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 566.0635, exptl (MH<sup>+</sup>) 567.0729. <sup>1</sup>H NMR (600 MHz, methanol-d<sub>4</sub>) δ 7.96 (d, <i>J</i> = 3.1 Hz, 1H), 7.76 (d, <i>J</i> = 2.9 Hz, 1H), 7.46–7.40 (m, 2H), 7.16–7.10 (m, 1H), 6.17 (s, 1H), 4.14–4.04 (m, 4H), 3.98–3.91 (m, 2H), 3.86–3.81 (m, 1H), 3.09 (s, 1H), 2.77 (s, 1H), 2.61–2.43 (m, 3H), 2.32 (s, 1H), 1.15 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 174.62, 167.33, 164.22, 163.33, 161.74, 144.69, 141.24, 132.28, 132.19, 125.12, 124.12, 121.00, 120.75, 116.37, 116.16, 73.93, 67.52, 61.16, 59.04, 57.59, 54.01, 39.55, 14.52.</div></div><div id="sec4-1-1-22" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 3-(4-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-3-yl)propanoic Acid (<b>47</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 580.0791, exptl (MH<sup>+</sup>) 581.0861. <sup>1</sup>H NMR (600 MHz, acetone-<i>d</i><sub>6</sub>) δ 9.94 (s, 1H), 7.98 (d, <i>J</i> = 3.1 Hz, 1H), 7.80 (d, <i>J</i> = 3.1 Hz, 1H), 7.54–7.52 (m, 1H), 7.42 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 7.15 (td, <i>J</i> = 8.5, 2.6 Hz, 1H), 6.18 (s, 1H), 4.32 (d, <i>J</i> = 18.1 Hz, 1H), 4.05–4.01 (m, 3H), 3.93 (dd, <i>J</i> = 11.4, 2.8 Hz, 1H), 3.83–3.80 (m, 1H), 3.74–3.70 (m, 1H), 3.50–3.47 (m, 1H), 2.92–2.86 (m, 1H), 2.67–2.61 (m, 2H), 2.52–2.47 (m, 1H), 2.45–2.37 (m, 1H), 2.11–2.08 (m, 1H), 1.85–1.80 (m, 1H), 1.13 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (150 MHz, acetone-<i>d</i><sub>6</sub>) δ 173.59, 165.45, 162.83, 162.11, 160.47, 147.63, 144.17, 143.48, 140.71, 131.29, 131.23, 123.73, 122.84, 122.78, 119.54, 119.38, 115.34, 115.20, 96.43, 70.08, 66.78, 59.80, 59.67, 59.28, 58.69, 53.49, 53.45, 52.41, 13.66.</div></div><div id="sec4-1-1-23" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 3-(4-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (<b>48</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 580.0791, exptl (MH<sup>+</sup>) 581.086.<sup>1</sup>H NMR (600 MHz, acetone-<i>d</i><sub>6</sub>) δ 9.72 (s, 1H), 7.97 (d, <i>J</i> = 2.9 Hz, 1H), 7.79 (t, <i>J</i> = 3.2 Hz, 1H), 7.53–7.49 (m, 1H), 7.44 (dd, <i>J</i> = 8.5, 2.5 Hz, 1H), 7.15–7.11 (m, 1H), 6.19 (s, 1H), 4.10–3.99 (m, 3H), 3.97–3.88 (m, 2H), 3.75–3.71 (m, 1H), 3.69–3.65 (m, 1H), 2.99–2.73 (m, 2H), 2.51–2.33 (m, 3H), 2.23 (t, <i>J</i> = 10.5 Hz, 1H), 1.84–1.71 (m, 2H), 1.13 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (150 MHz, acetone-<i>d</i><sub>6</sub>) δ 173.63, 173.55, 165.38, 162.77, 162.73, 162.15, 160.50, 146.46, 146.40, 144.24, 144.22, 143.47, 143.45, 140.60, 131.14, 131.11, 131.09, 131.05, 123.75, 123.70, 122.94, 122.90, 122.88, 119.66, 119.49, 115.14, 115.10, 115.00, 114.96, 97.76, 97.62, 74.83, 74.80, 66.47, 66.40, 59.35, 59.34, 58.76, 58.73, 58.49, 58.30, 56.35, 56.28, 53.27, 53.03, 13.64.</div></div><div id="sec4-1-1-24" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (3<i>S</i>)-4-((6-(2,4-Dichlorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic Acid (<b>49</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 524.0688, exptl (MH<sup>+</sup>) 525.0749. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.00–7.94 (m, 1H), 7.79 (s, 1H), 7.48 (s, 1H), 7.45 (t, <i>J</i> = 9.3 Hz, 1H), 7.31 (d, <i>J</i> = 8.4 Hz, 1H), 6.18 (s, 1H), 4.53–4.42 (m, 1H), 4.35–4.23 (m, 1H), 4.17–4.09 (m, 1H), 4.08–4.04 (m, 3H), 3.93–3.84 (m, 2H), 3.69 (d, <i>J</i> = 19.4 Hz, 1H), 3.42 (s, 1H), 2.79 (d, <i>J</i> = 26.1 Hz, 1H), 1.15 (td, <i>J</i> = 7.1, 2.8 Hz, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 172.80, 167.07, 167.04, 163.04, 163.02, 148.81, 148.77, 144.99, 144.94, 141.87, 141.82, 135.09, 134.62, 134.53, 132.34, 130.34, 130.28, 128.95, 128.88, 125.55, 69.40, 69.28, 67.10, 64.67, 64.33, 61.34, 56.42, 56.27, 51.28, 50.62, 14.44.</div></div><div id="sec4-1-1-25" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (<i>S</i>)-4-(((<i>R</i>)-6-(2,4-Dichlorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic Acid (<b>(<i>R</i>)-49</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 524.0688, exptl (MH<sup>+</sup>) 525.0771. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.94 (d, <i>J</i> = 2.1 Hz, 1H), 7.76 (d, <i>J</i> = 1.6 Hz, 1H), 7.44 (d, <i>J</i> = 12.0 Hz, 2H), 7.28 (d, <i>J</i> = 8.1 Hz, 1H), 6.18 (s, 1H), 4.52 (d, <i>J</i> = 17.1 Hz, 1H), 4.27 (d, <i>J</i> = 17.1 Hz, 1H), 4.15–4.02 (m, 4H), 3.87 (s, 2H), 3.70 (s, 1H), 3.42 (s, 1H), 2.76 (d, <i>J</i> = 8.1 Hz, 1H), 1.14 (t, <i>J</i> = 6.9 Hz, 3H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 172.93, 167.01, 163.00, 148.85, 144.95, 141.86, 135.08, 134.58, 132.36, 130.32, 128.89, 125.60, 69.20, 66.94, 64.31, 61.51, 61.34, 55.93, 50.63, 14.45</div></div><div id="sec4-1-1-26" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (<i>S</i>)-4-(((<i>S</i>)-6-(2,4-Dichlorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic Acid (<b>(<i>S</i>)-49</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 524.0688, exptl (MH<sup>+</sup>) 525.0790. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.22 (dd, <i>J</i> = 18.6, 3.0 Hz, 2H), 7.55 (dd, <i>J</i> = 5.2, 3.1 Hz, 2H), 7.42 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 6.32 (s, 1H), 5.08 (d, <i>J</i> = 17.2 Hz, 1H), 4.42 (d, <i>J</i> = 11.4 Hz, 1H), 4.08 (q, <i>J</i> = 7.1 Hz, 2H), 3.95 (dd, <i>J</i> = 12.3, 3.5 Hz, 1H), 3.81–3.78 (m, 2H), 3.75–3.69 (m, 1H), 3.39–3.34 (m, 1H), 3.08 (s, 1H), 2.92–2.87 (m, 1H), 1.15–1.13 (m, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 175.16, 167.03, 164.30, 163.13, 163.10, 161.82, 147.93, 144.92, 141.05, 141.02, 132.48, 132.44, 132.39, 132.35, 125.54, 125.51, 123.99, 123.97, 123.90, 123.87, 121.07, 120.82, 116.42, 116.40, 116.21, 116.19, 111.37, 106.06, 75.59, 75.33, 66.26, 66.05, 61.51, 61.34, 57.97, 56.07, 55.82, 53.92, 53.72, 14.51.</div></div><div id="sec4-1-1-27" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> (3<i>R</i>)-4-((6-(2,4-Dichlorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic Acid (<b>(<i>R</i>)-50</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 524.0688, exptl (MH<sup>+</sup>) 525.0761. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.02 (d, <i>J</i> = 3.0 Hz, 1H), 7.88 (d, <i>J</i> = 3.0 Hz, 1H), 7.51 (d, <i>J</i> = 8.6 Hz, 2H), 7.35 (d, <i>J</i> = 8.4 Hz, 1H), 6.21 (s, 1H), 4.58–4.42 (m, 2H), 4.17 (dd, <i>J</i> = 11.9, 3.4 Hz, 1H), 4.13–4.04 (m, 3H), 4.00–3.86 (m, 3H), 3.53–3.46 (m, 1H), 3.04–2.93 (m, 1H), 1.16 (t, <i>J</i> = 7.1 Hz, 3H).<sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ 171.30, 165.05, 159.98, 147.72, 146.78, 143.97, 138.80, 134.62, 133.24, 130.81, 129.67, 127.98, 125.28, 68.00, 65.73, 63.48, 60.76, 55.35, 53.11, 50.28, 13.95.</div></div><div id="sec4-1-1-28" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> (<i>R</i>)-4-(((<i>S</i>)-6-(2,4-Dichlorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic Acid (<b>(<i>S</i>)-50</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 524.0688, exptl (MH<sup>+</sup>) 525.0722. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.94 (s, 1H), 7.73 (s, 1H), 7.43 (d, <i>J</i> = 9.5 Hz, 2H), 7.29 (d, <i>J</i> = 7.9 Hz, 1H), 6.16 (s, 1H), 4.17–3.95 (m, 5H), 3.93–3.77 (m, 2H), 3.74–3.68 (m, 1H), 3.51 (s, 1H), 3.30–3.16 (m, 2H), 1.14 (t, <i>J</i> = 6.8 Hz, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 172.96, 167.11, 163.09, 148.80, 144.92, 141.89, 135.09, 134.65, 132.32, 130.35, 128.87, 125.50, 69.35, 67.11, 64.33, 61.51, 61.33, 56.28, 50.61, 14.44.</div></div><div id="sec4-1-1-29" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (3<i>S</i>)-4-((6-(2-Chloro-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic Acid (<b>51</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 508.0983, exptl (MH<sup>+</sup>) 509.1089. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.97 (t, <i>J</i> = 2.8 Hz, 1H), 7.80 (d, <i>J</i> = 2.7 Hz, 1H), 7.51–7.45 (m, 1H), 7.24 (dt, <i>J</i> = 8.7, 2.5 Hz, 1H), 7.10–7.05 (m, 1H), 6.19 (s, 1H), 4.54–4.44 (m, 1H), 4.32–4.25 (m, 1H), 4.17–4.02 (m, 4H), 3.95–3.83 (m, 2H), 3.69 (d, <i>J</i> = 16.4 Hz, 1H), 3.44 (s, 1H), 2.83 (s, 1H), 1.15 (td, <i>J</i> = 7.1, 2.6 Hz, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 172.85, 167.09, 164.46, 163.04, 161.99, 148.67, 145.02, 144.97, 139.34, 134.66, 134.57, 134.47, 132.66, 132.57, 125.56, 117.87, 117.81, 117.62, 117.56, 115.86, 115.79, 115.65, 115.58, 69.33, 66.99, 64.83, 64.48, 56.45, 56.29, 51.32, 50.68, 14.44.</div></div><div id="sec4-1-1-30" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (3<i>S</i>)-4-((6-(2-Chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic Acid (<b>52</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 494.0827, exptl (MH<sup>+</sup>) 495.0931. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.97 (t, <i>J</i> = 2.6 Hz, 1H), 7.79 (d, <i>J</i> = 2.7 Hz, 1H), 7.50–7.44 (m, 1H), 7.24 (dt, <i>J</i> = 8.7, 2.4 Hz, 1H), 7.08–7.04 (m, 1H), 6.17 (s, 1H), 4.52–4.42 (m, 1H), 4.34–4.22 (m, 1H), 4.16–4.00 (m, 2H), 3.95–3.83 (m, 2H), 3.70–3.67 (m, 1H), 3.62 (s, 3H), 3.42 (s, 1H), 2.82 (s, 1H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 172.92, 167.60, 164.47, 163.07, 162.00, 148.80, 144.99, 144.95, 139.06, 134.73, 134.65, 134.55, 132.50, 132.40, 125.50, 117.97, 117.90, 117.72, 117.65, 115.81, 115.75, 115.60, 115.54, 73.53, 69.46, 67.12, 64.79, 64.47, 62.27, 56.42, 56.32, 51.72, 51.36, 14.40.</div></div><div id="sec4-1-1-31" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> (<i>S</i>)-4-(((<i>R</i>)-6-(2-Chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic Acid (<b>(<i>R</i>)-52</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 494.0827, exptl (MH<sup>+</sup>) 495.0910. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.97 (d, <i>J</i> = 3.1 Hz, 1H), 7.79 (d, <i>J</i> = 3.0 Hz, 1H), 7.47–7.45 (m, 1H), 7.24 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 7.06 (td, <i>J</i> = 8.4, 2.5 Hz, 1H), 6.17 (s, 1H), 4.52 (d, <i>J</i> = 16.8 Hz, 1H), 4.28 (d, <i>J</i> = 16.3 Hz, 1H), 4.16–4.06 (m, 2H), 3.93–3.85 (m, 2H), 3.71 (s, 1H), 3.62 (s, 3H), 3.44 (s, 1H), 2.78 (s, 1H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 171.58, 166.16, 162.68, 161.63, 161.03, 147.54, 143.61, 137.74, 133.29, 133.22, 131.10, 131.04, 124.22, 116.54, 116.38, 114.36, 114.22, 67.82, 65.48, 63.01, 60.14, 54.95, 50.36, 49.29.</div></div><div id="sec4-1-1-32" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> (3<i>S</i>)-4-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic Acid (<b>53</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 552.0478, exptl (MH<sup>+</sup>) 553.0568. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.97 (t, <i>J</i> = 2.8 Hz, 1H), 7.79 (t, <i>J</i> = 2.7 Hz, 1H), 7.52–7.45 (m, 1H), 7.42 (dt, <i>J</i> = 8.4, 2.5 Hz, 1H), 7.14–7.10 (m, 1H), 6.17 (s, 1H), 4.55–4.44 (m, 1H), 4.38–4.23 (m, 1H), 4.17–4.01 (m, 4H), 3.95–3.84 (m, 2H), 3.70 (d, <i>J</i> = 17.6 Hz, 1H), 3.53–3.36 (m, 1H), 2.84–2.73 (m, 1H), 1.15 (td, <i>J</i> = 7.1, 2.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 174.31, 167.27, 164.23, 163.29, 163.24, 161.75, 148.83, 147.90, 144.90, 144.88, 141.30, 141.17, 141.14, 132.52, 132.44, 132.35, 125.22, 123.94, 123.85, 121.00, 120.91, 120.75, 120.66, 116.39, 116.33, 116.18, 116.12, 100.84, 70.00, 69.72, 67.40, 67.24, 66.34, 65.49, 61.22, 61.19, 58.43, 56.19, 51.94, 51.18, 14.53.</div></div><div id="sec4-1-1-33" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> (<i>S</i>)-4-(((<i>R</i>)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic Acid (<b>(<i>R</i>)-53</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 552.0478, exptl (MH<sup>+</sup>) 553.0585. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 8.11 (d, <i>J</i> = 3.0 Hz, 1H), 8.06 (d, <i>J</i> = 3.0 Hz, 1H), 7.67 (dd, <i>J</i> = 8.7, 5.9 Hz, 1H), 7.51 (dd, <i>J</i> = 8.4, 2.5 Hz, 1H), 7.22 (td, <i>J</i> = 8.4, 2.5 Hz, 1H), 6.29 (s, 1H), 4.65 (d, <i>J</i> = 16.2 Hz, 1H), 4.38 (t, <i>J</i> = 4.1 Hz, 1H), 4.30–4.19 (m, 3H), 4.16–4.10 (m, 2H), 4.08–3.98 (m, 2H), 3.89–3.82 (m, 1H), 3.40–3.34 (m, 1H), 1.16 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 170.12, 168.39, 165.70, 164.97, 162.47, 158.91, 151.71, 146.23, 146.15, 139.16, 139.12, 133.62, 133.53, 128.19, 123.94, 123.84, 121.50, 121.25, 116.94, 116.72, 108.83, 66.99, 66.54, 64.96, 64.57, 63.25, 62.23, 58.32, 56.04, 55.95, 54.64, 51.76, 14.39.</div></div><div id="sec4-1-1-34" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Ethyl 4-(2-Bromo-4-fluorophenyl)-6-(((<i>R</i>)-3-(hydroxymethyl)morpholino)methyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate (<b>54</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 538.0686, exptl (MH<sup>+</sup>) 539.0734. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.96 (t, <i>J</i> = 3.3 Hz, 1H), 7.74 (d, <i>J</i> = 2.8 Hz, 1H), 7.49–7.37 (m, 2H), 7.09 (t, <i>J</i> = 7.9 Hz, 1H), 6.16 (d, <i>J</i> = 2.9 Hz, 1H), 4.48–4.45 (m, 1H), 4.14–3.98 (m, 3H), 3.96–3.91 (m, 1H), 3.88–3.69 (m, 4H), 3.68–3.62 (m, 1H), 2.93–2.77 (m, 1H), 2.73–2.65 (m, 1H), 2.64–2.53 (m, 1H), 1.15 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 166.10, 166.08, 162.32, 162.07, 160.67, 147.69, 147.37, 144.99, 143.22, 140.16, 140.13, 140.06, 140.04, 130.83, 130.77, 130.70, 123.60, 123.58, 119.54, 119.50, 119.37, 119.33, 114.80, 114.66, 97.48, 96.94, 68.78, 68.76, 66.74, 66.67, 61.74, 61.24, 59.63, 59.45, 59.06, 58.49, 58.43, 53.65, 52.91, 51.93, 51.80, 13.17.</div></div><div id="sec4-1-1-35" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> (2<i>R</i>,3<i>S</i>)-4-(((<i>R</i>)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)-2-methylmorpholine-3-carboxylic Acid (<b>55</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 566.0635, exptl (MH<sup>+</sup>) 567.0724. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.97 (d, <i>J</i> = 3.0 Hz, 1H), 7.78 (d, <i>J</i> = 2.6 Hz, 1H), 7.47–7.42 (m, 2H), 7.13 (td, <i>J</i> = 8.4, 2.1 Hz, 1H), 6.15 (s, 1H), 4.36 (d, <i>J</i> = 16.6 Hz, 1H), 4.07–4.02 (m, 4H), 3.90–3.83 (m, 2H), 3.25 (s, 2H), 2.90 (s, 1H), 1.34 (d, <i>J</i> = 6.2 Hz, 3H), 1.14 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 171.58, 165.58, 162.52, 161.67, 160.86, 146.99, 143.65, 139.77, 131.15, 131.09, 124.05, 122.55, 122.49, 119.65, 119.49, 115.0, 114.85, 109.99, 73.90, 71.95, 65.07, 59.92, 55.70, 51.28, 17.29, 13.11.</div></div><div id="sec4-1-1-36" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> (3<i>S</i>)-4-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)-6,6-dimethylmorpholine-3-carboxylic Acid (<b>56</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 580.0791, exptl (MH<sup>+</sup>) 581.0873. <sup>1</sup>H NMR (600 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.93 (d, <i>J</i> = 3.1 Hz, 1H), 7.76 (d, <i>J</i> = 3.0 Hz, 1H), 7.49–7.47 (m, 1H), 7.41 (dd, <i>J</i> = 8.4, 2.6 Hz, 1H), 7.11 (td, <i>J</i> = 8.4, 2.5 Hz, 1H), 6.17 (s, 1H), 4.35 (d, <i>J</i> = 17.2 Hz, 1H), 4.14–3.99 (m, 5H), 3.49 (s, 1H), 3.00 (d, <i>J</i> = 11.5 Hz, 1H), 2.54–2.48 (m, 1H), 1.36 (s, 3H), 1.33 (s, 3H), 1.15 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (100 MHz, methanol-<i>d</i><sub>4</sub>) δ 175.16, 167.03, 164.30, 163.09, 161.82, 147.93, 144.92, 141.05, 141.02, 132.48, 132.44, 132.39, 132.35, 125.54, 125.51, 123.99, 123.97, 123.90, 123.87, 121.07, 120.82, 116.42, 116.40, 116.21, 116.19, 111.37, 75.59, 75.33, 66.26, 66.05, 61.51, 61.34, 57.97, 56.07, 55.82, 53.92, 53.72, 14.51.</div></div><div id="sec4-1-1-37" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> (<i>S</i>)-1-(((<i>R</i>)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)-4,4-difluoropyrrolidine-2-carboxylic Acid (<b>57</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 572.0341, exptl (MH<sup>+</sup>) 573.0399. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.92 (d, <i>J</i> = 2.9 Hz, 1H), 7.73 (d, <i>J</i> = 2.9 Hz, 1H), 7.48–7.40 (m, 2H), 7.17–7.07 (m, 1H), 6.15 (s, 1H), 4.45 (d, <i>J</i> = 16.3 Hz, 1H), 4.20 (d, <i>J</i> = 16.3 Hz, 1H), 4.05 (q, <i>J</i> = 7.1 Hz, 2H), 3.96 (t, <i>J</i> = 7.9 Hz, 1H), 3.66 (q, <i>J</i> = 11.3 Hz, 1H), 3.24 (q, 11.3 Hz, 1H), 2.89–2.72 (m, 1H), 2.65–2.52 (m, 1H), 1.14 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (150 MHz, methanol-<i>d</i><sub>4</sub>) δ 174.51, 167.22, 163.81, 163.15, 162.16, 148.62, 147.38, 144.75, 141.33, 141.31, 132.34, 132.28, 130.57, 128.93, 127.29, 125.11, 124.06, 123.99, 120.98, 120.82, 116.32, 116.18, 64.99, 61.83, 61.63, 61.44, 61.24, 58.77, 53.86, 40.35, 40.18, 40.01, 14.51.</div></div><div id="sec4-1-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> General Procedures for the Synthesis of 3-((<i>R</i>)-4-(((<i>R</i>)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (<b>58</b>)</h3><div id="sec4-1-2-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (<i>R</i>)-(<i>S</i>)-1-Isopropoxy-1-oxopropan-2-yl 4-(2-Bromo-4-fluorophenyl)-6-methyl-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate (<b>(<i>R</i>)-58I-2</b>)</h4><div class="NLM_p">2-Thiazolecarboxamidine hydrochloride (1.64 g, 0.01 mol), 2-bromo-4-fluorobenzaldehyde (2.03 g, 0.01 mol), (<i>S</i>)-1-isopropoxy-1-oxopropan-2-yl 3-oxobutanoate (2.16 g, 0.01 mol), anhydrous sodium acetate (0.82 g, 0.01 mol), and <i>n</i>-propanol (10 mL) were added in turn to a flask. The mixture was stirred at 80 °C for 16 h. After the reaction, the mixture was cooled to 30 °C, kept at 30 °C, and stirred for 6 h. The resulting mixture was filtered. The filter cake was washed with water (330 mL) and dried in vacuo at 60 °C for 8 h to obtain the crude product (compound <b>58l-2</b>). To the crude product, <i>n</i>-propanol (19.2 g) was added. The mixture was heated until the crude product dissolved completely, then it was cooled to 30 °C, kept at 30 °C, and stirred and allowed to crystallize for 3 h. The resulting mixture was filtered. The filter cake was washed with <i>n</i>-propanol (2 g) and dried in vacuo at 60 °C for 8 h to obtain the product (compound <b>(<i>R</i>)-58l-2</b>) as a yellow solid (1.22 g, 24%). The absolute stereochemistry of <b>(<i>R</i>)-58l-2</b> was determined by an X-ray-diffraction study (see the <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>).<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/jm-2017-01914y_m001.gif" alt="" /></img></span></div><div class="NLM_p last">MS (ESI, positive ion) <i>m</i>/<i>z</i>: 510.0 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.0 (s, 1H), 7.97 (d, 1H), 7.90 (d, 1H), 7.54 (dd, 1H), 7.37 (dd, 1H), 7.25 (td, 1H), 5.99 (s, 1H), 4.83–4.76 (m, 2H), 2.49 (s, 3H), 1.32 (d, 3H), 1.04–1.02 (m, 6H).</div></div><div id="sec4-1-2-2" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (<i>R</i>)-Ethyl 4-(2-Bromo-4-fluorophenyl)-6-methyl-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate (<b>58I-3</b>)</h4><div class="NLM_p">Anhydrous ethanol (44.6 g) and lithium (0.243 g, 0.035 mol) were added to a flask in turn. The mixture was stirred at 43 °C until the lithium was consumed entirely, and then a solution of <b>(<i>R</i>)-58l-2</b> (5.1 g, 0.01 mol) in ethanol (44.6 g) was added. The reaction mixture was allowed to warm to 78 °C and was stirred for 1.5 h under a nitrogen atmosphere. After the reaction, the reaction mixture was cooled to 10 °C, kept at 10 °C, and stirred for 8 h. The mixture was filtered. The filtrate was washed with anhydrous ethanol (5 g) and water (50 g) in turn, and then dried in vacuo at 60 °C for 8 h to obtain the product (compound <b>58l-3</b>) as a yellow solid (2.97 g, 70%).<span class="NLM_disp-formula" id="ueq2"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/jm-2017-01914y_m002.gif" alt="" /></img></span></div><div class="NLM_p last">MS (ESI, positive ion) <i>m</i>/<i>z</i>: 424.0 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.88 (s, 1H), 7.97 (d, 1H), 7.89 (d, 1H), 7.54 (dd, 1H), 7.35 (dd, 1H), 7.23 (td, 1H), 5.96 (s, 1H), 3.93 (q, 2H), 2.46 (s, 3H), 1.03 (t, 3H).</div></div><div id="sec4-1-2-3" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (<i>R</i>)-Ethyl 4-(2-Bromo-4-fluorophenyl)-6-(bromomethyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate (<b>58I-4</b>)</h4><div class="NLM_p">(<i>R</i>)-Ethyl 4-(2-bromo-4-fluorophenyl)-6-methyl-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate (compound <b>58l-3</b>, 4.24 g, 0.01 mol) and CCl<sub>4</sub> (80 mL), followed by NBS (1.96 g, 0.011 mol), were added to a flask at 70 °C. The mixture was stirred for 30 min. After the reaction, the mixture was cooled and filtered. The filtrate was concentrated to obtain the product (compound <b>58l-4</b>) as a yellow solid (3.42 g, 68%).</div><div class="NLM_p last">MS (ESI, positive ion) <i>m</i>/<i>z</i>: 503.9 [M + H]<sup>+</sup>; <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.23 (s, 1H), 8.01 (d, 1H), 7.98 (d, 1H), 7.62 (dd, 1H), 7.42 (dd, 1H), 7.29 (td, 1H), 6.01 (s, 1H), 4.79 (br, 2H), 4.01 (q, 2H), 1.08 (t, 3H).</div></div><div id="sec4-1-2-4" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 3-((<i>R</i>)-4-(((<i>R</i>)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (<b>58</b>)</h4><div class="NLM_p last">(<i>R</i>)-Ethyl 4-(2-bromo-4-fluorophenyl)-6-(bromomethyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate (compound <b>58l-4</b>, 0.05 g, 0.001 mol), anhydrous ethanol (10 g), and (<i>R</i>)-3-(morpholin-2-yl)propanoic acid (0.175 g, 0.0011 mol) were added to a flask. The mixture was stirred at 25 °C under a nitrogen atmosphere for 6 h. After the reaction, the mixture was concentrated. Ethyl acetate (10 g) was added to the residue, and the resulting mixture was washed with water (15 mL × 2). The organic layer was concentrated to give 3-((<i>R</i>)-4-(((<i>R</i>)-6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic acid (compound <b>58</b>) as tawny oil (0.38 g, 65%). HRMS: calcd (M) 580.0791, exptl (MH<sup>+</sup>) 581.086. <sup>1</sup>H NMR (600 MHz, DMSO<i>-d</i><sub>6</sub>) δ 12.04 (s, 1H), 9.65 (s, 1H), 8.02 (d, <i>J</i> = 3.1 Hz, 1H), 7.94 (d, <i>J</i> = 3.1 Hz, 1H), 7.56 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 7.40–7.38 (m, 1H), 7.22 (td, <i>J</i> = 8.5, 2.6 Hz, 1H), 6.03 (s, 1H), 3.99–3.92 (m, 2H), 3.90–3.87 (m, 3H), 3.58 (td, <i>J</i> = 11.2, 1.9 Hz, 1H), 3.53–3.47 (m, 1H), 2.80–2.75 (m, 2H), 2.35 (td, <i>J</i> = 11.4, 3.0 Hz, 1H), 2.31–2.23 (m, 2H), 2.02 (t, <i>J</i> = 10.5 Hz, 1H), 1.69–1.56 (m, 2H), 1.06 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) δ 174.69, 165.64, 162.46, 162.07, 160.42, 146.84, 144.36, 144.09, 140.70, 140.68, 131.41, 131.35, 125.14, 123.08, 123.01, 120.14, 119.98, 116.03, 115.89, 97.59, 74.92, 66.54, 59.86, 58.66, 58.29, 56.26, 53.26, 29.98, 28.52, 14.46.</div></div></div><div id="sec4-1-2-5" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 3-((<i>S</i>)-4-(((<i>R</i>)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (<b>59</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 580.0791, exptl (MH<sup>+</sup>) 581.0862. <sup>1</sup>H NMR (600 MHz, acetone-<i>d</i><sub>6</sub>) δ 9.72 (s, 1H), 7.97 (d, <i>J</i> = 3.1 Hz, 1H), 7.80 (d, <i>J</i> = 3.0 Hz, 1H), 7.55–7.49 (m, 1H), 7.44 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 7.13 (td, <i>J</i> = 8.4, 2.5 Hz, 1H), 6.19 (s, 1H), 4.09 (d, <i>J</i> = 16.8 Hz, 1H), 4.03 (q, <i>J</i> = 7.1 Hz, 2H), 3.95 (d, <i>J</i> = 16.6 Hz, 1H), 3.90 (d, <i>J</i> = 11.1 Hz, 1H), 3.74–3.68 (m, 2H), 2.98 (d, <i>J</i> = 8.6 Hz, 1H), 2.74 (d, <i>J</i> = 7.3 Hz, 1H), 2.54–2.41 (m, 3H), 2.37 (s, 1H), 2.29–2.20 (m, 1H), 1.83–1.78 (m, 2H), 1.13 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (150 MHz, acetone-<i>d</i><sub>6</sub>) δ 173.66, 165.38, 162.77, 162.16, 160.51, 146.47, 144.28, 143.46, 140.59, 131.17, 131.12, 123.77, 122.92, 122.86, 119.65, 119.49, 115.15, 115.01, 97.80, 74.81, 66.37, 59.38, 58.72, 58.45, 56.30, 53.01, 13.64.</div></div><div id="sec4-1-2-6" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 3-((3<i>S</i>)-4-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-3-yl)propanoic Acid (<b>60</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 580.0791, exptl (MH<sup>+</sup>) 581.086. <sup>1</sup>H NMR (600 MHz, acetone-<i>d</i><sub>6</sub>) δ 9.93 (s, 1H), 7.98 (d, <i>J</i> = 3.1 Hz, 1H), 7.80 (d, <i>J</i> = 3.1 Hz, 1H), 7.54–7.51 (m, 1H), 7.42 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 7.16 (td, <i>J</i> = 8.5, 2.6 Hz, 1H), 6.18 (s, 1H), 4.33 (d, <i>J</i> = 18.0 Hz, 1H), 4.04–4.01 (m, 3H), 3.93 (dd, <i>J</i> = 11.4, 2.7 Hz, 1H), 3.83–3.80 (m, 1H), 3.77–3.70 (m, 1H), 3.51–3.47 (m, 1H), 3.01 (s, 1H), 2.90 (d, <i>J</i> = 10.8 Hz, 1H), 2.70–2.60 (m, 2H), 2.51–2.46 (m, 1H), 2.44–2.37 (m, 1H), 1.86–1.78 (m, 1H), 1.13 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (150 MHz, acetone-<i>d</i><sub>6</sub>) δ 173.65, 165.47, 162.80, 162.12, 160.48, 147.69, 144.26, 143.50, 140.66, 131.30, 131.24, 123.79, 122.83, 122.77, 119.55, 119.39, 115.36, 115.22, 96.47, 70.04, 66.75, 59.81, 59.33, 58.64, 53.46, 52.40, 13.66.</div></div><div id="sec4-1-2-7" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 3-((3<i>R</i>)-4-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-3-yl)propanoic Acid (<b>61</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 580.0791, exptl (MH<sup>+</sup>) 581.0862. <sup>1</sup>H NMR (600 MHz, acetone-<i>d</i><sub>6</sub>) δ 9.93 (s, 1H), 7.99 (d, <i>J</i> = 3.1 Hz, 1H), 7.79 (d, <i>J</i> = 3.1 Hz, 1H), 7.52–7.49 (m, 1H), 7.43 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 7.11 (td, <i>J</i> = 8.4, 2.6 Hz, 1H), 6.18 (s, 1H), 4.37 (d, <i>J</i> = 17.9 Hz, 1H), 4.05–4.01 (m, 3H), 3.89 (dd, <i>J</i> = 11.4, 2.7 Hz, 1H), 3.81–3.80 (m, 1H), 3.76–3.70 (m, 1H), 3.58–3.55 (m, 1H), 2.99–2.96 (m, 1H), 2.72–2.69 (m, 1H), 2.63–2.55 (m, 1H), 2.48–2.35 (m, 2H), 2.00–1.94 (m, 1H), 1.86–1.80 (m, 1H), 1.13 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (150 MHz, acetone-<i>d</i><sub>6</sub>) δ 173.51, 165.44, 162.86, 162.12, 160.48, 147.66, 147.59, 144.25, 143.48, 140.67, 131.19, 131.13, 123.73, 122.94, 122.88, 119.63, 119.47, 115.11, 114.97, 96.52, 69.62, 66.66, 59.32, 59.29, 58.81, 53.35, 51.28, 13.66.</div></div><div id="sec4-1-2-8" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> (3<i>S</i>)-4-((6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(1-methyl-1<i>H</i>-imidazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic Acid (<b>62</b>)</h3><div class="NLM_p last">The synthetic procedure was described in the <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>. HRMS: calcd (M) 549.1023, exptl (MH<sup>+</sup>) 550.1090. <sup>1</sup>H NMR (600 MHz, acetone-<i>d</i><sub>6</sub>) δ 7.46–7.43 (m, 1H), 7.42–7.39 (m, 1H), 7.21 (d, <i>J</i> = 4.5 Hz, 1H), 7.11–7.07 (m, 1H), 7.03 (s, 1H), 6.17 (d, <i>J</i> = 8.8 Hz, 1H), 4.34 (d, <i>J</i> = 17.7 Hz, 1H), 4.22 (d, <i>J</i> = 17.7 Hz, 1H), 4.18–4.11 (m, 1H), 4.05–4.01 (m, 3H), 3.99 (d, <i>J</i> = 7.2 Hz, 3H), 3.88–3.76 (m, 2H), 3.67–3.54 (m, 1H), 3.26–3.21 (m, 1H), 2.62–2.44 (m, 1H), 1.13 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (150 MHz, acetone-<i>d</i><sub>6</sub>) δ 171.71, 165.55, 165.54, 162.05, 160.41, 148.22, 143.00, 140.18, 140.16, 140.06, 140.04, 138.71, 138.69, 130.31, 130.25, 127.55, 127.54, 125.94, 125.92, 123.10, 123.05, 123.03, 119.86, 119.84, 119.69, 119.68, 114.76, 114.72, 114.63, 114.59, 95.59, 95.33, 69.22, 69.13, 67.04, 66.99, 62.12, 59.18, 58.16, 58.11, 54.79, 49.31, 48.37, 35.50, 13.68.</div></div><div id="sec4-1-2-9" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 3-((<i>R</i>)-4-(((<i>R</i>)-6-(2-Bromo-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (<b>63</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 566.0635, exptl (MH<sup>+</sup>) 567.0707. <sup>1</sup>H NMR (600 MHz, acetone-<i>d</i><sub>6</sub>) δ 9.76 (s, 1H), 7.97 (d, <i>J</i> = 3.1 Hz, 1H), 7.79 (d, <i>J</i> = 3.1 Hz, 1H), 7.49–7.47 (m, 1H), 7.44 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 7.11 (td, <i>J</i> = 8.4, 2.6 Hz, 1H), 6.17 (s, 1H), 4.00 (q, <i>J</i> = 17.2 Hz, 2H), 3.96–3.92 (m, 1H), 3.73 (td, <i>J</i> = 11.3, 2.3 Hz, 1H), 3.69–3.65 (m, 1H), 3.58 (s, 3H), 2.89–2.84 (m, 2H), 2.50–2.37 (m, 3H), 2.13 (t, <i>J</i> = 10.5 Hz, 1H), 1.77–1.74 (m, 2H). <sup>13</sup>C NMR (150 MHz, acetone-<i>d</i><sub>6</sub>) δ 173.56, 165.88, 162.73, 162.67, 162.16, 160.51, 146.77, 146.69, 144.40, 144.36, 143.49, 140.31, 140.29, 130.99, 130.94, 123.74, 122.99, 122.92, 119.79, 119.63, 115.10, 114.96, 97.27, 74.8’1, 66.47, 58.66, 58.28, 56.44, 56.41, 53.24, 50.35.</div></div><div id="sec4-1-2-10" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 3-((<i>R</i>)-4-(((<i>R</i>)-6-(2-Chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (<b>64</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 522.1140, exptl (MH<sup>+</sup>) 523.1240. <sup>1</sup>H NMR (400 MHz, methanol-<i>d</i><sub>4</sub>) δ 7.96 (d, <i>J</i> = 3.0 Hz, 1H), 7.75 (d, <i>J</i> = 3.0 Hz, 1H), 7.43–7.39 (m, 1H), 7.23 (dd, <i>J</i> = 8.7, 2.3 Hz, 1H), 7.05 (td, <i>J</i> = 8.4, 2.3 Hz, 1H), 6.17 (s, 1H), 4.09–3.90 (m, 3H), 3.79 (t, <i>J</i> = 10.5 Hz, 1H), 3.73–3.68 (m, 1H), 3.61 (s, 3H), 2.93–2.77 (m, 2H), 2.55 (t, <i>J</i> = 10.1 Hz, 1H), 2.47–2.33 (m, 2H), 2.17 (t, <i>J</i> = 9.5 Hz, 1H), 1.76 (q, <i>J</i> = 7.1 Hz, 2H). <sup>13</sup>C NMR (101 MHz, methanol-<i>d</i><sub>4</sub>) δ 175.91, 166.37, 162.94, 161.82, 160.47, 146.79, 145.70, 143.37, 137.88, 137.85, 133.46, 133.36, 130.82, 130.73, 123.72, 116.55, 116.30, 114.27, 114.05, 98.21, 74.84, 66.20, 57.98, 56.39, 55.69, 53.02, 50.25, 29.54.</div></div><div id="sec4-1-2-11" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 3-((<i>R</i>)-4-(((<i>R</i>)-6-(2,4-Dichlorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (<b>65</b>)</h3><div class="NLM_p last">HRMS: calcd (M) 538.0844, exptl (MH<sup>+</sup>) 539.0488. <sup>1</sup>H NMR (600 MHz, acetone-<i>d</i><sub>6</sub>) δ 9.78 (s, 1H), 7.97 (d, <i>J</i> = 3.1 Hz, 1H), 7.79 (d, <i>J</i> = 3.1 Hz, 1H), 7.49 (d, <i>J</i> = 2.1 Hz, 1H), 7.46 (d, <i>J</i> = 8.4 Hz, 1H), 7.31 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 6.19 (s, 1H), 4.00 (q, <i>J</i> = 17.2 Hz, 2H), 3.95–3.92 (m, 1H), 3.73 (td, <i>J</i> = 11.1, 2.2 Hz, 1H), 3.75–3.71 (m, 1H), 3.58 (s, 3H), 2.86 (t, <i>J</i> = 12.6 Hz, 2H), 2.50–2.37 (m, 3H), 2.13 (t, <i>J</i> = 10.5 Hz, 1H), 1.77–1.74 (dd, <i>J</i> = 14.1, 7.4 Hz, 2H). <sup>13</sup>C NMR (150 MHz, acetone-<i>d</i><sub>6</sub>) δ 173.54, 165.80, 162.59, 146.87, 144.63, 143.51, 141.15, 133.52, 133.00, 130.99, 129.07, 127.69, 123.79, 96.72, 74.80, 66.46, 58.28, 56.51, 56.42, 53.24, 50.38.</div></div><div id="sec4-1-2-12" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 3-((<i>S</i>)-1-(((<i>R</i>)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)-4,4-difluoropyrrolidin-2-yl)propanoic Acid (<b>66</b>)</h3><div class="NLM_p last">The synthetic procedure was described in the <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>. HRMS: calcd (M) 600.0654, exptl (MH<sup>+</sup>) 601.0723. <sup>1</sup>H NMR (600 MHz, acetone) δ 7.95 (d, <i>J</i> = 3.1 Hz, 1H), 7.81 (d, <i>J</i> = 3.1 Hz, 1H), 7.59–7.56 (m, 1H), 7.44 (dd, <i>J</i> = 8.5, 2.6 Hz, 1H), 7.16 (td, <i>J</i> = 8.5, 2.6 Hz, 1H), 6.19 (s, 1H), 4.29 (q, <i>J</i> = 17.1 Hz, 2H), 4.03 (q, <i>J</i> = 7.1 Hz, 2H), 3.64–3.59 (m, 1H), 3.25–3.21 (m, 1H), 3.10–3.02 (m, 1H), 2.70–2.59 (m, 1H), 2.58–2.50 (m, 1H), 2.49–2.41 (m, 1H), 2.28–2.16 (m, 2H), 1.93–1.86 (m, 1H), 1.12 (t, <i>J</i> = 7.1 Hz, 3H).<sup>13</sup>C NMR (150 MHz, acetone-<i>d</i><sub>6</sub>) δ 173.78, 165.37, 162.73, 162.19, 160.54, 147.13, 144.38, 143.44, 140.64, 140.61, 131.40, 131.35, 129.81, 128.19, 126.54, 123.96, 122.77, 122.71, 119.57, 119.41, 115.34, 115.20, 97.99, 63.21, 63.18, 62.10, 61.91, 61.71, 59.46, 58.15, 51.84, 40.60, 40.44, 40.28, 29.27, 27.73, 13.60.</div></div><div id="sec4-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Molecular Docking</h3><div class="NLM_p last">For docking purposes, the crystallographic coordinates of the HBcAg (PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5E0I">5E0I</a>) were obtained from the protein data bank (<a href="http://www.rcsb.org" class="extLink">www.rcsb.org</a>). Hydrogen atoms were added to the structure to allow for appropriate ionization at physiological pH. The protonated state of several important residues, such as His106, His142, Tyr599, Glu751, and His640, were adjusted by using SYBYL7.3 (Tripos, St. Louis, MO) to favor the formation of reasonable hydrogen bonds with the ligand. Molecular-docking analysis was carried out by the SURFLEX module of the SYBYL package in order to explore the interaction model for the active site of HBcAg with its ligand. All atoms located within the range of 6.0 Å from any atom of the original ligand were selected for the active-site analysis, and the corresponding amino acid residue was, therefore, involved in the active-site analysis even if only one of its atoms was selected. Other default parameters were adopted in the SURFLEX-docking calculations. All calculations were performed on a CCNU Grid based computational environment (CCNU Grid website: <a href="http://www.202.114.32.71:8090/ccnu/chem/platform.xml" class="extLink">http://www.202.114.32.71:8090/ccnu/chem/platform.xml</a>).</div></div><div id="sec4-3" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> In Vitro Biological Testing</h3><div id="sec4-3-1" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> General Considerations</h4><div class="NLM_p last">All final compounds were examined for known classes of assay-interference compounds (pan assay-interference compounds, PAINS),<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> which were classified as negative.</div></div><div id="sec4-4" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> In Vitro Anti-HBV Activity in HepG2.2.15</h4><div class="NLM_p">HBV replicon cells, HepG2.2.15, were seeded into 96-well plates at 4 × 10<sup>5</sup> cells/well, treated with cell-culture medium (RPMI 1640 containing 10% FBS, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, 100 units/mL penicillin, and 10 μg/mL streptomycin), and incubated overnight at 37 °C. The control and test compounds were 3-fold diluted with medium and added into the plates with a 0.5% final DMSO concentration. The plates were then incubated at 37 °C in a 5% carbon dioxide atmosphere and refreshed with compound-containing medium every 3 days. On day 7, the HepG2.2.15 supernatant was collected and HBV DNA was extracted using the QIAamp 96 DNA Blood Kit (QIAGEN 51161, Hilden, Germany). The HBV DNA was quantified by real-time PCR. The primers and probe used were as follows:</div><div class="NLM_p">HBV forward primer: 5′-GTGTCTGCGGGCGTTTTATCA-3′</div><div class="NLM_p">HBV reverse primer: 5′-GACAAACGGGCAACATACCTT-3′</div><div class="NLM_p">HBV probe: 5′FAM-CCTCTKCATCCTGCTGCTATGCCTCATC-3′</div><div class="NLM_p">A standard curve was generated by plotting Ct value versus the amount of the HBV-plasmid standard, and the quantity of each sample was estimated on the basis of the Ct-value projection on the standard curve; the percent of HBV inhibition by compound was calculated using the following equation:<span class="NLM_disp-formula"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/jm-2017-01914y_m003.gif" alt="" /></img></span></div><div class="NLM_p last">The EC<sub>50</sub> were plotted with GraphPad Prism 4 using the equation below.<span class="NLM_disp-formula"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/jm-2017-01914y_m004.gif" alt="" /></img></span>where <i>X</i> is the logarithm of the concentration, and <i>Y</i> is the response. <i>Y</i> starts at the bottom and goes to the top with a sigmoid shape. This is identical to the “four parameter logistic equation”.</div></div><div id="sec4-5" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> hERG assay</h4><div class="NLM_p last">In vitro electrophysiology manual-patch-clamp assays of selected compounds on hERG channels were conducted in PharmaCore Laboratories, Ltd. (Jiangsu, China) in compliance with their Standard Operating Procedures. In detail, HEK293 cells were perfused with an extracellular solution, and membrane currents were recorded by a HEKA EPC-10 USB patch-clamp amplifier and a PATCHMASTER acquisition program (HEKA Instruments Inc., Lambrecht, Germany) at room temperature. The electrophysiological-voltage protocol for the hERG-current recordings was the following: Cells were voltage clamped at a holding potential of −80 mV. The hERG current was activated by depolarizing at +20 mV for 2 s, after which the current was taken back to −50 mV for 5 s to remove the inactivation and observe the deactivating tail current. The stimulation frequency was once every 15 s. The current amplitude was the peak value of the tail current. The channel current was recorded in the whole-cell recording mode. The extracellular fluid was perfused and recorded continuously until stabilization. Then, the extracellular fluid containing the tested compound was perfused and recorded until the inhibition of the hERG current reached a steady state. Data were analyzed using PATCHMASTER V2 × 60 (HEKA Instruments Inc., Lambrecht, Germany) and Origin 8.5 (OriginLab Corporation, Northampton, MA) software programs and Microsoft Excel.</div></div><div id="sec4-6" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Microsomal-Stability Assay</h4><div class="NLM_p last">Microsomes were preincubated with a test compound for 10 min at 37 °C in 100 mM potassium phosphate buffer (pH 7.4). The reactions were initiated by adding NADPH to give a final incubation volume of 45 μL. The incubations contained 1 μM test compound, 0.5 mg/mL liver microsomal protein, and 2 mM NADPH in 100 mM potassium phosphate buffer (pH 7.4). After incubation times of 0, 15, 30, and 60 min at 37 °C, stop solution was added (150 μL/well) to terminate the reaction. Following precipitation and centrifugation, the amounts of compound remaining in the samples were determined by LC-MS/MS.</div></div><div id="sec4-7" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> Cytochrome-P450 (Cyp450)-Induction-Screening Assay: Enzyme-Activity Induction</h4><div class="NLM_p">Cryopreserved hepatocytes were thawed and counted to determine their yield, and their viability was measured. Hepatocytes at a concentration of 0.7 million cells/mL were transferred to collagen-coated 48-well plates for attachment (0.2 mL viable cells/well). After the hepatocytes attached to the collagen matrix, the plating medium was replaced with an incubation medium containing 2% (v/v) Matrigel (sandwich medium), and the hepatocytes were incubated until their use. All incubations were conducted at 37 °C, 5% CO<sub>2</sub>, and 95% humidity.</div><div class="NLM_p">After the cultures were established, the sandwich medium was removed and the hepatocytes were treated for 24 h with incubation solutions that contained a vehicle (0.1% DMSO) and a test compound or were a negative control or a positive control. The incubation solution was aspirated and replaced the appropriate fresh solution for an additional 24 h incubation. The total treatment period was 48 h. After the treatment period of 48 h, the incubation solution was aspirated. Hepatocytes were washed twice with HBSS, followed by the addition of the enzyme-substrate working solution. The hepatocytes were incubated for 30 min.</div><div class="NLM_p last">After the incubation, 75 μL of the samples were aspirated and quenched with 150 μL of the stop solution. The resulting mixtures were shaken for 10 min, which was followed by centrifugation at 4 °C and 3220<i>g</i> for 20 min. For each, an aliquot of the supernatant were mixed with 0.1% FA in water at a ratio of 1:4. The resulting samples were shaken for 10 min prior to analysis by LC-MS/MS. The concentrations of the three metabolites of the CYP-enzyme substrate, 1′-hydroxymidazolam, hydroxybupropion, and acetaminophen, in the human hepatocytes were quantitatively determined by LC-MS/MS after the proteins were precipitated.</div></div></div><div id="sec4-8" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> In Vivo Efficacy in the Hydrodynamic-Injection (HDI) Mouse Model</h3><div class="NLM_p">This study was conducted by WuXi AppTec Company, Ltd. (Shanghai, China). All the procedures in the study were in compliance with local animal-welfare legislation, the Guide for the Care and Use of Laboratory Animals, and protocols approved by the WuXi AppTec Institutional Animal Care and Use Committee (IACUC).</div><div class="NLM_p last">Female BALB/c mice (6–7 weeks old, 16–18 g) that were specific-pathogen free were supplied by Shanghai Lingchang Biotechnology Company, Ltd. (Shanghai, China). The study was approved by the WuXi IACUC (IACUC protocol R20160125-Mouse). On day 0, all the mice were hydrodynamically injected with pAAV2-HBV1.3mer plasmid DNA (genotype D) in a volume of normal saline equivalent to 8% of a mouse’s body weight within 5 s through a tail vein. From days 1 to 7, the mice in all the groups were orally dosed with the blank vehicle, 0.1 mg/kg entecavir, 50 mg/kg HEC72702, or 100 mg/kg HEC72702 at the indicated frequency. Plasma and liver samples were collected at the indicated time points for HBV-DNA quantification by real-time PCR.</div></div><div id="sec4-9" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Pharmacokinetic (PK) Analysis</h3><div class="NLM_p">All pharmacokinetic studies in male Sprague–Dawley (SD) rats and beagle dogs were conducted according to protocols approved by the Animal Care and Use Committee at the Laboratory Animal Center of HEC Pharma Group. Briefly, male SD rats were obtained from Hunan SJA Laboratory Animal Company, Ltd. (China) and maintained on a 12 h light–dark cycle with ad libitum access to food and water. Non-naïve beagle dogs supplied by Beijing Marshall Biotechnology Company, Ltd. (Beijing, China) were used in this study. The animals were confirmed healthy before being assigned to the study. Each animal was given a unique identification number marked on the ear and written on the cage card.</div><div class="NLM_p">The compounds were evaluated in Sprague–Dawley rats (6–7 weeks old, 190–240 g), which had fasted overnight before their dosings, and their food was returned 4 h after their dosings. There were three rats in the iv group and three rats in the po group, all of which had blood samples taken (iv group, 1 mg/kg; po group, 5 mg/kg). The compounds were dissolved in 5% DMSO, 5% solutol, and 90% saline for iv and po doses. Blood samples were collected at each time point, placed into tubes containing sodium heparin, and centrifuged at 12 000 rpm for 2 min at 4 °C to separate the plasma from the samples. Following centrifugation, the resulting plasma was transferred to clean tubes and stored frozen at −80 °C pending bioanalysis. Plasma concentrations were determined by LC-MS/MS, and the data were analyzed by a noncompartmental module of a WinNonlin 6.3. Any BLQs were omitted from the calculations.</div><div class="NLM_p last">All dogs (7–9 months old, 8–12 kg) fasted overnight before their first dosings; their food was returned immediately after the oral dosing and at 4 h post the first dosing. Reverse-osmosis (RO) water was available to all the animals, ad libitum<i>.</i> There were three dogs in the iv group and three dogs in the po group, all of which had blood samples taken (iv group, 1 mg/kg; po group, 5 mg/kg). The compounds were dissolved in 5% DMSO, 5% solutol, and 90% saline for the iv and po doses. Blood samples were collected at each time point, placed into tubes containing sodium heparin, and centrifuged at 12 000 rpm for 2 min at 4 °C to separate the plasma from the samples. Following centrifugation, the resulting plasma was transferred to clean tubes and stored frozen at −80 °C pending bioanalysis. Plasma concentrations were determined by LC-MS/MS, and the data were analyzed by a noncompartmental module of a WinNonlin 6.3. Any BLQs were omitted from the calculations.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i79"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01914">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15256" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15256" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01914" class="ext-link">10.1021/acs.jmedchem.7b01914</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Detailed experimental procedures for the synthesis of intermediates <b>58I-1</b> and analogues <b>35</b>, <b>62</b>, and <b>66</b>; characterization of compounds <b>6</b>–<b>25</b>; X-ray crystal structure of <b>(<i>R</i>)-58I-2</b>; <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of compound <b>58</b>; inhibition efficacy of <b>(<i>R</i>)-52</b> against four major HBV genotypes (A, B, C, and D); CYP inhibition assay; pharmacokinetic (PK) studies in mice; HBV-capsid-assembly-quenching assay (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01914/suppl_file/jm7b01914_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular-formula strings of the reported compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01914/suppl_file/jm7b01914_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01914/suppl_file/jm7b01914_si_001.pdf">jm7b01914_si_001.pdf (1.08 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01914/suppl_file/jm7b01914_si_002.csv">jm7b01914_si_002.csv (5.13 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b01914" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84167" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84167" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingyun Ren</span> - <span class="hlFld-Affiliation affiliation">The
State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan 523871, China</span>; 
    <span class="hlFld-Affiliation affiliation">Anti-infection
Innovation Department, New Drug Research Institute, HEC Pharma Group, Dong Guan 523871, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0000-0417" title="Orcid link">http://orcid.org/0000-0003-0000-0417</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#fa889f948b93949d838f94ba929f99d49994"><span class="__cf_email__" data-cfemail="0e7c6b607f676069777b604e666b6d206d60">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingjun Zhang</span> - <span class="hlFld-Affiliation affiliation">The
State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan 523871, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#fb81939a959c8292959c918e95bb939e98d59895"><span class="__cf_email__" data-cfemail="3d47555c535a4454535a5748537d55585e135e53">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xinchang Liu</span> - <span class="hlFld-Affiliation affiliation">The
State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan 523871, China</span>; 
    <span class="hlFld-Affiliation affiliation">Anti-infection
Innovation Department, New Drug Research Institute, HEC Pharma Group, Dong Guan 523871, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guanghua Yan</span> - <span class="hlFld-Affiliation affiliation">The
State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan 523871, China</span>; 
    <span class="hlFld-Affiliation affiliation">Anti-infection
Innovation Department, New Drug Research Institute, HEC Pharma Group, Dong Guan 523871, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Biao Nie</span> - <span class="hlFld-Affiliation affiliation">The
State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan 523871, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhifu Zou</span> - <span class="hlFld-Affiliation affiliation">The
State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan 523871, China</span>; 
    <span class="hlFld-Affiliation affiliation">Anti-infection
Innovation Department, New Drug Research Institute, HEC Pharma Group, Dong Guan 523871, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Li</span> - <span class="hlFld-Affiliation affiliation">The
State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan 523871, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yunfu Chen</span> - <span class="hlFld-Affiliation affiliation">The
State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan 523871, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu Wei</span> - <span class="hlFld-Affiliation affiliation">The
State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan 523871, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianzhou Huang</span> - <span class="hlFld-Affiliation affiliation">The
State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan 523871, China</span>; 
    <span class="hlFld-Affiliation affiliation">Anti-infection
Innovation Department, New Drug Research Institute, HEC Pharma Group, Dong Guan 523871, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhonghua Luo</span> - <span class="hlFld-Affiliation affiliation">The
State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan 523871, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Baohua Gu</span> - <span class="hlFld-Affiliation affiliation">The
State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan 523871, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Siegfried Goldmann</span> - <span class="hlFld-Affiliation affiliation">The
State Key Laboratory of Anti-Infection Drug Development, HEC Pharma Group, Dong Guan 523871, China</span>; 
    <span class="hlFld-Affiliation affiliation">Anti-infection
Innovation Department, New Drug Research Institute, HEC Pharma Group, Dong Guan 523871, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4776-0360" title="Orcid link">http://orcid.org/0000-0002-4776-0360</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiancun Zhang</span> - <span class="hlFld-Affiliation affiliation">Guangzhou
Institute of Biomedicine and Health, Chinese
Academy of Sciences, Guangzhou 510530, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i80">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72483" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72483" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This project was supported by the National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the Thirteenth Five-Year Plan Period of China (nos. 2017ZX09201006004 and 2016ZX09101065). We thank Dr. Wenchao Yang at the Central China Normal University for the molecular-docking analysis. In addition, we thank Wuxi AppTec for working together with us on the in vitro and in vivo anti-HBV-activity experiments, Shanghai Chem Explorer and Pharma Core Laboratories for the hERG-inhibition experiments, and the Research Institute for Liver Diseases (Shanghai) Company, Ltd., for the induction test on the CYP enzymes.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i81" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i81"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i82" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i82"> Abbreviations Used</h2><tr><td class="NLM_term">HBV</td><td class="NLM_def"><p class="first last">hepatitis B virus</p></td></tr><tr><td class="NLM_term">CHB</td><td class="NLM_def"><p class="first last">chronic hepatitis B</p></td></tr><tr><td class="NLM_term">HAP</td><td class="NLM_def"><p class="first last">heteroaryldihydropyrimidine</p></td></tr><tr><td class="NLM_term">HBsAg</td><td class="NLM_def"><p class="first last">HBV surface antigen</p></td></tr><tr><td class="NLM_term">pgRNA</td><td class="NLM_def"><p class="first last">pregenomic RNA</p></td></tr><tr><td class="NLM_term">cccDNA</td><td class="NLM_def"><p class="first last">covalently closed circular DNA</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-à-go-go-related gene</p></td></tr><tr><td class="NLM_term">ADMET</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, excretion, and toxicity</p></td></tr><tr><td class="NLM_term">HDI</td><td class="NLM_def"><p class="first last">hydrodynamic injection</p></td></tr><tr><td class="NLM_term">ETV</td><td class="NLM_def"><p class="first last">entecavir</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last"><i>N</i>-bromosuccinimide</p></td></tr><tr><td class="NLM_term">PE</td><td class="NLM_def"><p class="first last">petroleum ether</p></td></tr><tr><td class="NLM_term">EA</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">IPA</td><td class="NLM_def"><p class="first last">2-propanol</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">qPCR</td><td class="NLM_def"><p class="first last">quantitative polymerase chain reaction</p></td></tr><tr><td class="NLM_term">q.d.</td><td class="NLM_def"><p class="first last">once daily</p></td></tr><tr><td class="NLM_term">b.i.d.</td><td class="NLM_def"><p class="first last">twice daily</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsome</p></td></tr><tr><td class="NLM_term">DLM</td><td class="NLM_def"><p class="first last">dog liver microsome.</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08438" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08438" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Ganem, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prince, A. M.</span><span> </span><span class="NLM_article-title">Hepatitis B virus infection-natural history and clinical consequences</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">1118</span><span class="NLM_x">–</span> <span class="NLM_lpage">1129</span><span class="refDoi"> DOI: 10.1056/NEJMra031087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1056%2FNEJMra031087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=15014185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitV2qurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=1118-1129&author=D.+Ganemauthor=A.+M.+Prince&title=Hepatitis+B+virus+infection-natural+history+and+clinical+consequences&doi=10.1056%2FNEJMra031087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B virus infection-natural history and clinical consequences</span></div><div class="casAuthors">Ganem, Don; Prince, Alfred M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1118-1129</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review discusses the recent advances in the understanding of the natural history and pathogenesis of hepatitis B virus infection, with particular ref. to the implications for antiviral therapy.  The administration of interferons, and the use antiviral drugs such as lamivudine and other nucleoside analogs are particularly described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEhbSUYzgtnLVg90H21EOLACvtfcHk0ljKD4_klhF1WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitV2qurs%253D&md5=b8a9d038ccbaaef6077329ada84b8212</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra031087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra031087%26sid%3Dliteratum%253Aachs%26aulast%3DGanem%26aufirst%3DD.%26aulast%3DPrince%26aufirst%3DA.%2BM.%26atitle%3DHepatitis%2520B%2520virus%2520infection-natural%2520history%2520and%2520clinical%2520consequences%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D1118%26epage%3D1129%26doi%3D10.1056%2FNEJMra031087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Shepard, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiore, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, B. P.</span><span> </span><span class="NLM_article-title">Hepatitis B virus infection: epidemiology and vaccination</span> <span class="citation_source-journal">Epidemiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1093/epirev/mxj009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1093%2Fepirev%2Fmxj009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=16754644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A280%3ADC%252BD28vjsVahsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2006&pages=112-125&author=C.+W.+Shepardauthor=E.+P.+Simardauthor=L.+Finelliauthor=A.+E.+Fioreauthor=B.+P.+Bell&title=Hepatitis+B+virus+infection%3A+epidemiology+and+vaccination&doi=10.1093%2Fepirev%2Fmxj009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B virus infection: epidemiology and vaccination</span></div><div class="casAuthors">Shepard Colin W; Simard Edgar P; Finelli Lyn; Fiore Anthony E; Bell Beth P</div><div class="citationInfo"><span class="NLM_cas:title">Epidemiologic reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112-25</span>
        ISSN:<span class="NLM_cas:issn">0193-936X</span>.
    </div><div class="casAbstract">Worldwide, two billion people have been infected with hepatitis B virus (HBV), 360 million have chronic infection, and 600,000 die each year from HBV-related liver disease or hepatocellular carcinoma.  This comprehensive review of hepatitis B epidemiology and vaccines focuses on definitive and influential studies and highlights current trends, policies, and directions.  HBV can be transmitted vertically, through sexual or household contact, or by unsafe injections, but chronic infections acquired during infancy or childhood account for a disproportionately large share of worldwide morbidity and mortality.  Vaccination against HBV infection can be started at birth and provides long-term protection against infection in more than 90% of healthy people.  In the 1990s, many industrialized countries and a few less-developed countries implemented universal hepatitis B immunization and experienced measurable reductions in HBV-related disease.  For example, in Taiwan, the prevalence of chronic infection in children declined by more than 90%.  Many resource-poor nations have recently initiated universal hepatitis B immunization programs with assistance from the Global Alliance for Vaccines and Immunization.  Further progress towards the elimination of HBV transmission will require sustainable vaccination programs with improved vaccination coverage, practical methods of measuring the impact of vaccination programs, and targeted vaccination efforts for communities at high risk of infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS2UhAXwGC9Lv9pSBfyDvp7fW6udTcc2eZ3g2rEMVFkN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vjsVahsA%253D%253D&md5=59540288bd15ae148dc1b162c798c94b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Fepirev%2Fmxj009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fepirev%252Fmxj009%26sid%3Dliteratum%253Aachs%26aulast%3DShepard%26aufirst%3DC.%2BW.%26aulast%3DSimard%26aufirst%3DE.%2BP.%26aulast%3DFinelli%26aufirst%3DL.%26aulast%3DFiore%26aufirst%3DA.%2BE.%26aulast%3DBell%26aufirst%3DB.%2BP.%26atitle%3DHepatitis%2520B%2520virus%2520infection%253A%2520epidemiology%2520and%2520vaccination%26jtitle%3DEpidemiol.%2520Rev.%26date%3D2006%26volume%3D28%26spage%3D112%26epage%3D125%26doi%3D10.1093%2Fepirev%2Fmxj009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Perrillo, R.</span><span> </span><span class="NLM_article-title">Benefits and risks of interferon therapy for hepatitis B</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">S103</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span><span class="refDoi"> DOI: 10.1002/hep.22956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1002%2Fhep.22956" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=S103-111&author=R.+Perrillo&title=Benefits+and+risks+of+interferon+therapy+for+hepatitis+B&doi=10.1002%2Fhep.22956"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fhep.22956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22956%26sid%3Dliteratum%253Aachs%26aulast%3DPerrillo%26aufirst%3DR.%26atitle%3DBenefits%2520and%2520risks%2520of%2520interferon%2520therapy%2520for%2520hepatitis%2520B%26jtitle%3DHepatology%26date%3D2009%26volume%3D49%26spage%3DS103%26epage%3D111%26doi%3D10.1002%2Fhep.22956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Tipples, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bain, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kneteman, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyrrell, D. L.</span><span> </span><span class="NLM_article-title">Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">714</span><span class="NLM_x">–</span> <span class="NLM_lpage">717</span><span class="refDoi"> DOI: 10.1002/hep.510240340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1002%2Fhep.510240340" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1996&pages=714-717&author=G.+A.+Tipplesauthor=M.+M.+Maauthor=K.+P.+Fischerauthor=V.+G.+Bainauthor=N.+M.+Knetemanauthor=D.+L.+Tyrrell&title=Mutation+in+HBV+RNA-dependent+DNA+polymerase+confers+resistance+to+lamivudine+in+vivo&doi=10.1002%2Fhep.510240340"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fhep.510240340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.510240340%26sid%3Dliteratum%253Aachs%26aulast%3DTipples%26aufirst%3DG.%2BA.%26aulast%3DMa%26aufirst%3DM.%2BM.%26aulast%3DFischer%26aufirst%3DK.%2BP.%26aulast%3DBain%26aufirst%3DV.%2BG.%26aulast%3DKneteman%26aufirst%3DN.%2BM.%26aulast%3DTyrrell%26aufirst%3DD.%2BL.%26atitle%3DMutation%2520in%2520HBV%2520RNA-dependent%2520DNA%2520polymerase%2520confers%2520resistance%2520to%2520lamivudine%2520in%2520vivo%26jtitle%3DHepatology%26date%3D1996%26volume%3D24%26spage%3D714%26epage%3D717%26doi%3D10.1002%2Fhep.510240340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Papatheodoridis, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manolakopoulos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dusheiko, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archimandritis, A. J.</span><span> </span><span class="NLM_article-title">Therapeutic strategies in the management of patients with chronic hepatitis B virus infection</span> <span class="citation_source-journal">Lancet Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1016/S1473-3099(07)70264-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1016%2FS1473-3099%2807%2970264-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=18053766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsl2gsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=167-178&author=G.+V.+Papatheodoridisauthor=S.+Manolakopoulosauthor=G.+Dusheikoauthor=A.+J.+Archimandritis&title=Therapeutic+strategies+in+the+management+of+patients+with+chronic+hepatitis+B+virus+infection&doi=10.1016%2FS1473-3099%2807%2970264-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies in the management of patients with chronic hepatitis B virus infection</span></div><div class="casAuthors">Papatheodoridis, George V.; Manolakopoulos, Spilios; Dusheiko, Geoffrey; Archimandritis, Athanasios J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-178</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Currently available options for the treatment of chronic hepatitis B virus (HBV) infection include std. and pegylated interferon alfa and four oral antiviral agents (lamivudine, adefovir, entecavir, and telbivudine).  These treatment strategies are either therapies of finite duration that aim to achieve sustained off-therapy responses, or long-term treatments that aim to maintain on-therapy remission.  Pegylated interferon alfa may offer higher sustained off-therapy responses after 1 yr, but most patients do not respond.  Oral antivirals are the only candidates for long-term treatment of patients with chronic HBV infection.  Viral suppression has favorable effects on patients' outcome and modifies the natural history of the disease.  Viral resistance is the main drawback of long-term antiviral therapy.  Lamivudine monotherapy is assocd. with higher resistance (year 1, 10-27%; year 2, 37-48%; year 4, 60-65%) than adefovir (year 1, 0%; year 2, 3%; year 5, 29%) or telbivudine (year 1, 3-4%; year 2, 9-22%).  Entecavir resistance is rare in naive individuals (year 4, <1%), but increases over time in lamivudine-resistant patients (year 4, 43%).  The best strategy for long-term therapy in chronic HBV infection has yet to be established.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri_6VaaZsnh7Vg90H21EOLACvtfcHk0ljN-K_7xTgcwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsl2gsbk%253D&md5=35b812a4d84d8130aec3d1676fe1735e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2807%2970264-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252807%252970264-5%26sid%3Dliteratum%253Aachs%26aulast%3DPapatheodoridis%26aufirst%3DG.%2BV.%26aulast%3DManolakopoulos%26aufirst%3DS.%26aulast%3DDusheiko%26aufirst%3DG.%26aulast%3DArchimandritis%26aufirst%3DA.%2BJ.%26atitle%3DTherapeutic%2520strategies%2520in%2520the%2520management%2520of%2520patients%2520with%2520chronic%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2008%26volume%3D8%26spage%3D167%26epage%3D178%26doi%3D10.1016%2FS1473-3099%2807%2970264-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Petersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lütgehetmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Weizsäcker, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haberkorn, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollok, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erbes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seitz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, S.</span><span> </span><span class="NLM_article-title">Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">341</span><span class="refDoi"> DOI: 10.1038/nbt1389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1038%2Fnbt1389" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=335-341&author=J.+Petersenauthor=M.+Dandriauthor=W.+Mierauthor=M.+L%C3%BCtgehetmannauthor=T.+Volzauthor=F.+von+Weizs%C3%A4ckerauthor=U.+Haberkornauthor=L.+Fischerauthor=J.+Pollokauthor=B.+Erbesauthor=S.+Seitzauthor=S.+Urban&title=Prevention+of+hepatitis+B+virus+infection+in+vivo+by+entry+inhibitors+derived+from+the+large+envelope+protein&doi=10.1038%2Fnbt1389"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnbt1389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1389%26sid%3Dliteratum%253Aachs%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DDandri%26aufirst%3DM.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DL%25C3%25BCtgehetmann%26aufirst%3DM.%26aulast%3DVolz%26aufirst%3DT.%26aulast%3Dvon%2BWeizs%25C3%25A4cker%26aufirst%3DF.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DFischer%26aufirst%3DL.%26aulast%3DPollok%26aufirst%3DJ.%26aulast%3DErbes%26aufirst%3DB.%26aulast%3DSeitz%26aufirst%3DS.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DPrevention%2520of%2520hepatitis%2520B%2520virus%2520infection%2520in%2520vivo%2520by%2520entry%2520inhibitors%2520derived%2520from%2520the%2520large%2520envelope%2520protein%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D335%26epage%3D341%26doi%3D10.1038%2Fnbt1389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Steven, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watts, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belnap, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wingfield, P. T.</span><span> </span><span class="NLM_article-title">Structure, assembly, and antigenicity of hepatitis B virus capsid proteins</span> <span class="citation_source-journal">Adv. Virus Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">164</span><span class="refDoi"> DOI: 10.1016/S0065-3527(05)64005-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1016%2FS0065-3527%2805%2964005-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2005&pages=125-164&author=A.+C.+Stevenauthor=J.+F.+Conwayauthor=N.+Chengauthor=N.+R.+Wattsauthor=D.+M.+Belnapauthor=A.+Harrisauthor=S.+J.+Stahlauthor=P.+T.+Wingfield&title=Structure%2C+assembly%2C+and+antigenicity+of+hepatitis+B+virus+capsid+proteins&doi=10.1016%2FS0065-3527%2805%2964005-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0065-3527%2805%2964005-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-3527%252805%252964005-5%26sid%3Dliteratum%253Aachs%26aulast%3DSteven%26aufirst%3DA.%2BC.%26aulast%3DConway%26aufirst%3DJ.%2BF.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DWatts%26aufirst%3DN.%2BR.%26aulast%3DBelnap%26aufirst%3DD.%2BM.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DStahl%26aufirst%3DS.%2BJ.%26aulast%3DWingfield%26aufirst%3DP.%2BT.%26atitle%3DStructure%252C%2520assembly%252C%2520and%2520antigenicity%2520of%2520hepatitis%2520B%2520virus%2520capsid%2520proteins%26jtitle%3DAdv.%2520Virus%2520Res.%26date%3D2005%26volume%3D64%26spage%3D125%26epage%3D164%26doi%3D10.1016%2FS0065-3527%2805%2964005-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Chain, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, R.</span><span> </span><span class="NLM_article-title">Variability and conservation in hepatitis B virus core protein</span> <span class="citation_source-journal">BMC Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="refDoi"> DOI: 10.1186/1471-2180-5-33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1186%2F1471-2180-5-33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=15921513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A280%3ADC%252BD2MzkvVCmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=33&author=B.+M.+Chainauthor=R.+Myers&title=Variability+and+conservation+in+hepatitis+B+virus+core+protein&doi=10.1186%2F1471-2180-5-33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Variability and conservation in hepatitis B virus core protein</span></div><div class="casAuthors">Chain Benjamin M; Myers Richard</div><div class="citationInfo"><span class="NLM_cas:title">BMC microbiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Hepatitis B core protein (HBVc) has been extensively studied from both a structural and immunological point of view, but the evolutionary forces driving sequence variation within core are incompletely understood.  RESULTS:  In this study, the observed variation in HBVc protein sequence has been examined in a collection of a large number of HBVc protein sequences from public sequence repositories.  An alignment of several hundred sequences was carried out, and used to analyse the distribution of polymorphisms along the HBVc.  Polymorphisms were found at 44 out of 185 amino acid positions analysed and were clustered predominantly in those parts of HBVc forming the outer surface and spike on intact capsid.  The relationship between HBVc diversity and HBV genotype was examined.  The position of variable amino acids along the sequence was examined in terms of the structural constraints of capsid and envelope assembly, and also in terms of immunological recognition by T and B cells.  CONCLUSION:  Over three quarters of amino acids within the HBVc sequence are non-polymorphic, and variation is focused to a few amino acids.  Phylogenetic analysis suggests that core protein specific forces constrain its diversity within the context of overall HBV genome evolution.  As a consequence, core protein is not a reliable predictor of virus genotype.  The structural requirements of capsid assembly are likely to play a major role in limiting diversity.  The phylogenetic analysis further suggests that immunological selection does not play a major role in driving HBVc diversity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGMvprrY2YZTslzEEsg76ufW6udTcc2ea-3vRMMiaiYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzkvVCmsA%253D%253D&md5=e6268379aa887b05e0ead45823a0b09f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1186%2F1471-2180-5-33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2180-5-33%26sid%3Dliteratum%253Aachs%26aulast%3DChain%26aufirst%3DB.%2BM.%26aulast%3DMyers%26aufirst%3DR.%26atitle%3DVariability%2520and%2520conservation%2520in%2520hepatitis%2520B%2520virus%2520core%2520protein%26jtitle%3DBMC%2520Microbiol.%26date%3D2005%26volume%3D5%26spage%3D33%26doi%3D10.1186%2F1471-2180-5-33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Choi, I.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y. G.</span><span> </span><span class="NLM_article-title">Interaction and assembly of HBV structural proteins: novel target sites of anti-HBV agents</span> <span class="citation_source-journal">Infect. Disord.: Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span><span class="refDoi"> DOI: 10.2174/187152607782110077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.2174%2F187152607782110077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=17897061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWiurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=251-256&author=I.-G.+Choiauthor=Y.+G.+Yu&title=Interaction+and+assembly+of+HBV+structural+proteins%3A+novel+target+sites+of+anti-HBV+agents&doi=10.2174%2F187152607782110077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction and assembly of HBV structural proteins: novel target sites of anti-HBV agents</span></div><div class="casAuthors">Choi, In-Geol; Yu, Yeon Gyu</div><div class="citationInfo"><span class="NLM_cas:title">Infectious Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">251-256</span>CODEN:
                <span class="NLM_cas:coden">IDDTAD</span>;
        ISSN:<span class="NLM_cas:issn">1871-5265</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Human hepatitis B virus (HBV) causes chronic hepatitis disease which is a major public health problem worldwide.  HBV has 4 genes encoding viral DNA polymerase, protein X and two structural proteins, the surface and core proteins.  HBV DNA polymerase has been a primary target for the development of anti-HBV agents due to its enzymic nature, and several nucleoside derivs. that inhibit HBV polymerase are currently used as anti-HBV therapeutics.  On the other hand, accumulating information on the capsid assembly and the maturation process of HBV particles provides addnl. approaches for the development of anti-HBV agents.  Proper interaction between core proteins is required for assembly of the nucleocapsid, and the specificity of the interactions between the capsid and surface proteins is essential for the maturation of active HBV in infected cells.  In this article, the assembly process of active HBV particles and approaches to utilize the interactions of HBV structural proteins as target site for the development of anti-HBV agents are reviewed.  In particular, novel approaches to target the assembly process and the interaction between HBV structural proteins are introduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq50CrrHZFnrVg90H21EOLACvtfcHk0ljoxFT6GaFXDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWiurzL&md5=ba31304a1729e7371d2ddebc63ab3909</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F187152607782110077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152607782110077%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DI.-G.%26aulast%3DYu%26aufirst%3DY.%2BG.%26atitle%3DInteraction%2520and%2520assembly%2520of%2520HBV%2520structural%2520proteins%253A%2520novel%2520target%2520sites%2520of%2520anti-HBV%2520agents%26jtitle%3DInfect.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2007%26volume%3D7%26spage%3D251%26epage%3D256%26doi%3D10.2174%2F187152607782110077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Delaney, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colledge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Painter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locarnini, S.</span><span> </span><span class="NLM_article-title">Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3057</span><span class="NLM_x">–</span> <span class="NLM_lpage">3060</span><span class="refDoi"> DOI: 10.1128/AAC.46.9.3057-3060.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1128%2FAAC.46.9.3057-3060.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=12183271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmtl2kurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=3057-3060&author=W.+E.+Delaneyauthor=R.+Edwardsauthor=D.+Colledgeauthor=T.+Shawauthor=P.+Furmanauthor=G.+Painterauthor=S.+Locarnini&title=Phenylpropenamide+derivatives+AT-61+and+AT-130+inhibit+replication+of+wild-type+and+lamivudine-resistant+strains+of+hepatitis+B+virus+in+vitro&doi=10.1128%2FAAC.46.9.3057-3060.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro</span></div><div class="casAuthors">Delaney, William E., IV; Edwards, Ros; Colledge, Danni; Shaw, Tim; Furman, Phil; Painter, George; Locarnini, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3057-3060</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The phenylpropenamide derivs. AT-61 and AT-130 are nonnucleoside analog inhibitors of hepatitis B virus (HBV) replication.  They inhibited the replication of wild-type HBV with 50% inhibitory concns. of 21.2±9.5 and 2.40±0.92 μM, resp., compared to 0.064±0.020 μM lamivudine.  There were no significant differences in sensitivity between wild-type and nucleoside analog-resistant (rtL180M, rtM204I, and rtL180M + rtM204V) HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4UNW_6bFxUrVg90H21EOLACvtfcHk0ljoxFT6GaFXDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmtl2kurw%253D&md5=ffb8ff070fda879480d93597468cbd9b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1128%2FAAC.46.9.3057-3060.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.46.9.3057-3060.2002%26sid%3Dliteratum%253Aachs%26aulast%3DDelaney%26aufirst%3DW.%2BE.%26aulast%3DEdwards%26aufirst%3DR.%26aulast%3DColledge%26aufirst%3DD.%26aulast%3DShaw%26aufirst%3DT.%26aulast%3DFurman%26aufirst%3DP.%26aulast%3DPainter%26aufirst%3DG.%26aulast%3DLocarnini%26aufirst%3DS.%26atitle%3DPhenylpropenamide%2520derivatives%2520AT-61%2520and%2520AT-130%2520inhibit%2520replication%2520of%2520wild-type%2520and%2520lamivudine-resistant%2520strains%2520of%2520hepatitis%2520B%2520virus%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2002%26volume%3D46%26spage%3D3057%26epage%3D3060%26doi%3D10.1128%2FAAC.46.9.3057-3060.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Wang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naduthambi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosley, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sofia, M. J.</span><span> </span><span class="NLM_article-title">Phenylpropenamide derivatives: antihepatitis B virus activity of the Z isomer, SAR and the search for novel analogs</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4642</span><span class="NLM_x">–</span> <span class="NLM_lpage">4647</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.05.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1016%2Fj.bmcl.2011.05.077" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4642-4647&author=P.+Wangauthor=D.+Naduthambiauthor=R.+T.+Mosleyauthor=C.+Niuauthor=P.+A.+Furmanauthor=M.+J.+Ottoauthor=M.+J.+Sofia&title=Phenylpropenamide+derivatives%3A+antihepatitis+B+virus+activity+of+the+Z+isomer%2C+SAR+and+the+search+for+novel+analogs&doi=10.1016%2Fj.bmcl.2011.05.077"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.05.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.05.077%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DNaduthambi%26aufirst%3DD.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DPhenylpropenamide%2520derivatives%253A%2520antihepatitis%2520B%2520virus%2520activity%2520of%2520the%2520Z%2520isomer%252C%2520SAR%2520and%2520the%2520search%2520for%2520novel%2520analogs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4642%26epage%3D4647%26doi%3D10.1016%2Fj.bmcl.2011.05.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Campagna, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuconati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J. T.</span><span> </span><span class="NLM_article-title">Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">6931</span><span class="NLM_x">–</span> <span class="NLM_lpage">6942</span><span class="refDoi"> DOI: 10.1128/JVI.00582-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1128%2FJVI.00582-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=23576513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptlKrsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=6931-6942&author=M.+R.+Campagnaauthor=F.+Liuauthor=R.+Maoauthor=C.+Millsauthor=D.+Caiauthor=F.+Guoauthor=X.+Zhaoauthor=H.+Yeauthor=A.+Cuconatiauthor=H.+Guoauthor=J.+Changauthor=X.+Xuauthor=T.+M.+Blockauthor=J.+T.+Guo&title=Sulfamoylbenzamide+derivatives+inhibit+the+assembly+of+hepatitis+B+virus+nucleocapsids&doi=10.1128%2FJVI.00582-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids</span></div><div class="casAuthors">Campagna, Matthew R.; Liu, Fei; Mao, Richeng; Mills, Courtney; Cai, Dawei; Guo, Fang; Zhao, Xuesen; Ye, Hong; Cuconati, Andrea; Guo, Haitao; Chang, Jinhong; Xu, Xiaodong; Block, Timothy M.; Guo, Ju-Tao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6931-6942</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Chronic hepatitis B virus (HBV) infection, a serious public health problem leading to cirrhosis and hepatocellular carcinoma, is currently treated with either pegylated alpha interferon (pegIFN-α) or one of the five nucleos(t)ide analog viral DNA polymerase inhibitors.  However, neither pegIFN-α nor nucleos(t)ide analogs are capable of reliably curing the viral infection.  In order to develop novel antiviral drugs against HBV, we established a cell-based screening assay by using an immortalized mouse hepatocyte-derived stable cell line supporting a high level of HBV replication in a tetracycline-inducible manner.  Screening of a library consisting of 26,900 small mols. led to the discovery of a series of sulfamoylbenzamide (SBA) derivs. that significantly reduced the amt. of cytoplasmic HBV DNA.  Structure-activity relationship studies have thus far identified a group of fluorine-substituted SBAs with submicromolar antiviral activity against HBV in human hepatoma cells.  Mechanistic analyses reveal that the compds. dose dependently inhibit the formation of pregenomic RNA (pgRNA)-contg. nucleocapsids of HBV but not other animal hepadnaviruses, such as woodchuck hepatitis virus (WHV) and duck hepatitis B virus (DHBV).  Moreover, heterologous genetic complementation studies of capsid protein, DNA polymerase, and pgRNA between HBV and WHV suggest that HBV capsid protein confers sensitivity to the SBAs.  In summary, SBAs represent a novel chem. entity with superior activity and a unique antiviral mechanism and are thus warranted for further development as novel antiviral therapeutics for the treatment of chronic hepatitis B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNUsTkQKVBQbVg90H21EOLACvtfcHk0lh42Q7GxK6UQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptlKrsr0%253D&md5=80cd9d05d889ecf1bd2f6c28f7946bcf</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FJVI.00582-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00582-13%26sid%3Dliteratum%253Aachs%26aulast%3DCampagna%26aufirst%3DM.%2BR.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DMao%26aufirst%3DR.%26aulast%3DMills%26aufirst%3DC.%26aulast%3DCai%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DCuconati%26aufirst%3DA.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DBlock%26aufirst%3DT.%2BM.%26aulast%3DGuo%26aufirst%3DJ.%2BT.%26atitle%3DSulfamoylbenzamide%2520derivatives%2520inhibit%2520the%2520assembly%2520of%2520hepatitis%2520B%2520virus%2520nucleocapsids%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D6931%26epage%3D6942%26doi%3D10.1128%2FJVI.00582-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nan, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuo, J. P.</span><span> </span><span class="NLM_article-title">Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">410</span><span class="NLM_x">–</span> <span class="NLM_lpage">418</span><span class="refDoi"> DOI: 10.1038/aps.2013.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1038%2Faps.2013.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=24487969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=410-418&author=L.+Yangauthor=L.+P.+Shiauthor=H.+J.+Chenauthor=X.+K.+Tongauthor=G.+F.+Wangauthor=Y.+M.+Zhangauthor=W.+L.+Wangauthor=C.+L.+Fengauthor=P.+L.+Heauthor=F.+H.+Zhuauthor=Y.+H.+Haoauthor=B.+J.+Wangauthor=D.+L.+Yangauthor=W.+Tangauthor=F.+J.+Nanauthor=J.+P.+Zuo&title=Isothiafludine%2C+a+novel+non-nucleoside+compound%2C+inhibits+hepatitis+B+virus+replication+through+blocking+pregenomic+RNA+encapsidation&doi=10.1038%2Faps.2013.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation</span></div><div class="casAuthors">Yang, Li; Shi, Li-ping; Chen, Hai-jun; Tong, Xian-Kun; Wang, Gui-feng; Zhang, Yang-ming; Wang, Wen-long; Feng, Chun-lan; He, Pei-lan; Zhu, Feng-hua; Hao, You-hua; Wang, Bao-ju; Yang, Dong-liang; Tang, Wei; Nan, Fa-jun; Zuo, Jian-ping</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">410-418</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aim: To investigate the action of isothiafludine (NZ-4), a deriv. of bis-heterocycle tandem pairs from the natural product leucamide A, on the replication cycle of hepatitis B virus (HBV) in vitro and in vivo.  Methods: HBV replication cycle was monitored in HepG2.2.15 cells using qPCR, qRT-PCR, and Southern and Northern blotting.  HBV protein expression and capsid assembly were detected using Western blotting and native agarose gel electrophoresis anal.  The interaction of pregenomic RNA (pgRNA) and the core protein was investigated by RNA immunopptn.  To evaluate the anti-HBV effect of NZ-4 in vivo, DHBV-infected ducks were orally administered NZ-4 (25, 50 or 100 mg·kg-1·d-1) for 15 d.  Results: NZ-4 suppressed intracellular HBV replication in HepG2.2.15 cells with an IC50 value of 1.33 μmol/L, whereas the compd. inhibited the cell viability with an IC50 value of 50.4 μmol/L.  Furthermore, NZ-4 was active against the replication of various drug-resistant HBV mutants, including 3TC/ETV-dual-resistant and ADV-resistant HBV mutants.  NZ-4 (5, 10, 20 μmol/L) concn.-dependently reduced the encapsidated HBV pgRNA, resulting in the assembly of replication-deficient capsids in HepG2.2.15 cells.  Oral administration of NZ-4 dose-dependently inhibited DHBV DNA replication in the DHBV-infected ducks.  Conclusion: NZ-4 inhibits HBV replication by interfering with the interaction between pgRNA and HBcAg in the capsid assembly process, thus increasing the replication-deficient HBV capsids.  Such mechanism of action might provide a new therapeutic strategy to combat HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfXI1ksk5-erVg90H21EOLACvtfcHk0lh42Q7GxK6UQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2itrs%253D&md5=7a046b35ab2f26aa43cf52fa76f85dea</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Faps.2013.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2013.175%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DL.%2BP.%26aulast%3DChen%26aufirst%3DH.%2BJ.%26aulast%3DTong%26aufirst%3DX.%2BK.%26aulast%3DWang%26aufirst%3DG.%2BF.%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DFeng%26aufirst%3DC.%2BL.%26aulast%3DHe%26aufirst%3DP.%2BL.%26aulast%3DZhu%26aufirst%3DF.%2BH.%26aulast%3DHao%26aufirst%3DY.%2BH.%26aulast%3DWang%26aufirst%3DB.%2BJ.%26aulast%3DYang%26aufirst%3DD.%2BL.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DNan%26aufirst%3DF.%2BJ.%26aulast%3DZuo%26aufirst%3DJ.%2BP.%26atitle%3DIsothiafludine%252C%2520a%2520novel%2520non-nucleoside%2520compound%252C%2520inhibits%2520hepatitis%2520B%2520virus%2520replication%2520through%2520blocking%2520pregenomic%2520RNA%2520encapsidation%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2014%26volume%3D35%26spage%3D410%26epage%3D418%26doi%3D10.1038%2Faps.2013.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Levin, J.</span><span> </span><span class="NLM_article-title">NVR 3–778, a first-in-class HBV core inhibitor, alone and in combination with pegylated-interferon (peg-IFN alpha-2a), in treatment-naïve HBeAg-positive patients: early reductions in HBV DNA and HBeAg</span>. Presented at the EASL International Liver Congress, Barcelona, April 14–17,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Levin%2C+J.+NVR+3%E2%80%93778%2C+a+first-in-class+HBV+core+inhibitor%2C+alone+and+in+combination+with+pegylated-interferon+%28peg-IFN+alpha-2a%29%2C+in+treatment-na%C3%AFve+HBeAg-positive+patients%3A+early+reductions+in+HBV+DNA+and+HBeAg.+Presented+at+the+EASL+International+Liver+Congress%2C+Barcelona%2C+April+14%E2%80%9317%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DJ.%26atitle%3DNVR%25203%25E2%2580%2593778%252C%2520a%2520first-in-class%2520HBV%2520core%2520inhibitor%252C%2520alone%2520and%2520in%2520combination%2520with%2520pegylated-interferon%2520%2528peg-IFN%2520alpha-2a%2529%252C%2520in%2520treatment-na%25C3%25AFve%2520HBeAg-positive%2520patients%253A%2520early%2520reductions%2520in%2520HBV%2520DNA%2520and%2520HBeAg%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Levin, J.</span><span> </span><span class="NLM_article-title">Safety, tolerability and pharmacokinetics of JNJ-56136379, a novel HBV capsid assembly modulator, in healthy subjects</span>. Presented at the AASLD Liver Meeting, Boston, Nov 11–15,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Levin%2C+J.+Safety%2C+tolerability+and+pharmacokinetics+of+JNJ-56136379%2C+a+novel+HBV+capsid+assembly+modulator%2C+in+healthy+subjects.+Presented+at+the+AASLD+Liver+Meeting%2C+Boston%2C+Nov+11%E2%80%9315%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DJ.%26atitle%3DSafety%252C%2520tolerability%2520and%2520pharmacokinetics%2520of%2520JNJ-56136379%252C%2520a%2520novel%2520HBV%2520capsid%2520assembly%2520modulator%252C%2520in%2520healthy%2520subjects%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Deres, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroder, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paessens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hacker, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niewohner, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pleiss, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoltefuss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graef, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koletzki, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masantschek, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reimann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaeger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckermann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlemmer, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haebich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubsamen-Waigmann, H.</span><span> </span><span class="NLM_article-title">Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">893</span><span class="NLM_x">–</span> <span class="NLM_lpage">896</span><span class="refDoi"> DOI: 10.1126/science.1077215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1126%2Fscience.1077215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=12574631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1Sgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=893-896&author=K.+Deresauthor=C.+H.+Schroderauthor=A.+Paessensauthor=S.+Goldmannauthor=H.+J.+Hackerauthor=O.+Weberauthor=T.+Kramerauthor=U.+Niewohnerauthor=U.+Pleissauthor=J.+Stoltefussauthor=E.+Graefauthor=D.+Koletzkiauthor=R.+N.+Masantschekauthor=A.+Reimannauthor=R.+Jaegerauthor=R.+Grossauthor=B.+Beckermannauthor=K.+H.+Schlemmerauthor=D.+Haebichauthor=H.+Rubsamen-Waigmann&title=Inhibition+of+hepatitis+B+virus+replication+by+drug-induced+depletion+of+nucleocapsids&doi=10.1126%2Fscience.1077215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Hepatitis B Virus Replication by Drug-Induced Depletion of Nucleocapsids</span></div><div class="casAuthors">Deres, Karl; Schroeder, Claus H.; Paessens, Arnold; Goldmann, Siegfried; Hacker, Hans Joerg; Weber, Olaf; Kraemer, Thomas; Niewoehner, Ulrich; Pleiss, Ulrich; Stoltefuss, Juergen; Graef, Erwin; Koletzki, Diana; Masantschek, Ralf N. A.; Reimann, Anja; Jaeger, Rainer; Gro, Rainer; Beckermann, Bernhard; Schlemmer, Karl-Heinz; Haebich, Dieter; Ruebsamen-Waigmann, Helga</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">5608</span>),
    <span class="NLM_cas:pages">893-896</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Chronic hepatitis B virus (HBV) infection is a major cause of liver disease.  Only interferon-α and the nucleosidic inhibitors of the viral polymerase, 3TC and adefovir, are approved for therapy.  However, these therapies are limited by the side effects of interferon and the substantial resistance of the virus to nucleosidic inhibitors.  Potent new antiviral compds. suitable for monotherapy or combination therapy are highly desired.  We describe non-nucleosidic inhibitors of HBV nucleocapsid maturation that possess in vitro and in vivo antiviral activity.  These inhibitors have potential for future therapeutic regimens to combat chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAlJUFASSEhLVg90H21EOLACvtfcHk0ljagfGi0J4L-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1Sgsg%253D%253D&md5=a5e74b45d335f74ba17ec9fe4d31e24b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscience.1077215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1077215%26sid%3Dliteratum%253Aachs%26aulast%3DDeres%26aufirst%3DK.%26aulast%3DSchroder%26aufirst%3DC.%2BH.%26aulast%3DPaessens%26aufirst%3DA.%26aulast%3DGoldmann%26aufirst%3DS.%26aulast%3DHacker%26aufirst%3DH.%2BJ.%26aulast%3DWeber%26aufirst%3DO.%26aulast%3DKramer%26aufirst%3DT.%26aulast%3DNiewohner%26aufirst%3DU.%26aulast%3DPleiss%26aufirst%3DU.%26aulast%3DStoltefuss%26aufirst%3DJ.%26aulast%3DGraef%26aufirst%3DE.%26aulast%3DKoletzki%26aufirst%3DD.%26aulast%3DMasantschek%26aufirst%3DR.%2BN.%26aulast%3DReimann%26aufirst%3DA.%26aulast%3DJaeger%26aufirst%3DR.%26aulast%3DGross%26aufirst%3DR.%26aulast%3DBeckermann%26aufirst%3DB.%26aulast%3DSchlemmer%26aufirst%3DK.%2BH.%26aulast%3DHaebich%26aufirst%3DD.%26aulast%3DRubsamen-Waigmann%26aufirst%3DH.%26atitle%3DInhibition%2520of%2520hepatitis%2520B%2520virus%2520replication%2520by%2520drug-induced%2520depletion%2520of%2520nucleocapsids%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D893%26epage%3D896%26doi%3D10.1126%2Fscience.1077215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Bourne, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zlotnick, A.</span><span> </span><span class="NLM_article-title">Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">11055</span><span class="NLM_x">–</span> <span class="NLM_lpage">11061</span><span class="refDoi"> DOI: 10.1128/JVI.00933-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1128%2FJVI.00933-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=16943288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KhurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=11055-11061&author=C.+R.+Bourneauthor=M.+G.+Finnauthor=A.+Zlotnick&title=Global+structural+changes+in+hepatitis+B+virus+capsids+induced+by+the+assembly+effector+HAP1&doi=10.1128%2FJVI.00933-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1</span></div><div class="casAuthors">Bourne, Christina R.; Finn, M. G.; Zlotnick, Adam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">11055-11061</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) is a leading cause of liver disease and hepatocellular carcinoma; over 400 million people are chronically infected with HBV.  Specific anti-HBV treatments, like most antivirals, target enzymes that are similar to host proteins.  Virus capsid protein has no human homolog, making its assembly a promising but undeveloped therapeutic target.  HAP1 [methyl 4-(2-chloro-4-fluorophenyl)-6-methyl-2-(pyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate], a heteroaryldihydropyrimidine, is a potent HBV capsid assembly activator and misdirector.  Knowledge of the structural basis for this activity would directly benefit the development of capsid-targeting therapeutic strategies.  This report details the crystal structures of icosahedral HBV capsids with and without HAP1.  We show that HAP1 leads to global structural changes by movements of subunits as connected rigid bodies.  The obsd. movements cause the fivefold vertices to protrude from the liganded capsid, the threefold vertices to open, and the quasi-sixfold vertices to flatten, explaining the effects of HAP1 on assembled capsids and on the assembly process.  We have identified a likely HAP1-binding site that bridges elements of secondary structure within a capsid-bound monomer, offering explanation for assembly activation.  This site also interferes with interactions between capsid proteins, leading to quaternary changes and presumably assembly misdirection.  These results demonstrate the plasticity of HBV capsids and the mol. basis for a tenable antiviral strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpdf0rkzY6lbVg90H21EOLACvtfcHk0ljagfGi0J4L-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KhurrJ&md5=9d176d66a1d3c2e323203877c225be6e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1128%2FJVI.00933-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00933-06%26sid%3Dliteratum%253Aachs%26aulast%3DBourne%26aufirst%3DC.%2BR.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DGlobal%2520structural%2520changes%2520in%2520hepatitis%2520B%2520virus%2520capsids%2520induced%2520by%2520the%2520assembly%2520effector%2520HAP1%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D11055%26epage%3D11061%26doi%3D10.1128%2FJVI.00933-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Brezillon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunelle, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massinet, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamant, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DaSilva, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berissi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belghiti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannoun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puerstinger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wimmer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neyts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hantz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soussan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morosan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremsdorf, D.</span><span> </span><span class="NLM_article-title">Antiviral activity of Bay 41–4109 on hepatitis B virus in humanized Alb-uPA/SCID mice</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e25096</span><span class="refDoi"> DOI: 10.1371/journal.pone.0025096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1371%2Fjournal.pone.0025096" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e25096&author=N.+Brezillonauthor=M.+N.+Brunelleauthor=H.+Massinetauthor=E.+Giangauthor=C.+Lamantauthor=L.+DaSilvaauthor=S.+Berissiauthor=J.+Belghitiauthor=L.+Hannounauthor=G.+Puerstingerauthor=E.+Wimmerauthor=J.+Neytsauthor=O.+Hantzauthor=P.+Soussanauthor=S.+Morosanauthor=D.+Kremsdorf&title=Antiviral+activity+of+Bay+41%E2%80%934109+on+hepatitis+B+virus+in+humanized+Alb-uPA%2FSCID+mice&doi=10.1371%2Fjournal.pone.0025096"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0025096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0025096%26sid%3Dliteratum%253Aachs%26aulast%3DBrezillon%26aufirst%3DN.%26aulast%3DBrunelle%26aufirst%3DM.%2BN.%26aulast%3DMassinet%26aufirst%3DH.%26aulast%3DGiang%26aufirst%3DE.%26aulast%3DLamant%26aufirst%3DC.%26aulast%3DDaSilva%26aufirst%3DL.%26aulast%3DBerissi%26aufirst%3DS.%26aulast%3DBelghiti%26aufirst%3DJ.%26aulast%3DHannoun%26aufirst%3DL.%26aulast%3DPuerstinger%26aufirst%3DG.%26aulast%3DWimmer%26aufirst%3DE.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DHantz%26aufirst%3DO.%26aulast%3DSoussan%26aufirst%3DP.%26aulast%3DMorosan%26aufirst%3DS.%26aulast%3DKremsdorf%26aufirst%3DD.%26atitle%3DAntiviral%2520activity%2520of%2520Bay%252041%25E2%2580%25934109%2520on%2520hepatitis%2520B%2520virus%2520in%2520humanized%2520Alb-uPA%252FSCID%2520mice%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De25096%26doi%3D10.1371%2Fjournal.pone.0025096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Shi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, H. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, X. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, M. Y.</span><span> </span><span class="NLM_article-title">NMR-spectroscopy-based metabonomic approach to the analysis of Bay41–4109, a novel anti-HBV compound, induced hepatotoxicity in rats</span> <span class="citation_source-journal">Toxicol. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">173</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span><span class="refDoi"> DOI: 10.1016/j.toxlet.2007.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1016%2Fj.toxlet.2007.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=17826925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVeqsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2007&pages=161-167&author=C.+Shiauthor=C.+Q.+Wuauthor=A.+M.+Caoauthor=H.+Z.+Shengauthor=X.+Z.+Yanauthor=M.+Y.+Liao&title=NMR-spectroscopy-based+metabonomic+approach+to+the+analysis+of+Bay41%E2%80%934109%2C+a+novel+anti-HBV+compound%2C+induced+hepatotoxicity+in+rats&doi=10.1016%2Fj.toxlet.2007.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">NMR-spectroscopy-based metabonomic approach to the analysis of Bay41-4109, a novel anti-HBV compound, induced hepatotoxicity in rats</span></div><div class="casAuthors">Shi, Chang; Wu, Chun-qi; Cao, An-min; Sheng, He-Zhang; Yan, Xian-zhong; Liao, Ming-yang</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-167</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An integrated metabonomics study using high-resoln. 1H NMR spectroscopy has been applied to investigate the biochem. compn. of urine, serum, liver tissue aq. exts. (acetonitrile/water) and liver tissue lipidic exts. (chloroform/methanol) obtained from control and Bay41-4109 treated rats (10, 50, 400 mg kg-1 d-1 for 5 days, i.g.).  Principal components anal. was used to visualize similarities and differences in biochem. profiles.  The results showed the effects induced by Bay41-4109 at 400 mg kg-1 d-1 are different from those induced at 10, 50 mg kg-1 d-1.  The biochem. profiles of 400 mg kg-1 d-1 group might reflect the hepatotoxicity of Bay41-4109 more exactly.  The elevation in the level of 3-HB, lactate, 2-hydroxy-acetol and D-glucose was found in the urine, and the levels of VLDL/LDL(CH2)n, VLDL/LDL-CH3, 2-oxo-3-methyl-n-valerate, 3-HB, lactate, acetate, taurine, 2-hydroxy-isovalerate in serum were increased significantly in 400 mg kg-1 d-1 group.  The predominant changes identified in liver tissue aq. exts. included an increase in the signal intensities of lactate, 3-amino-isovalerate, pyruvate, choline, trimethylamine-N-oxide (TMAO) and a redn. in the intensities of taurine, hippurate and D-glucose.  In liver tissue chloroform/methanol exts., there was a remarkably increase in many of the lipid signals including the triglyceride terminal Me, methylene groups, and CH2CO, N+(CH3)3, CH2OPO2, CH2OCOR.  These observations all provide evidence that fatty acid metab. disorder and mitochondrial inability might contribute to the hepatotoxicity of Bay41-4109.  The application of 1H NMR spectroscopy to an array of biol. samples comprising urine, serum and liver tissue exts. yields new insight into the hepatotoxicity of xenobiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEdIWT-FpgZLVg90H21EOLACvtfcHk0lhX0URtx4jRHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVeqsrrP&md5=89bd5589fb93920c51723e5b75c99673</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.toxlet.2007.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxlet.2007.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DC.%2BQ.%26aulast%3DCao%26aufirst%3DA.%2BM.%26aulast%3DSheng%26aufirst%3DH.%2BZ.%26aulast%3DYan%26aufirst%3DX.%2BZ.%26aulast%3DLiao%26aufirst%3DM.%2BY.%26atitle%3DNMR-spectroscopy-based%2520metabonomic%2520approach%2520to%2520the%2520analysis%2520of%2520Bay41%25E2%2580%25934109%252C%2520a%2520novel%2520anti-HBV%2520compound%252C%2520induced%2520hepatotoxicity%2520in%2520rats%26jtitle%3DToxicol.%2520Lett.%26date%3D2007%26volume%3D173%26spage%3D161%26epage%3D167%26doi%3D10.1016%2Fj.toxlet.2007.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Qiu, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayweg, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, G. Z.</span><span> </span><span class="NLM_article-title">Design and synthesis of orally bioavailable 4-methyl heteroaryldihydropyrimidine based hepatitis B Virus (HBV) capsid inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">7651</span><span class="NLM_x">–</span> <span class="NLM_lpage">7666</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00879</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00879" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7651-7666&author=Z.+X.+Qiuauthor=X.+F.+Linauthor=M.+W.+Zhouauthor=Y.+F.+Liuauthor=W.+Zhuauthor=W.+M.+Chenauthor=W.+X.+Zhangauthor=L.+Guoauthor=H.+X.+Liuauthor=G.+L.+Wuauthor=M.+W.+Huangauthor=M.+Jiangauthor=Z.+H.+Xuauthor=Z.+Zhouauthor=N.+Qinauthor=S.+Renauthor=H.+X.+Qiuauthor=S.+Zhongauthor=Y.+X.+Zhangauthor=Y.+Zhangauthor=X.+Y.+Wuauthor=L.+P.+Shiauthor=F.+Shenauthor=Y.+Maoauthor=X.+Zhouauthor=W.+G.+Yangauthor=J.+Z.+Wuauthor=G.+Yangauthor=A.+V.+Maywegauthor=H.+C.+Shenauthor=G.+Z.+Tang&title=Design+and+synthesis+of+orally+bioavailable+4-methyl+heteroaryldihydropyrimidine+based+hepatitis+B+Virus+%28HBV%29+capsid+inhibitors&doi=10.1021%2Facs.jmedchem.6b00879"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00879%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DZ.%2BX.%26aulast%3DLin%26aufirst%3DX.%2BF.%26aulast%3DZhou%26aufirst%3DM.%2BW.%26aulast%3DLiu%26aufirst%3DY.%2BF.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DW.%2BM.%26aulast%3DZhang%26aufirst%3DW.%2BX.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%2BX.%26aulast%3DWu%26aufirst%3DG.%2BL.%26aulast%3DHuang%26aufirst%3DM.%2BW.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DZ.%2BH.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DQin%26aufirst%3DN.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DH.%2BX.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%2BX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%2BY.%26aulast%3DShi%26aufirst%3DL.%2BP.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DW.%2BG.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DTang%26aufirst%3DG.%2BZ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520orally%2520bioavailable%25204-methyl%2520heteroaryldihydropyrimidine%2520based%2520hepatitis%2520B%2520Virus%2520%2528HBV%2529%2520capsid%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7651%26epage%3D7666%26doi%3D10.1021%2Facs.jmedchem.6b00879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Qiu, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaviani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J. A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayweg, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span> </span><span class="NLM_article-title">Discovery and pre-clinical characterization of third-generation 4-H heteroaryldihydropyrimidine (HAP) analogues as hepatitis B virus (HBV) capsid inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">3352</span><span class="NLM_x">–</span> <span class="NLM_lpage">3371</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00083</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00083" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFWjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3352-3371&author=Z.+X.+Qiuauthor=X.+F.+Linauthor=W.+X.+Zhangauthor=M.+W.+Zhouauthor=L.+Guoauthor=B.+Kocerauthor=G.+Wuauthor=Z.+Zhangauthor=H.+Liuauthor=H.+Shiauthor=B.+Kouauthor=T.+Huauthor=Y.+Huauthor=M.+Huangauthor=S.+F.+Yanauthor=Z.+Xuauthor=Z.+Zhouauthor=N.+Qinauthor=Y.+F.+Wangauthor=S.+Renauthor=H.+Qiuauthor=Y.+Zhangauthor=Y.+Zhangauthor=X.+Wuauthor=K.+Sunauthor=S.+Zhongauthor=J.+Xieauthor=G.+Ottavianiauthor=Y.+Zhouauthor=l.+Zhuauthor=X.+Tianauthor=L.+Shiauthor=F.+Shenauthor=Y.+Maoauthor=X.+Zhouauthor=L.+Gaoauthor=J.+A.+T.+Youngauthor=J.+Z.+Wuauthor=G.+Yangauthor=A.+V.+Maywegauthor=H.+C.+Shenauthor=G.+Tangauthor=W.+Zhu&title=Discovery+and+pre-clinical+characterization+of+third-generation+4-H+heteroaryldihydropyrimidine+%28HAP%29+analogues+as+hepatitis+B+virus+%28HBV%29+capsid+inhibitors&doi=10.1021%2Facs.jmedchem.7b00083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors</span></div><div class="casAuthors">Qiu, Zongxing; Lin, Xianfeng; Zhang, Weixing; Zhou, Mingwei; Guo, Lei; Kocer, Buelent; Wu, Guolong; Zhang, Zhisen; Liu, Haixia; Shi, Houguang; Kou, Buyu; Hu, Taishan; Hu, Yimin; Huang, Mengwei; Yan, S. Frank; Xu, Zhiheng; Zhou, Zheng; Qin, Ning; Wang, Yue Fen; Ren, Shuang; Qiu, Hongxia; Zhang, Yuxia; Zhang, Yi; Wu, Xiaoyue; Sun, Kai; Zhong, Sheng; Xie, Jianxun; Ottaviani, Giorgio; Zhou, Yuan; Zhu, Lina; Tian, Xiaojun; Shi, Liping; Shen, Fang; Mao, Yi; Zhou, Xue; Gao, Lu; Young, John A. T.; Wu, Jim Zhen; Yang, Guang; Mayweg, Alexander V.; Shen, Hong C.; Tang, Guozhi; Zhu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3352-3371</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Described herein are the discovery and structure-activity relationship (SAR) studies of the third-generation 4-H heteroaryldihydropyrimidines (4-H HAPs) (I) featuring the introduction of a C6 carboxyl group as novel HBV capsid inhibitors.  This new series of 4-H HAPs showed improved anti-HBV activity and better drug-like properties compared to the first- and second-generation 4-H HAPs.  X-ray crystallog. study of analog 12 (HAP_R01) with Cp149 Y132A mutant hexamer clearly elucidated the role of C6 carboxyl group played for the increased binding affinity, which formed strong hydrogen bonding interactions with capsid protein and coordinated waters.  The representative analog 10 (HAP_R10) was extensively characterized in vitro (ADMET) and in vivo (mouse PK and PD) and subsequently selected for further development as oral anti-HBV infection agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolNkEF9n_vqrVg90H21EOLACvtfcHk0ljBsn8eFdXhEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFWjtbw%253D&md5=6c2a89c594f2c735855f64aca2240837</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00083%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DZ.%2BX.%26aulast%3DLin%26aufirst%3DX.%2BF.%26aulast%3DZhang%26aufirst%3DW.%2BX.%26aulast%3DZhou%26aufirst%3DM.%2BW.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DKou%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DS.%2BF.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DQin%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DK.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DOttaviani%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3Dl.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DJ.%2BA.%2BT.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DW.%26atitle%3DDiscovery%2520and%2520pre-clinical%2520characterization%2520of%2520third-generation%25204-H%2520heteroaryldihydropyrimidine%2520%2528HAP%2529%2520analogues%2520as%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%2520capsid%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3352%26epage%3D3371%26doi%3D10.1021%2Facs.jmedchem.7b00083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Wang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Z. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. S.</span><span> </span><span class="NLM_article-title">In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">793</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span><span class="refDoi"> DOI: 10.3851/IMP2152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.3851%2FIMP2152" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=793-803&author=X.+Y.+Wangauthor=Z.+M.+Weiauthor=G.+Y.+Wuauthor=J.+H.+Wangauthor=Y.+J.+Zhangauthor=J.+Liauthor=H.+H.+Zhangauthor=X.+W.+Xieauthor=X.+Wangauthor=Z.+H.+Wangauthor=L.+Weiauthor=Y.+Wangauthor=H.+S.+Chen&title=In+vitro+inhibition+of+HBV+replication+by+a+novel+compound%2C+GLS4%2C+and+its+efficacy+against+adefovir-dipivoxil-resistant+HBV+mutations&doi=10.3851%2FIMP2152"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3851%2FIMP2152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2152%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DWei%26aufirst%3DZ.%2BM.%26aulast%3DWu%26aufirst%3DG.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26aulast%3DZhang%26aufirst%3DY.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%2BH.%26aulast%3DXie%26aufirst%3DX.%2BW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%2BH.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%2BS.%26atitle%3DIn%2520vitro%2520inhibition%2520of%2520HBV%2520replication%2520by%2520a%2520novel%2520compound%252C%2520GLS4%252C%2520and%2520its%2520efficacy%2520against%2520adefovir-dipivoxil-resistant%2520HBV%2520mutations%26jtitle%3DAntiviral%2520Ther.%26date%3D2012%26volume%3D17%26spage%3D793%26epage%3D803%26doi%3D10.3851%2FIMP2152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, D. F.</span><span> </span><span class="NLM_article-title">Effects of ketoconazole and rifampicin on the pharmacokinetics of GLS4, a novel anti-hepatitis B virus compound, in dogs</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1420</span><span class="NLM_x">–</span> <span class="NLM_lpage">1426</span><span class="refDoi"> DOI: 10.1038/aps.2013.76</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1038%2Faps.2013.76" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=1420-1426&author=X.+Zhouauthor=Z.+W.+Gaoauthor=J.+Mengauthor=X.+Y.+Chenauthor=D.+F.+Zhong&title=Effects+of+ketoconazole+and+rifampicin+on+the+pharmacokinetics+of+GLS4%2C+a+novel+anti-hepatitis+B+virus+compound%2C+in+dogs&doi=10.1038%2Faps.2013.76"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Faps.2013.76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2013.76%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DZ.%2BW.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%2BY.%26aulast%3DZhong%26aufirst%3DD.%2BF.%26atitle%3DEffects%2520of%2520ketoconazole%2520and%2520rifampicin%2520on%2520the%2520pharmacokinetics%2520of%2520GLS4%252C%2520a%2520novel%2520anti-hepatitis%2520B%2520virus%2520compound%252C%2520in%2520dogs%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2013%26volume%3D34%26spage%3D1420%26epage%3D1426%26doi%3D10.1038%2Faps.2013.76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arzumanyan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clayton, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schinazi, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feitelson, M. A.</span><span> </span><span class="NLM_article-title">Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5344</span><span class="NLM_x">–</span> <span class="NLM_lpage">5354</span><span class="refDoi"> DOI: 10.1128/AAC.01091-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1128%2FAAC.01091-13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=5344-5354&author=G.+Wuauthor=B.+Liuauthor=Y.+Zhangauthor=J.+Liauthor=A.+Arzumanyanauthor=M.+M.+Claytonauthor=R.+F.+Schinaziauthor=Z.+Wangauthor=S.+Goldmannauthor=Q.+Renauthor=F.+Zhangauthor=M.+A.+Feitelson&title=Preclinical+characterization+of+GLS4%2C+an+inhibitor+of+hepatitis+B+virus+core+particle+assembly&doi=10.1128%2FAAC.01091-13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1128%2FAAC.01091-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01091-13%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DArzumanyan%26aufirst%3DA.%26aulast%3DClayton%26aufirst%3DM.%2BM.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DGoldmann%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DFeitelson%26aufirst%3DM.%2BA.%26atitle%3DPreclinical%2520characterization%2520of%2520GLS4%252C%2520an%2520inhibitor%2520of%2520hepatitis%2520B%2520virus%2520core%2520particle%2520assembly%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D5344%26epage%3D5354%26doi%3D10.1128%2FAAC.01091-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Klumpp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espiritu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baydo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abendroth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efimov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, O. A.</span><span> </span><span class="NLM_article-title">High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">15196</span><span class="NLM_x">–</span> <span class="NLM_lpage">15201</span><span class="refDoi"> DOI: 10.1073/pnas.1513803112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1073%2Fpnas.1513803112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=26598693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWqsrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=15196-15201&author=K.+Klumppauthor=A.+M.+Lamauthor=C.+Lukacsauthor=R.+Vogelauthor=S.+Renauthor=C.+Espirituauthor=R.+Baydoauthor=K.+Atkinsauthor=J.+Abendrothauthor=G.+Liaoauthor=A.+Efimovauthor=G.+Hartmanauthor=O.+A.+Flores&title=High-resolution+crystal+structure+of+a+hepatitis+B+virus+replication+inhibitor+bound+to+the+viral+core+protein&doi=10.1073%2Fpnas.1513803112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein</span></div><div class="casAuthors">Klumpp, Klaus; Lam, Angela M.; Lukacs, Christine; Vogel, Robert; Ren, Suping; Espiritu, Christine; Baydo, Ruth; Atkins, Kateri; Abendroth, Jan; Liao, Guochun; Efimov, Andrey; Hartman, George; Flores, Osvaldo A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">15196-15201</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The hepatitis B virus (HBV) core protein is essential for HBV replication and an important target for antiviral drug discovery.  We report the first, to our knowledge, high-resoln. crystal structure of an antiviral compd. bound to the HBV core protein.  The compd. NVR-010-001-E2 can induce assembly of the HBV core wild-type and Y132A mutant proteins and thermostabilize the proteins with a Tm increase of more than 10 °C.  NVR-010-001-E2 binds at the dimer-dimer interface of the core proteins, forms a new interaction surface promoting protein-protein interaction, induces protein assembly, and increases stability.  The impact of naturally occurring core protein mutations on antiviral activity correlates with NVR-010-001-E2 binding interactions detd. by crystallog.  The crystal structure provides understanding of a drug efficacy mechanism related to the induction and stabilization of protein-protein interactions and enables structure-guided design to improve antiviral potency and drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYxV-odPonGbVg90H21EOLACvtfcHk0lhBzgsHcXT3bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWqsrbK&md5=bf487dda7165d1637fad0ebab8f46142</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1513803112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1513803112%26sid%3Dliteratum%253Aachs%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DLukacs%26aufirst%3DC.%26aulast%3DVogel%26aufirst%3DR.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DBaydo%26aufirst%3DR.%26aulast%3DAtkins%26aufirst%3DK.%26aulast%3DAbendroth%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DG.%26aulast%3DEfimov%26aufirst%3DA.%26aulast%3DHartman%26aufirst%3DG.%26aulast%3DFlores%26aufirst%3DO.%2BA.%26atitle%3DHigh-resolution%2520crystal%2520structure%2520of%2520a%2520hepatitis%2520B%2520virus%2520replication%2520inhibitor%2520bound%2520to%2520the%2520viral%2520core%2520protein%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D15196%26epage%3D15201%26doi%3D10.1073%2Fpnas.1513803112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Abbott, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sesti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Splawski, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buck, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timothy, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, S. A.</span><span> </span><span class="NLM_article-title">MiRP1 forms IKr potassium channels with hERG and is associated with cardiac arrhythmia</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">187</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)80728-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1016%2FS0092-8674%2800%2980728-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=1999&pages=175-187&author=G.+W.+Abbottauthor=F.+Sestiauthor=I.+Splawskiauthor=M.+E.+Buckauthor=M.+H.+Lehmannauthor=K.+W.+Timothyauthor=M.+T.+Keatingauthor=S.+A.+Goldstein&title=MiRP1+forms+IKr+potassium+channels+with+hERG+and+is+associated+with+cardiac+arrhythmia&doi=10.1016%2FS0092-8674%2800%2980728-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980728-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980728-X%26sid%3Dliteratum%253Aachs%26aulast%3DAbbott%26aufirst%3DG.%2BW.%26aulast%3DSesti%26aufirst%3DF.%26aulast%3DSplawski%26aufirst%3DI.%26aulast%3DBuck%26aufirst%3DM.%2BE.%26aulast%3DLehmann%26aufirst%3DM.%2BH.%26aulast%3DTimothy%26aufirst%3DK.%2BW.%26aulast%3DKeating%26aufirst%3DM.%2BT.%26aulast%3DGoldstein%26aufirst%3DS.%2BA.%26atitle%3DMiRP1%2520forms%2520IKr%2520potassium%2520channels%2520with%2520hERG%2520and%2520is%2520associated%2520with%2520cardiac%2520arrhythmia%26jtitle%3DCell%26date%3D1999%26volume%3D97%26spage%3D175%26epage%3D187%26doi%3D10.1016%2FS0092-8674%2800%2980728-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Fermini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossa, A. A.</span><span> </span><span class="NLM_article-title">The impact of drug-induced QT interval prolongation on drug discovery and development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span><span class="refDoi"> DOI: 10.1038/nrd1108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1038%2Fnrd1108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=439-447&author=B.+Ferminiauthor=A.+A.+Fossa&title=The+impact+of+drug-induced+QT+interval+prolongation+on+drug+discovery+and+development&doi=10.1038%2Fnrd1108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrd1108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1108%26sid%3Dliteratum%253Aachs%26aulast%3DFermini%26aufirst%3DB.%26aulast%3DFossa%26aufirst%3DA.%2BA.%26atitle%3DThe%2520impact%2520of%2520drug-induced%2520QT%2520interval%2520prolongation%2520on%2520drug%2520discovery%2520and%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D439%26epage%3D447%26doi%3D10.1038%2Fnrd1108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Jamieson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moir, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: highlights and hang-ups</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5029</span><span class="NLM_x">–</span> <span class="NLM_lpage">5046</span><span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0ljOLkNR4FiNQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Ren, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span> </span><span class="NLM_article-title">Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4)</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1042</span><span class="NLM_x">–</span> <span class="NLM_lpage">1056</span><span class="refDoi"> DOI: 10.1016/j.bmc.2016.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1016%2Fj.bmc.2016.12.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=1042-1056&author=Q.+Renauthor=X.+Liuauthor=Z.+Luoauthor=J.+Liauthor=C.+Wangauthor=S.+Goldmannauthor=J.+Zhangauthor=Y.+Zhang&title=Discovery+of+hepatitis+B+virus+capsid+assembly+inhibitors+leading+to+a+heteroaryldihydropyrimidine+based+clinical+candidate+%28GLS4%29&doi=10.1016%2Fj.bmc.2016.12.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DGoldmann%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520hepatitis%2520B%2520virus%2520capsid%2520assembly%2520inhibitors%2520leading%2520to%2520a%2520heteroaryldihydropyrimidine%2520based%2520clinical%2520candidate%2520%2528GLS4%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D1042%26epage%3D1056%26doi%3D10.1016%2Fj.bmc.2016.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Bourne, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zlotnick, A.</span><span> </span><span class="NLM_article-title">Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1</span> <span class="citation_source-journal">J. Virol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">11055</span><span class="NLM_x">–</span> <span class="NLM_lpage">11061</span><span class="refDoi"> DOI: 10.1128/JVI.00933-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1128%2FJVI.00933-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=16943288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KhurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=11055-11061&author=C.+R.+Bourneauthor=M.+G.+Finnauthor=A.+Zlotnick&title=Global+structural+changes+in+hepatitis+B+virus+capsids+induced+by+the+assembly+effector+HAP1&doi=10.1128%2FJVI.00933-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1</span></div><div class="casAuthors">Bourne, Christina R.; Finn, M. G.; Zlotnick, Adam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">11055-11061</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) is a leading cause of liver disease and hepatocellular carcinoma; over 400 million people are chronically infected with HBV.  Specific anti-HBV treatments, like most antivirals, target enzymes that are similar to host proteins.  Virus capsid protein has no human homolog, making its assembly a promising but undeveloped therapeutic target.  HAP1 [methyl 4-(2-chloro-4-fluorophenyl)-6-methyl-2-(pyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate], a heteroaryldihydropyrimidine, is a potent HBV capsid assembly activator and misdirector.  Knowledge of the structural basis for this activity would directly benefit the development of capsid-targeting therapeutic strategies.  This report details the crystal structures of icosahedral HBV capsids with and without HAP1.  We show that HAP1 leads to global structural changes by movements of subunits as connected rigid bodies.  The obsd. movements cause the fivefold vertices to protrude from the liganded capsid, the threefold vertices to open, and the quasi-sixfold vertices to flatten, explaining the effects of HAP1 on assembled capsids and on the assembly process.  We have identified a likely HAP1-binding site that bridges elements of secondary structure within a capsid-bound monomer, offering explanation for assembly activation.  This site also interferes with interactions between capsid proteins, leading to quaternary changes and presumably assembly misdirection.  These results demonstrate the plasticity of HBV capsids and the mol. basis for a tenable antiviral strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpdf0rkzY6lbVg90H21EOLACvtfcHk0ljOLkNR4FiNQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KhurrJ&md5=9d176d66a1d3c2e323203877c225be6e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1128%2FJVI.00933-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00933-06%26sid%3Dliteratum%253Aachs%26aulast%3DBourne%26aufirst%3DC.%2BR.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DGlobal%2520structural%2520changes%2520in%2520hepatitis%2520B%2520virus%2520capsids%2520induced%2520by%2520the%2520assembly%2520effector%2520HAP1%26jtitle%3DJ.%2520Virol%26date%3D2006%26volume%3D80%26spage%3D11055%26epage%3D11061%26doi%3D10.1128%2FJVI.00933-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Berke, J. M.; Verbinnen, T.; Tan, Y.; Dehertogh, P.; Vergauwen, K.; Vandyck, K.; Lenz, O.</span><span> </span><span class="NLM_article-title">The HBV capsid assembly modulator JNJ-379 is a potent inhibitor of viral replication across full length genotype A-H clinical isolates in vitro</span>. Presented at the AASLD Liver Meeting, Washington, DC, Oct 20–24,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Berke%2C+J.+M.%3B+Verbinnen%2C+T.%3B+Tan%2C+Y.%3B+Dehertogh%2C+P.%3B+Vergauwen%2C+K.%3B+Vandyck%2C+K.%3B+Lenz%2C+O.+The+HBV+capsid+assembly+modulator+JNJ-379+is+a+potent+inhibitor+of+viral+replication+across+full+length+genotype+A-H+clinical+isolates+in+vitro.+Presented+at+the+AASLD+Liver+Meeting%2C+Washington%2C+DC%2C+Oct+20%E2%80%9324%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520HBV%2520capsid%2520assembly%2520modulator%2520JNJ-379%2520is%2520a%2520potent%2520inhibitor%2520of%2520viral%2520replication%2520across%2520full%2520length%2520genotype%2520A-H%2520clinical%2520isolates%2520in%2520vitro%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Baell, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, G. A.</span><span> </span><span class="NLM_article-title">New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2719</span><span class="NLM_x">–</span> <span class="NLM_lpage">2740</span><span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+pan+assay+interference+compounds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0licqSnKnf52Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520pan%2520assay%2520interference%2520compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 9 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">WooChan Kim, Jung-Ah Kang, Minji Park, Pyeong-Hwa Jeong, Yoon Jun Kim, Yuri Cho, Sung-Gyoo Park, <span class="NLM_string-name hlFld-ContribAuthor">Yong-Chul Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Pyrimidine-Based Capsid Assembly Modulators as Potent Anti-HBV Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (9)
                                     , 5500-5518. <a href="https://doi.org/10.1021/acs.jmedchem.0c01938" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01938</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01938%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BPyrimidine-Based%252BCapsid%252BAssembly%252BModulators%252Bas%252BPotent%252BAnti-HBV%252BAgents%26aulast%3DKim%26aufirst%3DWooChan%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D09112020%26date%3D23042021%26volume%3D64%26issue%3D9%26spage%3D5500%26epage%3D5518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">George D. Hartman, Scott D. Kuduk, Christine Espiritu, <span class="NLM_string-name hlFld-ContribAuthor">Angela M. Lam</span>. </span><span class="cited-content_cbyCitation_article-title">P450s under Restriction (PURE) Screen Using HepaRG and Primary Human Hepatocytes for Discovery of Novel HBV Antivirals. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (10)
                                     , 1919-1927. <a href="https://doi.org/10.1021/acsmedchemlett.9b00630" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00630</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00630&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00630%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DP450s%252Bunder%252BRestriction%252B%252528PURE%252529%252BScreen%252BUsing%252BHepaRG%252Band%252BPrimary%252BHuman%252BHepatocytes%252Bfor%252BDiscovery%252Bof%252BNovel%252BHBV%252BAntivirals%26aulast%3DHartman%26aufirst%3DGeorge%2BD.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D19122019%26date%3D26022020%26date%3D02032020%26date%3D26022020%26volume%3D11%26issue%3D10%26spage%3D1919%26epage%3D1927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wuhong Chen, Feifei Liu, Qiliang Zhao, Xinna Ma, Dong Lu, Heng Li, Yanping Zeng, Xiankun Tong, Limin Zeng, Jia Liu, Li Yang, Jianping Zuo, <span class="NLM_string-name hlFld-ContribAuthor">Youhong Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Phthalazinone Derivatives as Novel Hepatitis B Virus Capsid Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (15)
                                     , 8134-8145. <a href="https://doi.org/10.1021/acs.jmedchem.0c00346" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00346</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00346%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPhthalazinone%252BDerivatives%252Bas%252BNovel%252BHepatitis%252BB%252BVirus%252BCapsid%252BInhibitors%26aulast%3DChen%26aufirst%3DWuhong%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26022020%26date%3D21072020%26volume%3D63%26issue%3D15%26spage%3D8134%26epage%3D8145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ye Wang, Wen-Yun Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Shu-Li You</span>. </span><span class="cited-content_cbyCitation_article-title">Ketones and Aldehydes as O-Nucleophiles in Iridium-Catalyzed Intramolecular Asymmetric Allylic Substitution Reaction. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (6)
                                     , 2228-2232. <a href="https://doi.org/10.1021/jacs.8b13182" title="DOI URL">https://doi.org/10.1021/jacs.8b13182</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.8b13182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.8b13182%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DKetones%252Band%252BAldehydes%252Bas%252BO-Nucleophiles%252Bin%252BIridium-Catalyzed%252BIntramolecular%252BAsymmetric%252BAllylic%252BSubstitution%252BReaction%26aulast%3DWang%26aufirst%3DYe%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D10122018%26date%3D31012019%26date%3D28012019%26volume%3D141%26issue%3D6%26spage%3D2228%26epage%3D2232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Piet  Herdewijn</span>, <span class="hlFld-ContribAuthor ">Weijie  Gu</span>, <span class="hlFld-ContribAuthor ">Erik  Clercq</span>. </span><span class="cited-content_cbyCitation_article-title">Anti‐DNA Virus Agents. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-41. <a href="https://doi.org/10.1002/0471266949.bmc237.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc237.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc237.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc237.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DAnti%2525E2%252580%252590DNA%252BVirus%252BAgents%26aulast%3DHerdewijn%26aufirst%3DPiet%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D41%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdolkarim  Farrokhzadeh</span>, <span class="hlFld-ContribAuthor ">Farideh  Badichi Akher</span>, <span class="hlFld-ContribAuthor ">Fisayo A.  Olotu</span>, <span class="hlFld-ContribAuthor ">Fanie R.  Van Heerden</span>. </span><span class="cited-content_cbyCitation_article-title">Impact of HEC72702 chirality on the selective inhibition of hepatitis B virus capsid dimer: A dynamics–structure–energetics perspective. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2021,</strong> <em>97 </em>
                                    (1)
                                     , 167-183. <a href="https://doi.org/10.1111/cbdd.13771" title="DOI URL">https://doi.org/10.1111/cbdd.13771</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13771%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DImpact%252Bof%252BHEC72702%252Bchirality%252Bon%252Bthe%252Bselective%252Binhibition%252Bof%252Bhepatitis%252BB%252Bvirus%252Bcapsid%252Bdimer%25253A%252BA%252Bdynamics%2525E2%252580%252593structure%2525E2%252580%252593energetics%252Bperspective%26aulast%3DFarrokhzadeh%26aufirst%3DAbdolkarim%26date%3D2021%26date%3D2020%26volume%3D97%26issue%3D1%26spage%3D167%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alicia  Regueiro-Ren</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclic sulfoxides and sulfones in drug design. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-30. <a href="https://doi.org/10.1016/bs.aihch.2020.10.003" title="DOI URL">https://doi.org/10.1016/bs.aihch.2020.10.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2020.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2020.10.003%26sid%3Dliteratum%253Aachs%26atitle%3DCyclic%252Bsulfoxides%252Band%252Bsulfones%252Bin%252Bdrug%252Bdesign%26aulast%3DRegueiro-Ren%26aufirst%3DAlicia%26date%3D2021%26spage%3D1%26epage%3D30%26pub%3DElsevier%26atitle%3DApplications%252Bof%252BHeterocycles%252Bin%252Bthe%252BDesign%252Bof%252BDrugs%252Band%252BAgricultural%252BProducts%26date%3D2021%26volume%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angeliki P.  Kourounakis</span>, <span class="hlFld-ContribAuthor ">Dimitrios  Xanthopoulos</span>, <span class="hlFld-ContribAuthor ">Ariadni  Tzara</span>. </span><span class="cited-content_cbyCitation_article-title">Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>40 </em>
                                    (2)
                                     , 709-752. <a href="https://doi.org/10.1002/med.21634" title="DOI URL">https://doi.org/10.1002/med.21634</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21634%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMorpholine%252Bas%252Ba%252Bprivileged%252Bstructure%25253A%252BA%252Breview%252Bon%252Bthe%252Bmedicinal%252Bchemistry%252Band%252Bpharmacological%252Bactivity%252Bof%252Bmorpholine%252Bcontaining%252Bbioactive%252Bmolecules%26aulast%3DKourounakis%26aufirst%3DAngeliki%2BP.%26date%3D2020%26volume%3D40%26issue%3D2%26spage%3D709%26epage%3D752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong-Jin  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Five-Membered Ring Systems: With N and S Atom. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 363-377. <a href="https://doi.org/10.1016/B978-0-12-819962-6.00009-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-819962-6.00009-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-819962-6.00009-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-819962-6.00009-9%26sid%3Dliteratum%253Aachs%26atitle%3DFive-Membered%252BRing%252BSystems%25253A%252BWith%252BN%252Band%252BS%252BAtom%26aulast%3DWu%26aufirst%3DYong-Jin%26date%3D2020%26spage%3D363%26epage%3D377%26pub%3DElsevier%26date%3D2020%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01914&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of the reported HBV-capsid inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01914&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Previous design structure of molecules from GLS4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01914&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Optimal-binding model for compounds <b>58</b> (left) and <b>60</b> (right) in the active site of the capsid docked by the SURFLEX module. The ligand is shown in sticks, and some key residues are shown in lines. Hydrogen bonds are shown in dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01914&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effects of treatment with <b>58</b> (HEC72702) on the inhibition of HBV replication in the HDI mouse model. Mice (<i>N</i> = 6) were orally dosed with the vehicle control, compound <b>58</b> (HEC72702, 50 or 100 mpk, b.i.d.), or ETV. (A) Levels of HBV DNA in plasma. At 2, 4, 6, and 8 days postinfection, the serum HBV of all the treatment group (groups 2–4) were quantified and showed significant reductions in HBV DNA compared with that of the vehicle control. Error bar indicate the standard error of the mean (<i>N</i> = 6). *** indicates p < 0.001 for 50 mpk HEC72702 b.i.d. vs the vehicle, <sup>###</sup> indicates p < 0.001 for 100 mpk HEC72702 b.i.d. vs the vehicle, and <sup>&&&</sup> indicates p < 0.001 for 0.1 mpk ETV q.d vs the vehicle. (B) Quantified levels of HBV DNA in mouse livers. All the treatment groups (group 2–4) had significant reductions in liver HBV DNA compared with the vehicle control. *** indicates p < 0.0001.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01914&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/medium/jm-2017-01914y_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>58</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-3/acs.jmedchem.7b01914/20180201/images/large/jm-2017-01914y_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01914&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 1.2 equiv NaOAc, EtOH, reflux, 16 h; (b) recrystallization with ethanol; (c) 2 equiv Li, EtOH, reflux, 2 h; (d) 1.1 equiv NBS, CCl<sub>4</sub>, reflux, 1 h; (e) K<sub>2</sub>CO<sub>3</sub>, EtOH, 25 °C, 2 h.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i83">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14541" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14541" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Ganem, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prince, A. M.</span><span> </span><span class="NLM_article-title">Hepatitis B virus infection-natural history and clinical consequences</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">1118</span><span class="NLM_x">–</span> <span class="NLM_lpage">1129</span><span class="refDoi"> DOI: 10.1056/NEJMra031087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1056%2FNEJMra031087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=15014185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD2cXitV2qurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=1118-1129&author=D.+Ganemauthor=A.+M.+Prince&title=Hepatitis+B+virus+infection-natural+history+and+clinical+consequences&doi=10.1056%2FNEJMra031087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B virus infection-natural history and clinical consequences</span></div><div class="casAuthors">Ganem, Don; Prince, Alfred M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1118-1129</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review discusses the recent advances in the understanding of the natural history and pathogenesis of hepatitis B virus infection, with particular ref. to the implications for antiviral therapy.  The administration of interferons, and the use antiviral drugs such as lamivudine and other nucleoside analogs are particularly described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEhbSUYzgtnLVg90H21EOLACvtfcHk0lj2r0GfpO1Bxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXitV2qurs%253D&md5=b8a9d038ccbaaef6077329ada84b8212</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra031087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra031087%26sid%3Dliteratum%253Aachs%26aulast%3DGanem%26aufirst%3DD.%26aulast%3DPrince%26aufirst%3DA.%2BM.%26atitle%3DHepatitis%2520B%2520virus%2520infection-natural%2520history%2520and%2520clinical%2520consequences%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D1118%26epage%3D1129%26doi%3D10.1056%2FNEJMra031087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Shepard, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finelli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiore, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, B. P.</span><span> </span><span class="NLM_article-title">Hepatitis B virus infection: epidemiology and vaccination</span> <span class="citation_source-journal">Epidemiol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">112</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1093/epirev/mxj009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1093%2Fepirev%2Fmxj009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=16754644" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A280%3ADC%252BD28vjsVahsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2006&pages=112-125&author=C.+W.+Shepardauthor=E.+P.+Simardauthor=L.+Finelliauthor=A.+E.+Fioreauthor=B.+P.+Bell&title=Hepatitis+B+virus+infection%3A+epidemiology+and+vaccination&doi=10.1093%2Fepirev%2Fmxj009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatitis B virus infection: epidemiology and vaccination</span></div><div class="casAuthors">Shepard Colin W; Simard Edgar P; Finelli Lyn; Fiore Anthony E; Bell Beth P</div><div class="citationInfo"><span class="NLM_cas:title">Epidemiologic reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112-25</span>
        ISSN:<span class="NLM_cas:issn">0193-936X</span>.
    </div><div class="casAbstract">Worldwide, two billion people have been infected with hepatitis B virus (HBV), 360 million have chronic infection, and 600,000 die each year from HBV-related liver disease or hepatocellular carcinoma.  This comprehensive review of hepatitis B epidemiology and vaccines focuses on definitive and influential studies and highlights current trends, policies, and directions.  HBV can be transmitted vertically, through sexual or household contact, or by unsafe injections, but chronic infections acquired during infancy or childhood account for a disproportionately large share of worldwide morbidity and mortality.  Vaccination against HBV infection can be started at birth and provides long-term protection against infection in more than 90% of healthy people.  In the 1990s, many industrialized countries and a few less-developed countries implemented universal hepatitis B immunization and experienced measurable reductions in HBV-related disease.  For example, in Taiwan, the prevalence of chronic infection in children declined by more than 90%.  Many resource-poor nations have recently initiated universal hepatitis B immunization programs with assistance from the Global Alliance for Vaccines and Immunization.  Further progress towards the elimination of HBV transmission will require sustainable vaccination programs with improved vaccination coverage, practical methods of measuring the impact of vaccination programs, and targeted vaccination efforts for communities at high risk of infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS2UhAXwGC9Lv9pSBfyDvp7fW6udTcc2ebQ0LjQt6cyhbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28vjsVahsA%253D%253D&md5=59540288bd15ae148dc1b162c798c94b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1093%2Fepirev%2Fmxj009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fepirev%252Fmxj009%26sid%3Dliteratum%253Aachs%26aulast%3DShepard%26aufirst%3DC.%2BW.%26aulast%3DSimard%26aufirst%3DE.%2BP.%26aulast%3DFinelli%26aufirst%3DL.%26aulast%3DFiore%26aufirst%3DA.%2BE.%26aulast%3DBell%26aufirst%3DB.%2BP.%26atitle%3DHepatitis%2520B%2520virus%2520infection%253A%2520epidemiology%2520and%2520vaccination%26jtitle%3DEpidemiol.%2520Rev.%26date%3D2006%26volume%3D28%26spage%3D112%26epage%3D125%26doi%3D10.1093%2Fepirev%2Fmxj009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Perrillo, R.</span><span> </span><span class="NLM_article-title">Benefits and risks of interferon therapy for hepatitis B</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">S103</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span><span class="refDoi"> DOI: 10.1002/hep.22956</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1002%2Fhep.22956" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=S103-111&author=R.+Perrillo&title=Benefits+and+risks+of+interferon+therapy+for+hepatitis+B&doi=10.1002%2Fhep.22956"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fhep.22956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.22956%26sid%3Dliteratum%253Aachs%26aulast%3DPerrillo%26aufirst%3DR.%26atitle%3DBenefits%2520and%2520risks%2520of%2520interferon%2520therapy%2520for%2520hepatitis%2520B%26jtitle%3DHepatology%26date%3D2009%26volume%3D49%26spage%3DS103%26epage%3D111%26doi%3D10.1002%2Fhep.22956" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Tipples, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bain, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kneteman, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyrrell, D. L.</span><span> </span><span class="NLM_article-title">Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo</span> <span class="citation_source-journal">Hepatology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">714</span><span class="NLM_x">–</span> <span class="NLM_lpage">717</span><span class="refDoi"> DOI: 10.1002/hep.510240340</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1002%2Fhep.510240340" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1996&pages=714-717&author=G.+A.+Tipplesauthor=M.+M.+Maauthor=K.+P.+Fischerauthor=V.+G.+Bainauthor=N.+M.+Knetemanauthor=D.+L.+Tyrrell&title=Mutation+in+HBV+RNA-dependent+DNA+polymerase+confers+resistance+to+lamivudine+in+vivo&doi=10.1002%2Fhep.510240340"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fhep.510240340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.510240340%26sid%3Dliteratum%253Aachs%26aulast%3DTipples%26aufirst%3DG.%2BA.%26aulast%3DMa%26aufirst%3DM.%2BM.%26aulast%3DFischer%26aufirst%3DK.%2BP.%26aulast%3DBain%26aufirst%3DV.%2BG.%26aulast%3DKneteman%26aufirst%3DN.%2BM.%26aulast%3DTyrrell%26aufirst%3DD.%2BL.%26atitle%3DMutation%2520in%2520HBV%2520RNA-dependent%2520DNA%2520polymerase%2520confers%2520resistance%2520to%2520lamivudine%2520in%2520vivo%26jtitle%3DHepatology%26date%3D1996%26volume%3D24%26spage%3D714%26epage%3D717%26doi%3D10.1002%2Fhep.510240340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Papatheodoridis, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manolakopoulos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dusheiko, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Archimandritis, A. J.</span><span> </span><span class="NLM_article-title">Therapeutic strategies in the management of patients with chronic hepatitis B virus infection</span> <span class="citation_source-journal">Lancet Infect. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">167</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1016/S1473-3099(07)70264-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1016%2FS1473-3099%2807%2970264-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=18053766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjsl2gsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=167-178&author=G.+V.+Papatheodoridisauthor=S.+Manolakopoulosauthor=G.+Dusheikoauthor=A.+J.+Archimandritis&title=Therapeutic+strategies+in+the+management+of+patients+with+chronic+hepatitis+B+virus+infection&doi=10.1016%2FS1473-3099%2807%2970264-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic strategies in the management of patients with chronic hepatitis B virus infection</span></div><div class="casAuthors">Papatheodoridis, George V.; Manolakopoulos, Spilios; Dusheiko, Geoffrey; Archimandritis, Athanasios J.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-178</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Currently available options for the treatment of chronic hepatitis B virus (HBV) infection include std. and pegylated interferon alfa and four oral antiviral agents (lamivudine, adefovir, entecavir, and telbivudine).  These treatment strategies are either therapies of finite duration that aim to achieve sustained off-therapy responses, or long-term treatments that aim to maintain on-therapy remission.  Pegylated interferon alfa may offer higher sustained off-therapy responses after 1 yr, but most patients do not respond.  Oral antivirals are the only candidates for long-term treatment of patients with chronic HBV infection.  Viral suppression has favorable effects on patients' outcome and modifies the natural history of the disease.  Viral resistance is the main drawback of long-term antiviral therapy.  Lamivudine monotherapy is assocd. with higher resistance (year 1, 10-27%; year 2, 37-48%; year 4, 60-65%) than adefovir (year 1, 0%; year 2, 3%; year 5, 29%) or telbivudine (year 1, 3-4%; year 2, 9-22%).  Entecavir resistance is rare in naive individuals (year 4, <1%), but increases over time in lamivudine-resistant patients (year 4, 43%).  The best strategy for long-term therapy in chronic HBV infection has yet to be established.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGri_6VaaZsnh7Vg90H21EOLACvtfcHk0lhJ0qWA3S-Xog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjsl2gsbk%253D&md5=35b812a4d84d8130aec3d1676fe1735e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2807%2970264-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252807%252970264-5%26sid%3Dliteratum%253Aachs%26aulast%3DPapatheodoridis%26aufirst%3DG.%2BV.%26aulast%3DManolakopoulos%26aufirst%3DS.%26aulast%3DDusheiko%26aufirst%3DG.%26aulast%3DArchimandritis%26aufirst%3DA.%2BJ.%26atitle%3DTherapeutic%2520strategies%2520in%2520the%2520management%2520of%2520patients%2520with%2520chronic%2520hepatitis%2520B%2520virus%2520infection%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2008%26volume%3D8%26spage%3D167%26epage%3D178%26doi%3D10.1016%2FS1473-3099%2807%2970264-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Petersen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dandri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lütgehetmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Volz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Weizsäcker, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haberkorn, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollok, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erbes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seitz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, S.</span><span> </span><span class="NLM_article-title">Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">341</span><span class="refDoi"> DOI: 10.1038/nbt1389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1038%2Fnbt1389" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=335-341&author=J.+Petersenauthor=M.+Dandriauthor=W.+Mierauthor=M.+L%C3%BCtgehetmannauthor=T.+Volzauthor=F.+von+Weizs%C3%A4ckerauthor=U.+Haberkornauthor=L.+Fischerauthor=J.+Pollokauthor=B.+Erbesauthor=S.+Seitzauthor=S.+Urban&title=Prevention+of+hepatitis+B+virus+infection+in+vivo+by+entry+inhibitors+derived+from+the+large+envelope+protein&doi=10.1038%2Fnbt1389"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnbt1389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1389%26sid%3Dliteratum%253Aachs%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DDandri%26aufirst%3DM.%26aulast%3DMier%26aufirst%3DW.%26aulast%3DL%25C3%25BCtgehetmann%26aufirst%3DM.%26aulast%3DVolz%26aufirst%3DT.%26aulast%3Dvon%2BWeizs%25C3%25A4cker%26aufirst%3DF.%26aulast%3DHaberkorn%26aufirst%3DU.%26aulast%3DFischer%26aufirst%3DL.%26aulast%3DPollok%26aufirst%3DJ.%26aulast%3DErbes%26aufirst%3DB.%26aulast%3DSeitz%26aufirst%3DS.%26aulast%3DUrban%26aufirst%3DS.%26atitle%3DPrevention%2520of%2520hepatitis%2520B%2520virus%2520infection%2520in%2520vivo%2520by%2520entry%2520inhibitors%2520derived%2520from%2520the%2520large%2520envelope%2520protein%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D335%26epage%3D341%26doi%3D10.1038%2Fnbt1389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Steven, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watts, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belnap, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stahl, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wingfield, P. T.</span><span> </span><span class="NLM_article-title">Structure, assembly, and antigenicity of hepatitis B virus capsid proteins</span> <span class="citation_source-journal">Adv. Virus Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">164</span><span class="refDoi"> DOI: 10.1016/S0065-3527(05)64005-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1016%2FS0065-3527%2805%2964005-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2005&pages=125-164&author=A.+C.+Stevenauthor=J.+F.+Conwayauthor=N.+Chengauthor=N.+R.+Wattsauthor=D.+M.+Belnapauthor=A.+Harrisauthor=S.+J.+Stahlauthor=P.+T.+Wingfield&title=Structure%2C+assembly%2C+and+antigenicity+of+hepatitis+B+virus+capsid+proteins&doi=10.1016%2FS0065-3527%2805%2964005-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0065-3527%2805%2964005-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0065-3527%252805%252964005-5%26sid%3Dliteratum%253Aachs%26aulast%3DSteven%26aufirst%3DA.%2BC.%26aulast%3DConway%26aufirst%3DJ.%2BF.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DWatts%26aufirst%3DN.%2BR.%26aulast%3DBelnap%26aufirst%3DD.%2BM.%26aulast%3DHarris%26aufirst%3DA.%26aulast%3DStahl%26aufirst%3DS.%2BJ.%26aulast%3DWingfield%26aufirst%3DP.%2BT.%26atitle%3DStructure%252C%2520assembly%252C%2520and%2520antigenicity%2520of%2520hepatitis%2520B%2520virus%2520capsid%2520proteins%26jtitle%3DAdv.%2520Virus%2520Res.%26date%3D2005%26volume%3D64%26spage%3D125%26epage%3D164%26doi%3D10.1016%2FS0065-3527%2805%2964005-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Chain, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, R.</span><span> </span><span class="NLM_article-title">Variability and conservation in hepatitis B virus core protein</span> <span class="citation_source-journal">BMC Microbiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">33</span><span class="refDoi"> DOI: 10.1186/1471-2180-5-33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1186%2F1471-2180-5-33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=15921513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A280%3ADC%252BD2MzkvVCmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=33&author=B.+M.+Chainauthor=R.+Myers&title=Variability+and+conservation+in+hepatitis+B+virus+core+protein&doi=10.1186%2F1471-2180-5-33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Variability and conservation in hepatitis B virus core protein</span></div><div class="casAuthors">Chain Benjamin M; Myers Richard</div><div class="citationInfo"><span class="NLM_cas:title">BMC microbiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Hepatitis B core protein (HBVc) has been extensively studied from both a structural and immunological point of view, but the evolutionary forces driving sequence variation within core are incompletely understood.  RESULTS:  In this study, the observed variation in HBVc protein sequence has been examined in a collection of a large number of HBVc protein sequences from public sequence repositories.  An alignment of several hundred sequences was carried out, and used to analyse the distribution of polymorphisms along the HBVc.  Polymorphisms were found at 44 out of 185 amino acid positions analysed and were clustered predominantly in those parts of HBVc forming the outer surface and spike on intact capsid.  The relationship between HBVc diversity and HBV genotype was examined.  The position of variable amino acids along the sequence was examined in terms of the structural constraints of capsid and envelope assembly, and also in terms of immunological recognition by T and B cells.  CONCLUSION:  Over three quarters of amino acids within the HBVc sequence are non-polymorphic, and variation is focused to a few amino acids.  Phylogenetic analysis suggests that core protein specific forces constrain its diversity within the context of overall HBV genome evolution.  As a consequence, core protein is not a reliable predictor of virus genotype.  The structural requirements of capsid assembly are likely to play a major role in limiting diversity.  The phylogenetic analysis further suggests that immunological selection does not play a major role in driving HBVc diversity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTGMvprrY2YZTslzEEsg76ufW6udTcc2eYyvCf4jy_p9Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzkvVCmsA%253D%253D&md5=e6268379aa887b05e0ead45823a0b09f</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1186%2F1471-2180-5-33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2180-5-33%26sid%3Dliteratum%253Aachs%26aulast%3DChain%26aufirst%3DB.%2BM.%26aulast%3DMyers%26aufirst%3DR.%26atitle%3DVariability%2520and%2520conservation%2520in%2520hepatitis%2520B%2520virus%2520core%2520protein%26jtitle%3DBMC%2520Microbiol.%26date%3D2005%26volume%3D5%26spage%3D33%26doi%3D10.1186%2F1471-2180-5-33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Choi, I.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y. G.</span><span> </span><span class="NLM_article-title">Interaction and assembly of HBV structural proteins: novel target sites of anti-HBV agents</span> <span class="citation_source-journal">Infect. Disord.: Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">256</span><span class="refDoi"> DOI: 10.2174/187152607782110077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.2174%2F187152607782110077" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=17897061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlWiurzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=251-256&author=I.-G.+Choiauthor=Y.+G.+Yu&title=Interaction+and+assembly+of+HBV+structural+proteins%3A+novel+target+sites+of+anti-HBV+agents&doi=10.2174%2F187152607782110077"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction and assembly of HBV structural proteins: novel target sites of anti-HBV agents</span></div><div class="casAuthors">Choi, In-Geol; Yu, Yeon Gyu</div><div class="citationInfo"><span class="NLM_cas:title">Infectious Disorders: Drug Targets</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">251-256</span>CODEN:
                <span class="NLM_cas:coden">IDDTAD</span>;
        ISSN:<span class="NLM_cas:issn">1871-5265</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Human hepatitis B virus (HBV) causes chronic hepatitis disease which is a major public health problem worldwide.  HBV has 4 genes encoding viral DNA polymerase, protein X and two structural proteins, the surface and core proteins.  HBV DNA polymerase has been a primary target for the development of anti-HBV agents due to its enzymic nature, and several nucleoside derivs. that inhibit HBV polymerase are currently used as anti-HBV therapeutics.  On the other hand, accumulating information on the capsid assembly and the maturation process of HBV particles provides addnl. approaches for the development of anti-HBV agents.  Proper interaction between core proteins is required for assembly of the nucleocapsid, and the specificity of the interactions between the capsid and surface proteins is essential for the maturation of active HBV in infected cells.  In this article, the assembly process of active HBV particles and approaches to utilize the interactions of HBV structural proteins as target site for the development of anti-HBV agents are reviewed.  In particular, novel approaches to target the assembly process and the interaction between HBV structural proteins are introduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq50CrrHZFnrVg90H21EOLACvtfcHk0lgeLNzXIYA83w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlWiurzL&md5=ba31304a1729e7371d2ddebc63ab3909</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F187152607782110077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187152607782110077%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DI.-G.%26aulast%3DYu%26aufirst%3DY.%2BG.%26atitle%3DInteraction%2520and%2520assembly%2520of%2520HBV%2520structural%2520proteins%253A%2520novel%2520target%2520sites%2520of%2520anti-HBV%2520agents%26jtitle%3DInfect.%2520Disord.%253A%2520Drug%2520Targets%26date%3D2007%26volume%3D7%26spage%3D251%26epage%3D256%26doi%3D10.2174%2F187152607782110077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Delaney, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colledge, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Painter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locarnini, S.</span><span> </span><span class="NLM_article-title">Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">3057</span><span class="NLM_x">–</span> <span class="NLM_lpage">3060</span><span class="refDoi"> DOI: 10.1128/AAC.46.9.3057-3060.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1128%2FAAC.46.9.3057-3060.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=12183271" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmtl2kurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2002&pages=3057-3060&author=W.+E.+Delaneyauthor=R.+Edwardsauthor=D.+Colledgeauthor=T.+Shawauthor=P.+Furmanauthor=G.+Painterauthor=S.+Locarnini&title=Phenylpropenamide+derivatives+AT-61+and+AT-130+inhibit+replication+of+wild-type+and+lamivudine-resistant+strains+of+hepatitis+B+virus+in+vitro&doi=10.1128%2FAAC.46.9.3057-3060.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro</span></div><div class="casAuthors">Delaney, William E., IV; Edwards, Ros; Colledge, Danni; Shaw, Tim; Furman, Phil; Painter, George; Locarnini, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3057-3060</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The phenylpropenamide derivs. AT-61 and AT-130 are nonnucleoside analog inhibitors of hepatitis B virus (HBV) replication.  They inhibited the replication of wild-type HBV with 50% inhibitory concns. of 21.2±9.5 and 2.40±0.92 μM, resp., compared to 0.064±0.020 μM lamivudine.  There were no significant differences in sensitivity between wild-type and nucleoside analog-resistant (rtL180M, rtM204I, and rtL180M + rtM204V) HBV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4UNW_6bFxUrVg90H21EOLACvtfcHk0lgeLNzXIYA83w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmtl2kurw%253D&md5=ffb8ff070fda879480d93597468cbd9b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1128%2FAAC.46.9.3057-3060.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.46.9.3057-3060.2002%26sid%3Dliteratum%253Aachs%26aulast%3DDelaney%26aufirst%3DW.%2BE.%26aulast%3DEdwards%26aufirst%3DR.%26aulast%3DColledge%26aufirst%3DD.%26aulast%3DShaw%26aufirst%3DT.%26aulast%3DFurman%26aufirst%3DP.%26aulast%3DPainter%26aufirst%3DG.%26aulast%3DLocarnini%26aufirst%3DS.%26atitle%3DPhenylpropenamide%2520derivatives%2520AT-61%2520and%2520AT-130%2520inhibit%2520replication%2520of%2520wild-type%2520and%2520lamivudine-resistant%2520strains%2520of%2520hepatitis%2520B%2520virus%2520in%2520vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2002%26volume%3D46%26spage%3D3057%26epage%3D3060%26doi%3D10.1128%2FAAC.46.9.3057-3060.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Wang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naduthambi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosley, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furman, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otto, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sofia, M. J.</span><span> </span><span class="NLM_article-title">Phenylpropenamide derivatives: antihepatitis B virus activity of the Z isomer, SAR and the search for novel analogs</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">4642</span><span class="NLM_x">–</span> <span class="NLM_lpage">4647</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.05.077</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1016%2Fj.bmcl.2011.05.077" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=4642-4647&author=P.+Wangauthor=D.+Naduthambiauthor=R.+T.+Mosleyauthor=C.+Niuauthor=P.+A.+Furmanauthor=M.+J.+Ottoauthor=M.+J.+Sofia&title=Phenylpropenamide+derivatives%3A+antihepatitis+B+virus+activity+of+the+Z+isomer%2C+SAR+and+the+search+for+novel+analogs&doi=10.1016%2Fj.bmcl.2011.05.077"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.05.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.05.077%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DP.%26aulast%3DNaduthambi%26aufirst%3DD.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26aulast%3DNiu%26aufirst%3DC.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DOtto%26aufirst%3DM.%2BJ.%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26atitle%3DPhenylpropenamide%2520derivatives%253A%2520antihepatitis%2520B%2520virus%2520activity%2520of%2520the%2520Z%2520isomer%252C%2520SAR%2520and%2520the%2520search%2520for%2520novel%2520analogs%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D4642%26epage%3D4647%26doi%3D10.1016%2Fj.bmcl.2011.05.077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Campagna, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuconati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, J. T.</span><span> </span><span class="NLM_article-title">Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">6931</span><span class="NLM_x">–</span> <span class="NLM_lpage">6942</span><span class="refDoi"> DOI: 10.1128/JVI.00582-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1128%2FJVI.00582-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=23576513" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptlKrsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=6931-6942&author=M.+R.+Campagnaauthor=F.+Liuauthor=R.+Maoauthor=C.+Millsauthor=D.+Caiauthor=F.+Guoauthor=X.+Zhaoauthor=H.+Yeauthor=A.+Cuconatiauthor=H.+Guoauthor=J.+Changauthor=X.+Xuauthor=T.+M.+Blockauthor=J.+T.+Guo&title=Sulfamoylbenzamide+derivatives+inhibit+the+assembly+of+hepatitis+B+virus+nucleocapsids&doi=10.1128%2FJVI.00582-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids</span></div><div class="casAuthors">Campagna, Matthew R.; Liu, Fei; Mao, Richeng; Mills, Courtney; Cai, Dawei; Guo, Fang; Zhao, Xuesen; Ye, Hong; Cuconati, Andrea; Guo, Haitao; Chang, Jinhong; Xu, Xiaodong; Block, Timothy M.; Guo, Ju-Tao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">6931-6942</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Chronic hepatitis B virus (HBV) infection, a serious public health problem leading to cirrhosis and hepatocellular carcinoma, is currently treated with either pegylated alpha interferon (pegIFN-α) or one of the five nucleos(t)ide analog viral DNA polymerase inhibitors.  However, neither pegIFN-α nor nucleos(t)ide analogs are capable of reliably curing the viral infection.  In order to develop novel antiviral drugs against HBV, we established a cell-based screening assay by using an immortalized mouse hepatocyte-derived stable cell line supporting a high level of HBV replication in a tetracycline-inducible manner.  Screening of a library consisting of 26,900 small mols. led to the discovery of a series of sulfamoylbenzamide (SBA) derivs. that significantly reduced the amt. of cytoplasmic HBV DNA.  Structure-activity relationship studies have thus far identified a group of fluorine-substituted SBAs with submicromolar antiviral activity against HBV in human hepatoma cells.  Mechanistic analyses reveal that the compds. dose dependently inhibit the formation of pregenomic RNA (pgRNA)-contg. nucleocapsids of HBV but not other animal hepadnaviruses, such as woodchuck hepatitis virus (WHV) and duck hepatitis B virus (DHBV).  Moreover, heterologous genetic complementation studies of capsid protein, DNA polymerase, and pgRNA between HBV and WHV suggest that HBV capsid protein confers sensitivity to the SBAs.  In summary, SBAs represent a novel chem. entity with superior activity and a unique antiviral mechanism and are thus warranted for further development as novel antiviral therapeutics for the treatment of chronic hepatitis B.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNUsTkQKVBQbVg90H21EOLACvtfcHk0lhMBt3EJ4s33A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptlKrsr0%253D&md5=80cd9d05d889ecf1bd2f6c28f7946bcf</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FJVI.00582-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00582-13%26sid%3Dliteratum%253Aachs%26aulast%3DCampagna%26aufirst%3DM.%2BR.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DMao%26aufirst%3DR.%26aulast%3DMills%26aufirst%3DC.%26aulast%3DCai%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DCuconati%26aufirst%3DA.%26aulast%3DGuo%26aufirst%3DH.%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DBlock%26aufirst%3DT.%2BM.%26aulast%3DGuo%26aufirst%3DJ.%2BT.%26atitle%3DSulfamoylbenzamide%2520derivatives%2520inhibit%2520the%2520assembly%2520of%2520hepatitis%2520B%2520virus%2520nucleocapsids%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D6931%26epage%3D6942%26doi%3D10.1128%2FJVI.00582-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, X. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, G. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hao, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nan, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuo, J. P.</span><span> </span><span class="NLM_article-title">Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">410</span><span class="NLM_x">–</span> <span class="NLM_lpage">418</span><span class="refDoi"> DOI: 10.1038/aps.2013.175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1038%2Faps.2013.175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=24487969" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtl2itrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=410-418&author=L.+Yangauthor=L.+P.+Shiauthor=H.+J.+Chenauthor=X.+K.+Tongauthor=G.+F.+Wangauthor=Y.+M.+Zhangauthor=W.+L.+Wangauthor=C.+L.+Fengauthor=P.+L.+Heauthor=F.+H.+Zhuauthor=Y.+H.+Haoauthor=B.+J.+Wangauthor=D.+L.+Yangauthor=W.+Tangauthor=F.+J.+Nanauthor=J.+P.+Zuo&title=Isothiafludine%2C+a+novel+non-nucleoside+compound%2C+inhibits+hepatitis+B+virus+replication+through+blocking+pregenomic+RNA+encapsidation&doi=10.1038%2Faps.2013.175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Isothiafludine, a novel non-nucleoside compound, inhibits hepatitis B virus replication through blocking pregenomic RNA encapsidation</span></div><div class="casAuthors">Yang, Li; Shi, Li-ping; Chen, Hai-jun; Tong, Xian-Kun; Wang, Gui-feng; Zhang, Yang-ming; Wang, Wen-long; Feng, Chun-lan; He, Pei-lan; Zhu, Feng-hua; Hao, You-hua; Wang, Bao-ju; Yang, Dong-liang; Tang, Wei; Nan, Fa-jun; Zuo, Jian-ping</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">410-418</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Aim: To investigate the action of isothiafludine (NZ-4), a deriv. of bis-heterocycle tandem pairs from the natural product leucamide A, on the replication cycle of hepatitis B virus (HBV) in vitro and in vivo.  Methods: HBV replication cycle was monitored in HepG2.2.15 cells using qPCR, qRT-PCR, and Southern and Northern blotting.  HBV protein expression and capsid assembly were detected using Western blotting and native agarose gel electrophoresis anal.  The interaction of pregenomic RNA (pgRNA) and the core protein was investigated by RNA immunopptn.  To evaluate the anti-HBV effect of NZ-4 in vivo, DHBV-infected ducks were orally administered NZ-4 (25, 50 or 100 mg·kg-1·d-1) for 15 d.  Results: NZ-4 suppressed intracellular HBV replication in HepG2.2.15 cells with an IC50 value of 1.33 μmol/L, whereas the compd. inhibited the cell viability with an IC50 value of 50.4 μmol/L.  Furthermore, NZ-4 was active against the replication of various drug-resistant HBV mutants, including 3TC/ETV-dual-resistant and ADV-resistant HBV mutants.  NZ-4 (5, 10, 20 μmol/L) concn.-dependently reduced the encapsidated HBV pgRNA, resulting in the assembly of replication-deficient capsids in HepG2.2.15 cells.  Oral administration of NZ-4 dose-dependently inhibited DHBV DNA replication in the DHBV-infected ducks.  Conclusion: NZ-4 inhibits HBV replication by interfering with the interaction between pgRNA and HBcAg in the capsid assembly process, thus increasing the replication-deficient HBV capsids.  Such mechanism of action might provide a new therapeutic strategy to combat HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfXI1ksk5-erVg90H21EOLACvtfcHk0lhMBt3EJ4s33A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtl2itrs%253D&md5=7a046b35ab2f26aa43cf52fa76f85dea</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Faps.2013.175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2013.175%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DL.%2BP.%26aulast%3DChen%26aufirst%3DH.%2BJ.%26aulast%3DTong%26aufirst%3DX.%2BK.%26aulast%3DWang%26aufirst%3DG.%2BF.%26aulast%3DZhang%26aufirst%3DY.%2BM.%26aulast%3DWang%26aufirst%3DW.%2BL.%26aulast%3DFeng%26aufirst%3DC.%2BL.%26aulast%3DHe%26aufirst%3DP.%2BL.%26aulast%3DZhu%26aufirst%3DF.%2BH.%26aulast%3DHao%26aufirst%3DY.%2BH.%26aulast%3DWang%26aufirst%3DB.%2BJ.%26aulast%3DYang%26aufirst%3DD.%2BL.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DNan%26aufirst%3DF.%2BJ.%26aulast%3DZuo%26aufirst%3DJ.%2BP.%26atitle%3DIsothiafludine%252C%2520a%2520novel%2520non-nucleoside%2520compound%252C%2520inhibits%2520hepatitis%2520B%2520virus%2520replication%2520through%2520blocking%2520pregenomic%2520RNA%2520encapsidation%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2014%26volume%3D35%26spage%3D410%26epage%3D418%26doi%3D10.1038%2Faps.2013.175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Levin, J.</span><span> </span><span class="NLM_article-title">NVR 3–778, a first-in-class HBV core inhibitor, alone and in combination with pegylated-interferon (peg-IFN alpha-2a), in treatment-naïve HBeAg-positive patients: early reductions in HBV DNA and HBeAg</span>. Presented at the EASL International Liver Congress, Barcelona, April 14–17,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Levin%2C+J.+NVR+3%E2%80%93778%2C+a+first-in-class+HBV+core+inhibitor%2C+alone+and+in+combination+with+pegylated-interferon+%28peg-IFN+alpha-2a%29%2C+in+treatment-na%C3%AFve+HBeAg-positive+patients%3A+early+reductions+in+HBV+DNA+and+HBeAg.+Presented+at+the+EASL+International+Liver+Congress%2C+Barcelona%2C+April+14%E2%80%9317%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DJ.%26atitle%3DNVR%25203%25E2%2580%2593778%252C%2520a%2520first-in-class%2520HBV%2520core%2520inhibitor%252C%2520alone%2520and%2520in%2520combination%2520with%2520pegylated-interferon%2520%2528peg-IFN%2520alpha-2a%2529%252C%2520in%2520treatment-na%25C3%25AFve%2520HBeAg-positive%2520patients%253A%2520early%2520reductions%2520in%2520HBV%2520DNA%2520and%2520HBeAg%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Levin, J.</span><span> </span><span class="NLM_article-title">Safety, tolerability and pharmacokinetics of JNJ-56136379, a novel HBV capsid assembly modulator, in healthy subjects</span>. Presented at the AASLD Liver Meeting, Boston, Nov 11–15,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Levin%2C+J.+Safety%2C+tolerability+and+pharmacokinetics+of+JNJ-56136379%2C+a+novel+HBV+capsid+assembly+modulator%2C+in+healthy+subjects.+Presented+at+the+AASLD+Liver+Meeting%2C+Boston%2C+Nov+11%E2%80%9315%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DLevin%26aufirst%3DJ.%26atitle%3DSafety%252C%2520tolerability%2520and%2520pharmacokinetics%2520of%2520JNJ-56136379%252C%2520a%2520novel%2520HBV%2520capsid%2520assembly%2520modulator%252C%2520in%2520healthy%2520subjects%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Deres, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroder, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paessens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hacker, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niewohner, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pleiss, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoltefuss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graef, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koletzki, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masantschek, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reimann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaeger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckermann, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlemmer, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haebich, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubsamen-Waigmann, H.</span><span> </span><span class="NLM_article-title">Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">893</span><span class="NLM_x">–</span> <span class="NLM_lpage">896</span><span class="refDoi"> DOI: 10.1126/science.1077215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1126%2Fscience.1077215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=12574631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1Sgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2003&pages=893-896&author=K.+Deresauthor=C.+H.+Schroderauthor=A.+Paessensauthor=S.+Goldmannauthor=H.+J.+Hackerauthor=O.+Weberauthor=T.+Kramerauthor=U.+Niewohnerauthor=U.+Pleissauthor=J.+Stoltefussauthor=E.+Graefauthor=D.+Koletzkiauthor=R.+N.+Masantschekauthor=A.+Reimannauthor=R.+Jaegerauthor=R.+Grossauthor=B.+Beckermannauthor=K.+H.+Schlemmerauthor=D.+Haebichauthor=H.+Rubsamen-Waigmann&title=Inhibition+of+hepatitis+B+virus+replication+by+drug-induced+depletion+of+nucleocapsids&doi=10.1126%2Fscience.1077215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Hepatitis B Virus Replication by Drug-Induced Depletion of Nucleocapsids</span></div><div class="casAuthors">Deres, Karl; Schroeder, Claus H.; Paessens, Arnold; Goldmann, Siegfried; Hacker, Hans Joerg; Weber, Olaf; Kraemer, Thomas; Niewoehner, Ulrich; Pleiss, Ulrich; Stoltefuss, Juergen; Graef, Erwin; Koletzki, Diana; Masantschek, Ralf N. A.; Reimann, Anja; Jaeger, Rainer; Gro, Rainer; Beckermann, Bernhard; Schlemmer, Karl-Heinz; Haebich, Dieter; Ruebsamen-Waigmann, Helga</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">5608</span>),
    <span class="NLM_cas:pages">893-896</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Chronic hepatitis B virus (HBV) infection is a major cause of liver disease.  Only interferon-α and the nucleosidic inhibitors of the viral polymerase, 3TC and adefovir, are approved for therapy.  However, these therapies are limited by the side effects of interferon and the substantial resistance of the virus to nucleosidic inhibitors.  Potent new antiviral compds. suitable for monotherapy or combination therapy are highly desired.  We describe non-nucleosidic inhibitors of HBV nucleocapsid maturation that possess in vitro and in vivo antiviral activity.  These inhibitors have potential for future therapeutic regimens to combat chronic HBV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAlJUFASSEhLVg90H21EOLACvtfcHk0linpepJG8PFoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1Sgsg%253D%253D&md5=a5e74b45d335f74ba17ec9fe4d31e24b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscience.1077215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1077215%26sid%3Dliteratum%253Aachs%26aulast%3DDeres%26aufirst%3DK.%26aulast%3DSchroder%26aufirst%3DC.%2BH.%26aulast%3DPaessens%26aufirst%3DA.%26aulast%3DGoldmann%26aufirst%3DS.%26aulast%3DHacker%26aufirst%3DH.%2BJ.%26aulast%3DWeber%26aufirst%3DO.%26aulast%3DKramer%26aufirst%3DT.%26aulast%3DNiewohner%26aufirst%3DU.%26aulast%3DPleiss%26aufirst%3DU.%26aulast%3DStoltefuss%26aufirst%3DJ.%26aulast%3DGraef%26aufirst%3DE.%26aulast%3DKoletzki%26aufirst%3DD.%26aulast%3DMasantschek%26aufirst%3DR.%2BN.%26aulast%3DReimann%26aufirst%3DA.%26aulast%3DJaeger%26aufirst%3DR.%26aulast%3DGross%26aufirst%3DR.%26aulast%3DBeckermann%26aufirst%3DB.%26aulast%3DSchlemmer%26aufirst%3DK.%2BH.%26aulast%3DHaebich%26aufirst%3DD.%26aulast%3DRubsamen-Waigmann%26aufirst%3DH.%26atitle%3DInhibition%2520of%2520hepatitis%2520B%2520virus%2520replication%2520by%2520drug-induced%2520depletion%2520of%2520nucleocapsids%26jtitle%3DScience%26date%3D2003%26volume%3D299%26spage%3D893%26epage%3D896%26doi%3D10.1126%2Fscience.1077215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Bourne, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zlotnick, A.</span><span> </span><span class="NLM_article-title">Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">11055</span><span class="NLM_x">–</span> <span class="NLM_lpage">11061</span><span class="refDoi"> DOI: 10.1128/JVI.00933-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1128%2FJVI.00933-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=16943288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KhurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=11055-11061&author=C.+R.+Bourneauthor=M.+G.+Finnauthor=A.+Zlotnick&title=Global+structural+changes+in+hepatitis+B+virus+capsids+induced+by+the+assembly+effector+HAP1&doi=10.1128%2FJVI.00933-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1</span></div><div class="casAuthors">Bourne, Christina R.; Finn, M. G.; Zlotnick, Adam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">11055-11061</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) is a leading cause of liver disease and hepatocellular carcinoma; over 400 million people are chronically infected with HBV.  Specific anti-HBV treatments, like most antivirals, target enzymes that are similar to host proteins.  Virus capsid protein has no human homolog, making its assembly a promising but undeveloped therapeutic target.  HAP1 [methyl 4-(2-chloro-4-fluorophenyl)-6-methyl-2-(pyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate], a heteroaryldihydropyrimidine, is a potent HBV capsid assembly activator and misdirector.  Knowledge of the structural basis for this activity would directly benefit the development of capsid-targeting therapeutic strategies.  This report details the crystal structures of icosahedral HBV capsids with and without HAP1.  We show that HAP1 leads to global structural changes by movements of subunits as connected rigid bodies.  The obsd. movements cause the fivefold vertices to protrude from the liganded capsid, the threefold vertices to open, and the quasi-sixfold vertices to flatten, explaining the effects of HAP1 on assembled capsids and on the assembly process.  We have identified a likely HAP1-binding site that bridges elements of secondary structure within a capsid-bound monomer, offering explanation for assembly activation.  This site also interferes with interactions between capsid proteins, leading to quaternary changes and presumably assembly misdirection.  These results demonstrate the plasticity of HBV capsids and the mol. basis for a tenable antiviral strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpdf0rkzY6lbVg90H21EOLACvtfcHk0linpepJG8PFoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KhurrJ&md5=9d176d66a1d3c2e323203877c225be6e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1128%2FJVI.00933-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00933-06%26sid%3Dliteratum%253Aachs%26aulast%3DBourne%26aufirst%3DC.%2BR.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DGlobal%2520structural%2520changes%2520in%2520hepatitis%2520B%2520virus%2520capsids%2520induced%2520by%2520the%2520assembly%2520effector%2520HAP1%26jtitle%3DJ.%2520Virol.%26date%3D2006%26volume%3D80%26spage%3D11055%26epage%3D11061%26doi%3D10.1128%2FJVI.00933-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Brezillon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunelle, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massinet, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamant, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DaSilva, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berissi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belghiti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hannoun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puerstinger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wimmer, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neyts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hantz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soussan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morosan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremsdorf, D.</span><span> </span><span class="NLM_article-title">Antiviral activity of Bay 41–4109 on hepatitis B virus in humanized Alb-uPA/SCID mice</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">e25096</span><span class="refDoi"> DOI: 10.1371/journal.pone.0025096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1371%2Fjournal.pone.0025096" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=e25096&author=N.+Brezillonauthor=M.+N.+Brunelleauthor=H.+Massinetauthor=E.+Giangauthor=C.+Lamantauthor=L.+DaSilvaauthor=S.+Berissiauthor=J.+Belghitiauthor=L.+Hannounauthor=G.+Puerstingerauthor=E.+Wimmerauthor=J.+Neytsauthor=O.+Hantzauthor=P.+Soussanauthor=S.+Morosanauthor=D.+Kremsdorf&title=Antiviral+activity+of+Bay+41%E2%80%934109+on+hepatitis+B+virus+in+humanized+Alb-uPA%2FSCID+mice&doi=10.1371%2Fjournal.pone.0025096"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0025096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0025096%26sid%3Dliteratum%253Aachs%26aulast%3DBrezillon%26aufirst%3DN.%26aulast%3DBrunelle%26aufirst%3DM.%2BN.%26aulast%3DMassinet%26aufirst%3DH.%26aulast%3DGiang%26aufirst%3DE.%26aulast%3DLamant%26aufirst%3DC.%26aulast%3DDaSilva%26aufirst%3DL.%26aulast%3DBerissi%26aufirst%3DS.%26aulast%3DBelghiti%26aufirst%3DJ.%26aulast%3DHannoun%26aufirst%3DL.%26aulast%3DPuerstinger%26aufirst%3DG.%26aulast%3DWimmer%26aufirst%3DE.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DHantz%26aufirst%3DO.%26aulast%3DSoussan%26aufirst%3DP.%26aulast%3DMorosan%26aufirst%3DS.%26aulast%3DKremsdorf%26aufirst%3DD.%26atitle%3DAntiviral%2520activity%2520of%2520Bay%252041%25E2%2580%25934109%2520on%2520hepatitis%2520B%2520virus%2520in%2520humanized%2520Alb-uPA%252FSCID%2520mice%26jtitle%3DPLoS%2520One%26date%3D2011%26volume%3D6%26spage%3De25096%26doi%3D10.1371%2Fjournal.pone.0025096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Shi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, H. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, X. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, M. Y.</span><span> </span><span class="NLM_article-title">NMR-spectroscopy-based metabonomic approach to the analysis of Bay41–4109, a novel anti-HBV compound, induced hepatotoxicity in rats</span> <span class="citation_source-journal">Toxicol. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">173</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">167</span><span class="refDoi"> DOI: 10.1016/j.toxlet.2007.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1016%2Fj.toxlet.2007.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=17826925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVeqsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2007&pages=161-167&author=C.+Shiauthor=C.+Q.+Wuauthor=A.+M.+Caoauthor=H.+Z.+Shengauthor=X.+Z.+Yanauthor=M.+Y.+Liao&title=NMR-spectroscopy-based+metabonomic+approach+to+the+analysis+of+Bay41%E2%80%934109%2C+a+novel+anti-HBV+compound%2C+induced+hepatotoxicity+in+rats&doi=10.1016%2Fj.toxlet.2007.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">NMR-spectroscopy-based metabonomic approach to the analysis of Bay41-4109, a novel anti-HBV compound, induced hepatotoxicity in rats</span></div><div class="casAuthors">Shi, Chang; Wu, Chun-qi; Cao, An-min; Sheng, He-Zhang; Yan, Xian-zhong; Liao, Ming-yang</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-167</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An integrated metabonomics study using high-resoln. 1H NMR spectroscopy has been applied to investigate the biochem. compn. of urine, serum, liver tissue aq. exts. (acetonitrile/water) and liver tissue lipidic exts. (chloroform/methanol) obtained from control and Bay41-4109 treated rats (10, 50, 400 mg kg-1 d-1 for 5 days, i.g.).  Principal components anal. was used to visualize similarities and differences in biochem. profiles.  The results showed the effects induced by Bay41-4109 at 400 mg kg-1 d-1 are different from those induced at 10, 50 mg kg-1 d-1.  The biochem. profiles of 400 mg kg-1 d-1 group might reflect the hepatotoxicity of Bay41-4109 more exactly.  The elevation in the level of 3-HB, lactate, 2-hydroxy-acetol and D-glucose was found in the urine, and the levels of VLDL/LDL(CH2)n, VLDL/LDL-CH3, 2-oxo-3-methyl-n-valerate, 3-HB, lactate, acetate, taurine, 2-hydroxy-isovalerate in serum were increased significantly in 400 mg kg-1 d-1 group.  The predominant changes identified in liver tissue aq. exts. included an increase in the signal intensities of lactate, 3-amino-isovalerate, pyruvate, choline, trimethylamine-N-oxide (TMAO) and a redn. in the intensities of taurine, hippurate and D-glucose.  In liver tissue chloroform/methanol exts., there was a remarkably increase in many of the lipid signals including the triglyceride terminal Me, methylene groups, and CH2CO, N+(CH3)3, CH2OPO2, CH2OCOR.  These observations all provide evidence that fatty acid metab. disorder and mitochondrial inability might contribute to the hepatotoxicity of Bay41-4109.  The application of 1H NMR spectroscopy to an array of biol. samples comprising urine, serum and liver tissue exts. yields new insight into the hepatotoxicity of xenobiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEdIWT-FpgZLVg90H21EOLACvtfcHk0liGvO0fTIG1Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVeqsrrP&md5=89bd5589fb93920c51723e5b75c99673</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.toxlet.2007.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.toxlet.2007.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DC.%2BQ.%26aulast%3DCao%26aufirst%3DA.%2BM.%26aulast%3DSheng%26aufirst%3DH.%2BZ.%26aulast%3DYan%26aufirst%3DX.%2BZ.%26aulast%3DLiao%26aufirst%3DM.%2BY.%26atitle%3DNMR-spectroscopy-based%2520metabonomic%2520approach%2520to%2520the%2520analysis%2520of%2520Bay41%25E2%2580%25934109%252C%2520a%2520novel%2520anti-HBV%2520compound%252C%2520induced%2520hepatotoxicity%2520in%2520rats%26jtitle%3DToxicol.%2520Lett.%26date%3D2007%26volume%3D173%26spage%3D161%26epage%3D167%26doi%3D10.1016%2Fj.toxlet.2007.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Qiu, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayweg, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, G. Z.</span><span> </span><span class="NLM_article-title">Design and synthesis of orally bioavailable 4-methyl heteroaryldihydropyrimidine based hepatitis B Virus (HBV) capsid inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">7651</span><span class="NLM_x">–</span> <span class="NLM_lpage">7666</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00879</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00879" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7651-7666&author=Z.+X.+Qiuauthor=X.+F.+Linauthor=M.+W.+Zhouauthor=Y.+F.+Liuauthor=W.+Zhuauthor=W.+M.+Chenauthor=W.+X.+Zhangauthor=L.+Guoauthor=H.+X.+Liuauthor=G.+L.+Wuauthor=M.+W.+Huangauthor=M.+Jiangauthor=Z.+H.+Xuauthor=Z.+Zhouauthor=N.+Qinauthor=S.+Renauthor=H.+X.+Qiuauthor=S.+Zhongauthor=Y.+X.+Zhangauthor=Y.+Zhangauthor=X.+Y.+Wuauthor=L.+P.+Shiauthor=F.+Shenauthor=Y.+Maoauthor=X.+Zhouauthor=W.+G.+Yangauthor=J.+Z.+Wuauthor=G.+Yangauthor=A.+V.+Maywegauthor=H.+C.+Shenauthor=G.+Z.+Tang&title=Design+and+synthesis+of+orally+bioavailable+4-methyl+heteroaryldihydropyrimidine+based+hepatitis+B+Virus+%28HBV%29+capsid+inhibitors&doi=10.1021%2Facs.jmedchem.6b00879"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00879%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DZ.%2BX.%26aulast%3DLin%26aufirst%3DX.%2BF.%26aulast%3DZhou%26aufirst%3DM.%2BW.%26aulast%3DLiu%26aufirst%3DY.%2BF.%26aulast%3DZhu%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DW.%2BM.%26aulast%3DZhang%26aufirst%3DW.%2BX.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DH.%2BX.%26aulast%3DWu%26aufirst%3DG.%2BL.%26aulast%3DHuang%26aufirst%3DM.%2BW.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DZ.%2BH.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DQin%26aufirst%3DN.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DH.%2BX.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%2BX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%2BY.%26aulast%3DShi%26aufirst%3DL.%2BP.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DW.%2BG.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DTang%26aufirst%3DG.%2BZ.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520orally%2520bioavailable%25204-methyl%2520heteroaryldihydropyrimidine%2520based%2520hepatitis%2520B%2520Virus%2520%2528HBV%2529%2520capsid%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7651%26epage%3D7666%26doi%3D10.1021%2Facs.jmedchem.6b00879" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Qiu, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, X. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kou, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ottaviani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J. A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayweg, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W.</span><span> </span><span class="NLM_article-title">Discovery and pre-clinical characterization of third-generation 4-H heteroaryldihydropyrimidine (HAP) analogues as hepatitis B virus (HBV) capsid inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">3352</span><span class="NLM_x">–</span> <span class="NLM_lpage">3371</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00083</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00083" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkvFWjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=3352-3371&author=Z.+X.+Qiuauthor=X.+F.+Linauthor=W.+X.+Zhangauthor=M.+W.+Zhouauthor=L.+Guoauthor=B.+Kocerauthor=G.+Wuauthor=Z.+Zhangauthor=H.+Liuauthor=H.+Shiauthor=B.+Kouauthor=T.+Huauthor=Y.+Huauthor=M.+Huangauthor=S.+F.+Yanauthor=Z.+Xuauthor=Z.+Zhouauthor=N.+Qinauthor=Y.+F.+Wangauthor=S.+Renauthor=H.+Qiuauthor=Y.+Zhangauthor=Y.+Zhangauthor=X.+Wuauthor=K.+Sunauthor=S.+Zhongauthor=J.+Xieauthor=G.+Ottavianiauthor=Y.+Zhouauthor=l.+Zhuauthor=X.+Tianauthor=L.+Shiauthor=F.+Shenauthor=Y.+Maoauthor=X.+Zhouauthor=L.+Gaoauthor=J.+A.+T.+Youngauthor=J.+Z.+Wuauthor=G.+Yangauthor=A.+V.+Maywegauthor=H.+C.+Shenauthor=G.+Tangauthor=W.+Zhu&title=Discovery+and+pre-clinical+characterization+of+third-generation+4-H+heteroaryldihydropyrimidine+%28HAP%29+analogues+as+hepatitis+B+virus+%28HBV%29+capsid+inhibitors&doi=10.1021%2Facs.jmedchem.7b00083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors</span></div><div class="casAuthors">Qiu, Zongxing; Lin, Xianfeng; Zhang, Weixing; Zhou, Mingwei; Guo, Lei; Kocer, Buelent; Wu, Guolong; Zhang, Zhisen; Liu, Haixia; Shi, Houguang; Kou, Buyu; Hu, Taishan; Hu, Yimin; Huang, Mengwei; Yan, S. Frank; Xu, Zhiheng; Zhou, Zheng; Qin, Ning; Wang, Yue Fen; Ren, Shuang; Qiu, Hongxia; Zhang, Yuxia; Zhang, Yi; Wu, Xiaoyue; Sun, Kai; Zhong, Sheng; Xie, Jianxun; Ottaviani, Giorgio; Zhou, Yuan; Zhu, Lina; Tian, Xiaojun; Shi, Liping; Shen, Fang; Mao, Yi; Zhou, Xue; Gao, Lu; Young, John A. T.; Wu, Jim Zhen; Yang, Guang; Mayweg, Alexander V.; Shen, Hong C.; Tang, Guozhi; Zhu, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3352-3371</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Described herein are the discovery and structure-activity relationship (SAR) studies of the third-generation 4-H heteroaryldihydropyrimidines (4-H HAPs) (I) featuring the introduction of a C6 carboxyl group as novel HBV capsid inhibitors.  This new series of 4-H HAPs showed improved anti-HBV activity and better drug-like properties compared to the first- and second-generation 4-H HAPs.  X-ray crystallog. study of analog 12 (HAP_R01) with Cp149 Y132A mutant hexamer clearly elucidated the role of C6 carboxyl group played for the increased binding affinity, which formed strong hydrogen bonding interactions with capsid protein and coordinated waters.  The representative analog 10 (HAP_R10) was extensively characterized in vitro (ADMET) and in vivo (mouse PK and PD) and subsequently selected for further development as oral anti-HBV infection agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolNkEF9n_vqrVg90H21EOLACvtfcHk0liGvO0fTIG1Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkvFWjtbw%253D&md5=6c2a89c594f2c735855f64aca2240837</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00083%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DZ.%2BX.%26aulast%3DLin%26aufirst%3DX.%2BF.%26aulast%3DZhang%26aufirst%3DW.%2BX.%26aulast%3DZhou%26aufirst%3DM.%2BW.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DKou%26aufirst%3DB.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DYan%26aufirst%3DS.%2BF.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DQin%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DK.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DOttaviani%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3Dl.%26aulast%3DTian%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DF.%26aulast%3DMao%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DYoung%26aufirst%3DJ.%2BA.%2BT.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DShen%26aufirst%3DH.%2BC.%26aulast%3DTang%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DW.%26atitle%3DDiscovery%2520and%2520pre-clinical%2520characterization%2520of%2520third-generation%25204-H%2520heteroaryldihydropyrimidine%2520%2528HAP%2529%2520analogues%2520as%2520hepatitis%2520B%2520virus%2520%2528HBV%2529%2520capsid%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D3352%26epage%3D3371%26doi%3D10.1021%2Facs.jmedchem.7b00083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Wang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, Z. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, G. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, X. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H. S.</span><span> </span><span class="NLM_article-title">In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir-dipivoxil-resistant HBV mutations</span> <span class="citation_source-journal">Antiviral Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">793</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span><span class="refDoi"> DOI: 10.3851/IMP2152</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.3851%2FIMP2152" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=793-803&author=X.+Y.+Wangauthor=Z.+M.+Weiauthor=G.+Y.+Wuauthor=J.+H.+Wangauthor=Y.+J.+Zhangauthor=J.+Liauthor=H.+H.+Zhangauthor=X.+W.+Xieauthor=X.+Wangauthor=Z.+H.+Wangauthor=L.+Weiauthor=Y.+Wangauthor=H.+S.+Chen&title=In+vitro+inhibition+of+HBV+replication+by+a+novel+compound%2C+GLS4%2C+and+its+efficacy+against+adefovir-dipivoxil-resistant+HBV+mutations&doi=10.3851%2FIMP2152"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3851%2FIMP2152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3851%252FIMP2152%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DWei%26aufirst%3DZ.%2BM.%26aulast%3DWu%26aufirst%3DG.%2BY.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26aulast%3DZhang%26aufirst%3DY.%2BJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%2BH.%26aulast%3DXie%26aufirst%3DX.%2BW.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DZ.%2BH.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%2BS.%26atitle%3DIn%2520vitro%2520inhibition%2520of%2520HBV%2520replication%2520by%2520a%2520novel%2520compound%252C%2520GLS4%252C%2520and%2520its%2520efficacy%2520against%2520adefovir-dipivoxil-resistant%2520HBV%2520mutations%26jtitle%3DAntiviral%2520Ther.%26date%3D2012%26volume%3D17%26spage%3D793%26epage%3D803%26doi%3D10.3851%2FIMP2152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, D. F.</span><span> </span><span class="NLM_article-title">Effects of ketoconazole and rifampicin on the pharmacokinetics of GLS4, a novel anti-hepatitis B virus compound, in dogs</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1420</span><span class="NLM_x">–</span> <span class="NLM_lpage">1426</span><span class="refDoi"> DOI: 10.1038/aps.2013.76</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1038%2Faps.2013.76" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=1420-1426&author=X.+Zhouauthor=Z.+W.+Gaoauthor=J.+Mengauthor=X.+Y.+Chenauthor=D.+F.+Zhong&title=Effects+of+ketoconazole+and+rifampicin+on+the+pharmacokinetics+of+GLS4%2C+a+novel+anti-hepatitis+B+virus+compound%2C+in+dogs&doi=10.1038%2Faps.2013.76"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Faps.2013.76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2013.76%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGao%26aufirst%3DZ.%2BW.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DX.%2BY.%26aulast%3DZhong%26aufirst%3DD.%2BF.%26atitle%3DEffects%2520of%2520ketoconazole%2520and%2520rifampicin%2520on%2520the%2520pharmacokinetics%2520of%2520GLS4%252C%2520a%2520novel%2520anti-hepatitis%2520B%2520virus%2520compound%252C%2520in%2520dogs%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2013%26volume%3D34%26spage%3D1420%26epage%3D1426%26doi%3D10.1038%2Faps.2013.76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Wu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arzumanyan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clayton, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schinazi, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feitelson, M. A.</span><span> </span><span class="NLM_article-title">Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">5344</span><span class="NLM_x">–</span> <span class="NLM_lpage">5354</span><span class="refDoi"> DOI: 10.1128/AAC.01091-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1128%2FAAC.01091-13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=5344-5354&author=G.+Wuauthor=B.+Liuauthor=Y.+Zhangauthor=J.+Liauthor=A.+Arzumanyanauthor=M.+M.+Claytonauthor=R.+F.+Schinaziauthor=Z.+Wangauthor=S.+Goldmannauthor=Q.+Renauthor=F.+Zhangauthor=M.+A.+Feitelson&title=Preclinical+characterization+of+GLS4%2C+an+inhibitor+of+hepatitis+B+virus+core+particle+assembly&doi=10.1128%2FAAC.01091-13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1128%2FAAC.01091-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01091-13%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DArzumanyan%26aufirst%3DA.%26aulast%3DClayton%26aufirst%3DM.%2BM.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DGoldmann%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DFeitelson%26aufirst%3DM.%2BA.%26atitle%3DPreclinical%2520characterization%2520of%2520GLS4%252C%2520an%2520inhibitor%2520of%2520hepatitis%2520B%2520virus%2520core%2520particle%2520assembly%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D5344%26epage%3D5354%26doi%3D10.1128%2FAAC.01091-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Klumpp, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukacs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espiritu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baydo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atkins, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abendroth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efimov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartman, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, O. A.</span><span> </span><span class="NLM_article-title">High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">15196</span><span class="NLM_x">–</span> <span class="NLM_lpage">15201</span><span class="refDoi"> DOI: 10.1073/pnas.1513803112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1073%2Fpnas.1513803112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=26598693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFWqsrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=15196-15201&author=K.+Klumppauthor=A.+M.+Lamauthor=C.+Lukacsauthor=R.+Vogelauthor=S.+Renauthor=C.+Espirituauthor=R.+Baydoauthor=K.+Atkinsauthor=J.+Abendrothauthor=G.+Liaoauthor=A.+Efimovauthor=G.+Hartmanauthor=O.+A.+Flores&title=High-resolution+crystal+structure+of+a+hepatitis+B+virus+replication+inhibitor+bound+to+the+viral+core+protein&doi=10.1073%2Fpnas.1513803112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein</span></div><div class="casAuthors">Klumpp, Klaus; Lam, Angela M.; Lukacs, Christine; Vogel, Robert; Ren, Suping; Espiritu, Christine; Baydo, Ruth; Atkins, Kateri; Abendroth, Jan; Liao, Guochun; Efimov, Andrey; Hartman, George; Flores, Osvaldo A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">15196-15201</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The hepatitis B virus (HBV) core protein is essential for HBV replication and an important target for antiviral drug discovery.  We report the first, to our knowledge, high-resoln. crystal structure of an antiviral compd. bound to the HBV core protein.  The compd. NVR-010-001-E2 can induce assembly of the HBV core wild-type and Y132A mutant proteins and thermostabilize the proteins with a Tm increase of more than 10 °C.  NVR-010-001-E2 binds at the dimer-dimer interface of the core proteins, forms a new interaction surface promoting protein-protein interaction, induces protein assembly, and increases stability.  The impact of naturally occurring core protein mutations on antiviral activity correlates with NVR-010-001-E2 binding interactions detd. by crystallog.  The crystal structure provides understanding of a drug efficacy mechanism related to the induction and stabilization of protein-protein interactions and enables structure-guided design to improve antiviral potency and drug-like properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYxV-odPonGbVg90H21EOLACvtfcHk0lhWdg06ZF6_cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFWqsrbK&md5=bf487dda7165d1637fad0ebab8f46142</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1513803112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1513803112%26sid%3Dliteratum%253Aachs%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DLam%26aufirst%3DA.%2BM.%26aulast%3DLukacs%26aufirst%3DC.%26aulast%3DVogel%26aufirst%3DR.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DEspiritu%26aufirst%3DC.%26aulast%3DBaydo%26aufirst%3DR.%26aulast%3DAtkins%26aufirst%3DK.%26aulast%3DAbendroth%26aufirst%3DJ.%26aulast%3DLiao%26aufirst%3DG.%26aulast%3DEfimov%26aufirst%3DA.%26aulast%3DHartman%26aufirst%3DG.%26aulast%3DFlores%26aufirst%3DO.%2BA.%26atitle%3DHigh-resolution%2520crystal%2520structure%2520of%2520a%2520hepatitis%2520B%2520virus%2520replication%2520inhibitor%2520bound%2520to%2520the%2520viral%2520core%2520protein%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D15196%26epage%3D15201%26doi%3D10.1073%2Fpnas.1513803112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Abbott, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sesti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Splawski, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buck, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timothy, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, S. A.</span><span> </span><span class="NLM_article-title">MiRP1 forms IKr potassium channels with hERG and is associated with cardiac arrhythmia</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">187</span><span class="refDoi"> DOI: 10.1016/S0092-8674(00)80728-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1016%2FS0092-8674%2800%2980728-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=1999&pages=175-187&author=G.+W.+Abbottauthor=F.+Sestiauthor=I.+Splawskiauthor=M.+E.+Buckauthor=M.+H.+Lehmannauthor=K.+W.+Timothyauthor=M.+T.+Keatingauthor=S.+A.+Goldstein&title=MiRP1+forms+IKr+potassium+channels+with+hERG+and+is+associated+with+cardiac+arrhythmia&doi=10.1016%2FS0092-8674%2800%2980728-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2800%2980728-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252800%252980728-X%26sid%3Dliteratum%253Aachs%26aulast%3DAbbott%26aufirst%3DG.%2BW.%26aulast%3DSesti%26aufirst%3DF.%26aulast%3DSplawski%26aufirst%3DI.%26aulast%3DBuck%26aufirst%3DM.%2BE.%26aulast%3DLehmann%26aufirst%3DM.%2BH.%26aulast%3DTimothy%26aufirst%3DK.%2BW.%26aulast%3DKeating%26aufirst%3DM.%2BT.%26aulast%3DGoldstein%26aufirst%3DS.%2BA.%26atitle%3DMiRP1%2520forms%2520IKr%2520potassium%2520channels%2520with%2520hERG%2520and%2520is%2520associated%2520with%2520cardiac%2520arrhythmia%26jtitle%3DCell%26date%3D1999%26volume%3D97%26spage%3D175%26epage%3D187%26doi%3D10.1016%2FS0092-8674%2800%2980728-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Fermini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fossa, A. A.</span><span> </span><span class="NLM_article-title">The impact of drug-induced QT interval prolongation on drug discovery and development</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span><span class="refDoi"> DOI: 10.1038/nrd1108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1038%2Fnrd1108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=439-447&author=B.+Ferminiauthor=A.+A.+Fossa&title=The+impact+of+drug-induced+QT+interval+prolongation+on+drug+discovery+and+development&doi=10.1038%2Fnrd1108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrd1108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1108%26sid%3Dliteratum%253Aachs%26aulast%3DFermini%26aufirst%3DB.%26aulast%3DFossa%26aufirst%3DA.%2BA.%26atitle%3DThe%2520impact%2520of%2520drug-induced%2520QT%2520interval%2520prolongation%2520on%2520drug%2520discovery%2520and%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D439%26epage%3D447%26doi%3D10.1038%2Fnrd1108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Jamieson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moir, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: highlights and hang-ups</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5029</span><span class="NLM_x">–</span> <span class="NLM_lpage">5046</span><span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0ljHaNNBVRoBvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Ren, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span> </span><span class="NLM_article-title">Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4)</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">1042</span><span class="NLM_x">–</span> <span class="NLM_lpage">1056</span><span class="refDoi"> DOI: 10.1016/j.bmc.2016.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1016%2Fj.bmc.2016.12.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=1042-1056&author=Q.+Renauthor=X.+Liuauthor=Z.+Luoauthor=J.+Liauthor=C.+Wangauthor=S.+Goldmannauthor=J.+Zhangauthor=Y.+Zhang&title=Discovery+of+hepatitis+B+virus+capsid+assembly+inhibitors+leading+to+a+heteroaryldihydropyrimidine+based+clinical+candidate+%28GLS4%29&doi=10.1016%2Fj.bmc.2016.12.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLuo%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DGoldmann%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520hepatitis%2520B%2520virus%2520capsid%2520assembly%2520inhibitors%2520leading%2520to%2520a%2520heteroaryldihydropyrimidine%2520based%2520clinical%2520candidate%2520%2528GLS4%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D1042%26epage%3D1056%26doi%3D10.1016%2Fj.bmc.2016.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Bourne, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zlotnick, A.</span><span> </span><span class="NLM_article-title">Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1</span> <span class="citation_source-journal">J. Virol</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">11055</span><span class="NLM_x">–</span> <span class="NLM_lpage">11061</span><span class="refDoi"> DOI: 10.1128/JVI.00933-06</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=10.1128%2FJVI.00933-06" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=16943288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1KhurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2006&pages=11055-11061&author=C.+R.+Bourneauthor=M.+G.+Finnauthor=A.+Zlotnick&title=Global+structural+changes+in+hepatitis+B+virus+capsids+induced+by+the+assembly+effector+HAP1&doi=10.1128%2FJVI.00933-06"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1</span></div><div class="casAuthors">Bourne, Christina R.; Finn, M. G.; Zlotnick, Adam</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">11055-11061</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Hepatitis B virus (HBV) is a leading cause of liver disease and hepatocellular carcinoma; over 400 million people are chronically infected with HBV.  Specific anti-HBV treatments, like most antivirals, target enzymes that are similar to host proteins.  Virus capsid protein has no human homolog, making its assembly a promising but undeveloped therapeutic target.  HAP1 [methyl 4-(2-chloro-4-fluorophenyl)-6-methyl-2-(pyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate], a heteroaryldihydropyrimidine, is a potent HBV capsid assembly activator and misdirector.  Knowledge of the structural basis for this activity would directly benefit the development of capsid-targeting therapeutic strategies.  This report details the crystal structures of icosahedral HBV capsids with and without HAP1.  We show that HAP1 leads to global structural changes by movements of subunits as connected rigid bodies.  The obsd. movements cause the fivefold vertices to protrude from the liganded capsid, the threefold vertices to open, and the quasi-sixfold vertices to flatten, explaining the effects of HAP1 on assembled capsids and on the assembly process.  We have identified a likely HAP1-binding site that bridges elements of secondary structure within a capsid-bound monomer, offering explanation for assembly activation.  This site also interferes with interactions between capsid proteins, leading to quaternary changes and presumably assembly misdirection.  These results demonstrate the plasticity of HBV capsids and the mol. basis for a tenable antiviral strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpdf0rkzY6lbVg90H21EOLACvtfcHk0ljHaNNBVRoBvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1KhurrJ&md5=9d176d66a1d3c2e323203877c225be6e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1128%2FJVI.00933-06&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00933-06%26sid%3Dliteratum%253Aachs%26aulast%3DBourne%26aufirst%3DC.%2BR.%26aulast%3DFinn%26aufirst%3DM.%2BG.%26aulast%3DZlotnick%26aufirst%3DA.%26atitle%3DGlobal%2520structural%2520changes%2520in%2520hepatitis%2520B%2520virus%2520capsids%2520induced%2520by%2520the%2520assembly%2520effector%2520HAP1%26jtitle%3DJ.%2520Virol%26date%3D2006%26volume%3D80%26spage%3D11055%26epage%3D11061%26doi%3D10.1128%2FJVI.00933-06" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Berke, J. M.; Verbinnen, T.; Tan, Y.; Dehertogh, P.; Vergauwen, K.; Vandyck, K.; Lenz, O.</span><span> </span><span class="NLM_article-title">The HBV capsid assembly modulator JNJ-379 is a potent inhibitor of viral replication across full length genotype A-H clinical isolates in vitro</span>. Presented at the AASLD Liver Meeting, Washington, DC, Oct 20–24,<span class="NLM_x"> </span><span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Berke%2C+J.+M.%3B+Verbinnen%2C+T.%3B+Tan%2C+Y.%3B+Dehertogh%2C+P.%3B+Vergauwen%2C+K.%3B+Vandyck%2C+K.%3B+Lenz%2C+O.+The+HBV+capsid+assembly+modulator+JNJ-379+is+a+potent+inhibitor+of+viral+replication+across+full+length+genotype+A-H+clinical+isolates+in+vitro.+Presented+at+the+AASLD+Liver+Meeting%2C+Washington%2C+DC%2C+Oct+20%E2%80%9324%2C+2017."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBerke%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520HBV%2520capsid%2520assembly%2520modulator%2520JNJ-379%2520is%2520a%2520potent%2520inhibitor%2520of%2520viral%2520replication%2520across%2520full%2520length%2520genotype%2520A-H%2520clinical%2520isolates%2520in%2520vitro%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Baell, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holloway, G. A.</span><span> </span><span class="NLM_article-title">New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2719</span><span class="NLM_x">–</span> <span class="NLM_lpage">2740</span><span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+substructure+filters+for+removal+of+pan+assay+interference+compounds+%28PAINS%29+from+screening+libraries+and+for+their+exclusion+in+bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0ljHaNNBVRoBvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520substructure%2520filters%2520for%2520removal%2520of%2520pan%2520assay%2520interference%2520compounds%2520%2528PAINS%2529%2520from%2520screening%2520libraries%2520and%2520for%2520their%2520exclusion%2520in%2520bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2G34" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2G34','PDB','2G34'); return false;">PDB: 2G34</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5E0I" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5E0I','PDB','5E0I'); return false;">PDB: 5E0I</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i79"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01914">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_23510"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01914">10.1021/acs.jmedchem.7b01914</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Detailed experimental procedures for the synthesis of intermediates <b>58I-1</b> and analogues <b>35</b>, <b>62</b>, and <b>66</b>; characterization of compounds <b>6</b>–<b>25</b>; X-ray crystal structure of <b>(<i>R</i>)-58I-2</b>; <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of compound <b>58</b>; inhibition efficacy of <b>(<i>R</i>)-52</b> against four major HBV genotypes (A, B, C, and D); CYP inhibition assay; pharmacokinetic (PK) studies in mice; HBV-capsid-assembly-quenching assay (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01914/suppl_file/jm7b01914_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular-formula strings of the reported compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01914/suppl_file/jm7b01914_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01914/suppl_file/jm7b01914_si_001.pdf">jm7b01914_si_001.pdf (1.08 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01914/suppl_file/jm7b01914_si_002.csv">jm7b01914_si_002.csv (5.13 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01914&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-3%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01914%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01914" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67996e1b7e823c40","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
